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Three staphylococcal enterotoxins (SE) A, B and C2 and the toxic 
shock syndrom e toxin -1  (TSST-1 ) were purified to  homogeneity by a sim­
ple two-step procedure involving dye ligand and fast protein liquid chro­
m atography. These toxins were all shown to  be >  99% pure as shown by 
SDS-PAGE. Crystallization trials were prepared for all four purified tox­
ins. Crystals of TSST -1  and SEC2 suitable for X-ray diffraction work were 
grown. Crystals of SEB were found to  be highly disordered and fu rther 
trials were not pursued. No crystals of SEA were obtained.
The 3D structure  of TSST-1 was determ ined using X-ray crystallog­
raphy to 2.5A and a final crystallographic .R-factor of 0.213. This toxin has 
a two dom ain structure  characteristic of SE. A s tru c tu ra l basis for the su- 
perantigenic properties of TSST-1 was elucidated. Based on our s truc tu ra l 
d a ta  in combination with other available d a ta  on TSST-1, a trim olecular 
model consisting of TSST-1 , the m ajor histocom patibility complex class 
II (MHC II) and T  cell receptor (TcR) was proposed. Subsequent X-ray 
crystallographic studies of the MHC II/T S S T - 1  complex have validated this 
general model. A brief comparison of the wild type TSST-1 structu re  w ith 
th a t of TSST -1  complexed to MHC II was undertaken. This highlighted 
some significant differences on the TSST-1 s tructu re  to  accom m odate the  
MHC II-bound peptide fragm ent.
A ttem pts were also m ade to elucidate the 3D structu re  of SEC2 by 
molecular replacem ent, using the refined TSST - 1  s truc tu re  as the search 
model. This proved to be ambitious and the s tructu re  of SEC2 could not 
be determ ined.
A TSST - 1  m u tan t (Lys 105 Glu) was crystallized, and the structu re
determined to 2.8A resolution.
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Sym bols and A bbreviations
(hkl) Unique reflection plane (or Miller indices)
20 Angle between incident and diffracted beams
A Angstroem units ( lA = 1 0 “ 8cm)
B  Atomic tem perature factor
d Days
F0 Observed structure  factor am plitude
h Hours
I  Reflection intensity
MFID Mean fractional isom orphous difference
min M inutes
M IR Multiple isomorphous replacem ent
P (uvw )  Patterson  function
R  Crystallographic agreem ent residual index
s Seconds
d In terplanar spacing of a set of planes in a  crystal
dmin M inimum value of d ie. the resolution limit
a ,  /?, 7  Real space unit cell angles
a c  Calculated protein phase angle
a n  Heavy atom  phase angle
a p  P rotein phase angle
a p ii  Heavy atom  derivative phase angle
F p , F p h  S tructure factor for native protein (P ) and heavy
atom  derivative (PH) 
rm s Root m ean square
F  (hkl) Structure factor
F Structure factor am plitude
A W avelength of incident X-ray
P Electron density
CT S tandard  deviation
Ag Antigen
CAM E Centre for Applied Microbiological Research
CDR Com plim entarity determ ining region
Con A Concanavalin A
EDTA Ethylenediam inetetraacetic acid
ELISA Enzyme linked im m unosorbant assay
FPLC Fast protein liquid chrom atography
HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid
HLA H um an leukocyte antigen
IEF Isoelectric focussing
IL Interleukin
M r Relative molecular mass
MHC M ajor histocom patibility complex
MRC Medical Research Council
NCS Non-crystallographic sym m etry
NMR Nuclear m agnetic resonance
PAGE Polyacrylamide-gel electrophoresis
PBS Phosphate buffered saline
PEG Polyethylene glycol
SAg Superantigen
SDS Sodium dodecyl sulphate
SEs Staphylococcal enterotoxins (A-E)
SIDS Sudden infant death  syndrom e
SRID Single radial immunodiffusion
SRS Synchrotron Radiation Source, Daresbury, UK.
TN F Tum or necrosis factor
TRIS Tris (hydroxy m et hyl) m et hylamine
TSS Toxic shock syndrom e
TSST - 1 Toxic shock syndrom e toxin - 1
TcR T cell receptor
y p Variable (3 gene segment of the  T  cell receptor
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1.1 T he R ole o f  Staphylococcal Toxins in D isease
Staphylococcus aureus produces a wide variety of biologically active 
extracellular virulence factors, known to be the  causative agents in the 
pathogenesis of a num ber of hum an diseases (Chesney et al., 1984). These 
virulence factors include: hyaluronidase, leucocidin, lipase, protease, co- 
agulase, haemolysins (A-D), exfoliative toxins, staphylococcal enterotoxins 
(SE) and  toxic shock syndrom e toxin - 1  (TSST-1) (T ranter and Brehm , 
1994). Some toxins produced by Streptococcus pyogenes (G roup A), share 
cross-reactivity w ith SEB and SEC1 (Johnson and Schlievert, 1984; Bo- 
hach et al., 1988; Abe et al., 1991; Alouf et al., 1991). These toxins have 
been described as ‘superantigens’ for their capacity to  stim ulate those T 
cells which possess a specific V(3 gene segment on the cell surface (Section 
1.6).
1.2 Toxic Shock Syndrom e Toxin-1 (T SST -1)
Toxic shock syndrom e (TSS) was first described by Todd and co­
workers in 1978 (Todd et al., 1978) as an acute fife-threatening m ultisystem  
disease (Table 1 .1 ). The disease is caused by a toxin, toxic shock syndrom e 
toxin - 1  (TSST-1), produced by some but not all strains of Staphylococcus 
aureus. In m enstrual cases the disease, which begins suddenly, was origi­
nally thought to  be exclusively restricted to extended tam pon use in young 
women (Davis et al., 1980; Shands et al., 1980), and  caused by significant
1
colonization of the vagina by TSST-l-producing strains of Staphylococcus 
aureus.
Subsequent research has shown th a t TSS is not exclusively a  m en­
strual event and can also occur after any surgical procedure in b o th  m en 
and women following post-operative wound infection (Schlievert, 1983). 
Between 15 - 30% of non-m enstrual cases occur as a  result of soft tissue 
infection and non-genital Staphylococcus aureus wounds (Schlievert, 1983; 
B lom ster-H autam aa and Schlievert, 1988). Toxic shock syndrom e tends 
to  occur if the infected person has none or very low levels of anti-TSST-1 
antibodies present (Crass and Bergdoll, 1986). Indeed the presence of high 
levels of anti-TSST-1 antibodies has been shown to  reduce the incidence 
of the sym ptom s of TSS (Staneck and Bonventre, 1984). Fatality  ra tes for 
m enstrual toxic shock syndrom e are currently approxim ately 1 0 % (Alouf 
et al., 1991). In non-m enstrual cases, in addition to  TSST - 1  the s taphy­
lococcal enterotoxins, in particular SEB and SEC1, m ay also cause toxic 
shock syndrom e (Schlievert, 1984; G arbe et al., 1985; Schlievert, 1986; 
K unstm ann et al., 1989; Bohach et al., 1990). Indeed, the SE make up ap­
proxim ately 50% of all non-m enstrual cases of TSS, such as infected burns, 
while the other 50% of cases are caused by TSST-1 (Lee et al., 1992a). 
The SE have also been shown to cause the sym ptom s of TSS in a  rabb it 
model (Sloane et al., 1991). Case reports of those adults who do not make 
a complete clinical recovery have been shown to  suffer num erous illnesses 
including a perm anent loss of hearing and extensive tissue necroses requir­
ing plastic surgery and this has been a ttrib u ted  to  capillary leakage (Lee 
et al., 1991).
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1.3 Staphylococcal E nterotoxins
The SE have long been known to cause staphylococcal food poison­
ing. Dack and co-workers (1930) were the first to  show th a t this illness 
was caused by toxins produced by Staphylococcus aureus by examining the 
uneaten portion of a three-layer cream cake. This cake was thought to  
be the source of food poisoning in eleven people resulting in cram ping, 
vomiting and diarrhoea. Laboratory analysis of the  cake revealed S taphy­
lococci. Growth media, inoculated w ith the contam inated cake, was then  
centrifuged and the supernatant given to  hum an volunteers. These volun­
teers became ill with the same signs and sym ptom s as the original eleven 
(Bergdoll, 1990). The toxic factors were nam ed enterotoxins because of 
their effect on the gastro-intestinal trac t. However, this is a misleading 
nam e because there is no fluid accum ulation when the toxins are assayed 
using the  standard  ligated rabbit ileal loop, as is norm ally seen w ith true  
enterotoxins such as Escherichia coli heat-labile enterotoxin (Iandolo and 
Tweeten, 1988; Sixma et al., 1991). Numerous foods have been im plicated 
in this type of food poisoning such as: dairy products, especially cream  and 
custard  fillings, and cooked m eats. The m ost im portan t source and  route 
of transm ission of such contam inated foods by Staphylococcus aureus is by 
food handlers. Indeed 30 - 40% of healthy individuals carry this organism , 
which is found mainly in the nose, hands, th ro a t and  skin (Bergdoll, 1990).
The clinical sym ptom s of staphylococcal food poisoning are: saliva­
tion, profuse vomiting, nausea, abdom inal cram ps and diarrhoea. These 
sym ptom s usually occur within 1 to 6  hours after ingestion of contam inated 
food bu t full recovery is usually seen between 24 to  48 hours. The severity 
of the sym ptom s depends on the am ount of toxin present and the quantity
of the contam inated food ingested as well as the absence of the necessary 
circulating antibodies. Fatalities are very rare  and  are only occasionally 
observed in the  very young or the elderly.
1.4 G eneral Toxin C haracteristics
1.4.1 Toxic Shock Syndrom e Toxin-1
T SST - 1  is a  single chain polypeptide which does not contain any nu­
cleic acid, carbohydrate, lipid or cofactor moieties. It has a M r of 22,049Da 
as deduced from  its nucleic acid sequence, which translates into 194 amino 
acids (B lom ster-H autam aa et al., 1986a). It can exist a t two different pis:
7.08 and 7.22, which may be a result of deam idation during the  production 
an d /o r purification processes (B lom ster-H autam aa et al., 1986b). TSST- 
1 does not contain any cysteine residues and shares about 24% sequence 
identity w ith the SE (Figure 1 .1 ). The toxin is trypsin  resistant b u t can 
be degraded by exposure to papain or pepsin (Reiser et al., 1983; Edwin 
and Kass, 1989).
T SST - 1  was independently isolated and purified by two groups in 
1981. Bergdoll and co-workers (Bergdoll et al., 1981) called their toxin 
SEF, whilst Schlievert and his colleagues referred to  it as pyrogenic exo­
toxin C (PEC ; Schlievert et al., 1981). Further detailed biochemical and 
immunological studies showed th a t SEF and PE C  were in fact identical 
and the toxin was renam ed toxic shock syndrom e toxin-1 (TSST-1) (Bon- 
ventre et al., 1983; Bergdoll and Schlievert, 1984). An ovine-derived form 
of T SST - 1  has been isolated from m astitis-infected anim als (Lee et al., 
1992b). Of the  194 residues, only nine are different com pared w ith ‘hu­
m an ’ TSST-1.
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1.4.2 S taphylococcal E nterotoxins
The structu rally  related SE can be classified in to  five serologically 
distinct groups: SEA (C asm an, 1960), SEB (Bergdoll et al., 1959), SEC 
(Bergdoll et al., 1965), SED (Casm an et al., 1967) and  SEE (Bergdoll et 
al., 1971). SEC can be fu rther subdivided into: SEC1 (B orja and Bergdoll, 
1967), SEC2 (Avena and Bergdoll, 1967) and SEC3 (Reiser et al., 1984) due 
to  m inor differences in their epitopes especially involving residues 2 0 , 2 2  
and 26 (Turner et al., 1992). The SE range in size from  26 - 29 kDa, possess 
between 228 and 239 am ino acids, and share 30-85% sequence homology. 
The gene sequences encoding all the SE have been elucidated (Betley et 
al., 1990). The am ino acid composition of the  SE are sim ilar w ith respect 
to  the high content of aspartic acid, lysine and  tyrosine residues, they 
all have one centrally located disulphide loop which varies in length from 
10 to 20 residues. The only sequence (Figure 1.1) where there is up to 
five sequential am ino acid residues identical am ongst all the SE, follows 
the second cysteine residue of : SEA, SEB, SEC1-3, SED and SEE. This 
sequence is close to  a conserved histidine residue though t to be involved 
in the emetic properties of SEA (Stelm a and Bergdoll, 1982). All SE exist 
with m ultiple isoelectric points which may be a ttr ib u te d  to  deam idation 
caused during the  culture or purification processes.
The SE can be split into two groups based on the ir sequence identity 
(M arrack and K appler, 1990). One group consists of SEA, SED and SEE, 
with SEA and SEE sharing 85% prim ary sequence sim ilarity (Huang et al., 
1987; Couch et al., 1988; Bayles and Iandolo, 1989). The o ther group com­
prises SEB and  the  SECs which share 63% sim ilarity (H uang and Bergdoll, 
1970; Schm idt and  Spero, 1983; Couch and Betley, 1989). All the toxins
are very soluble in water and salt solutions, are heat and  protease resistant, 
and can w ithstand extrem es of pH.
1.4.3 A nim al M odels
Many species of animals including rabbits, ra ts , kittens and prim ates 
(monkeys) have been tested in a ttem pts  to provide a suitable model for 
studying the biological activities of these toxins. R abbits have been used 
to  study shock induced by bo th  TSST-1 and SE. M ulti-organ dam age at au­
topsy was shown to occur after adm inistration of toxins to  rabbits (Reeves 
et al., 1986). R ats have been used for SE work b u t they do not possess a 
vomiting response and so cannot be com pared directly. Their capacity to 
tolerate higher doses of SE, which are fatal to  rabb its , has also been noted 
(Schlievert, 1982). The results of work carried out on the k itten  model has 
been considered unreliable and therefore discredited (Bergdoll, 1983). In 
contrast hum ans and prim ates do react in a similar m anner to  challenge 
with SE. For this reason monkeys have been the anim al of choice for ex­
perim ental work (Bergdoll, 1988). In contrast w ith other toxins such as 
cholera, which induce diarrhoea via the activation of the adenylate cyclase 
pathway, the SE do not. The basis of the emetic response to  SE, once 
they have passed through the gut wall, is still unclear. It m ay result from 
binding to  local receptors in the digestive tra c t which transm it signals via 
the sym pathetic and vagus nerves to  the subcortical vomiting centre of 
the brain. Alternatively the SE may activate the  release of leukotrienes 
from m ast cells (Alber et al., 1990). Controlled experim ents in monkeys in 
which these nerves were severed, showed no signs of emesis when adm inis­
tered with SE (Alouf et al., 1991).
1.5 D etection  o f  Staphylococcal Toxins
Biological assays for the SE such as the m onkey feeding test and  k it­
ten  test are expensive and cannot be used for routine detection of these 
toxins. Furtherm ore, animals may eventually develop tolerance to  the  tox­
ins (Bergdoll, 1988). Although they do not detect the  biological activity 
of the  SE, immunological assays have been developed which can rapidly 
determ ine the concentration of toxins in num erous samples. Indeed, there 
are now m any m ethods available for the identification and quantification 
of TSST-1 and SE (T ranter and Brehm , 1994), which differ according to 
the level of sensitivity required (Table 1.2). Due to  the fact th a t these 
toxins can bring about a  response a t nanom olar concentrations, only the 
ELISA, radioim m unoassay and reverse passive haem agglutination m ethods 
are suitable for screening purposes.
1.6 C onventional A ntigens and Superantigens
Conventional peptide antigens are the degradation products of a 
m uch larger invading pathogen or protein. These immunogenic peptide 
fragm ents are recognised as a linear epitope by the  T cell receptor (TcR) 
when complexed in the cleft of a m ajor histocom patibility complex class I 
or class II (MHC I or II) glycoprotein molecule on the  surface of an antigen 
presenting cell (Figure 1.2a; Germain and M argulies, 1993). C rystal s truc­
tures of the peptide fragm ents bound to  either the  MHC I or II show how 
they become incorporated into the binding site cleft (Brown et al., 1993; 
M adden et al., 1993). There are two types of TcR , the m ost com m on is 
a heterodim er of a  and /? chains (M arrack and  K appler, 1987), the  o ther 
being 7  and S chains; the 6 is equivalent to  the a  chain and the  7  equivalent
to the (3 chain. The 7 8 TcR  are found in the peripheral blood and tissues 
(Brenner et al., 1986; Ferrick et al., 1989).
All five germline encoded variable elements of the TcR  a  and (3 he t­
erodimer: V a , Jo , V/?, D/3 and J (3 make a contribution to  recognizing 
conventional antigens in this complex (M arrack and K appler, 1987). Non- 
germline encoded amino acid residues between these different elements may 
also be involved thus increasing the num ber of possible antigens recog­
nised. Figure 1.2a shows th a t the com plem entarity determ ining regions 
(CDR) CD R 1 and CDR 2  He directly above the two a  hefices of the MHC 
II molecule. The CDR3 region, generated by the V-D-J junctional residues, 
is located above the peptide fragm ent. As a consequence of this variation, 
there are over a million possible arrangem ents of these elements which allow 
only a very small proportion of all T  cells to be activated by a conventional 
antigen. It has been estim ated th a t these conventional antigens stim ulate 
between 0.0001% and 0.01% of resting T cells (K otb, 1992).
It is generally accepted (W hite et al., 1989; Cazenave et al., 1990; 
Choi et al., 1990; M arrack and Kappler, 1990; Pullen et al., 1991) th a t 
TSST-1 and the SE have an absolute requirem ent to  bind first to  the  ou t­
side of the MHC II molecules (Dellabona et al., 1990) expressed on antigen 
presenting cells (m onocytes/m acrophages, B cells or any cell fine expressing 
MHC II molecules) before binding to the TcR  V/? gene segm ent, (Figure 
1 .2 b). The MHC I molecules do not appear to  in teract w ith SE or TSST-1 
and are therefore not necessary for T  cell activation (Fraser, 1989). Unfike 
conventional antigens, these toxins do not need to  be processed before bind­
ing to the MHC II molecule and the TcR (Carlsson et al., 1988; Fleischer 
and Schrezenmeier, 1988; Norton et al., 1990). The toxin-M HC II complex
is then recognised by the TcR, specifically those T  cells expressing a partic­
ular receptor V/3 gene sequence, which is specific to  the toxin (Choi et al.f 
1989; Kappler et al., 1989; W hite et al., 1989). The V a portion does not 
appear to  be required for superantigenic activity (Gascoigne et al., 1991). 
The different V/? specificities for the SE and TSST-1 are shown in Table 
1.3.
This trim olecular complex brings about the subsequent stim ulation, 
proliferation and thym ic deletion of large num bers of specific V/3 T  cells. 
Due to their ability to  induce polyclonal stim ulation of T  cells based solely 
on the TcR  V/? type, ra ther than  on contributions from  bo th  a  and /? 
chains, these toxins have been called ‘superantigens’ (W hite et al., 1989). 
O ther superantigens include the mouse m am m ary tum our virus, Clostrid­
ium  perfringes enterotoxin, and Streptococcus pyrogenes toxins A-C (M ar­
rack et al., 1993; Micusan and Thibodeau, 1994). Superantigens can stim u­
late between 5% and 20% of the resting T cell population even at nanom olar 
concentrations (K otb, 1992). The clinical sym ptom s of illness caused by 
the SE and TSST - 1  m ay be due to an increase in the transcrip tion activa­
tion and subsequent circulatory levels of chemical messengers, or cytokines, 
such as interleukin-1 (IL-1) and tum our necrosis factor (T N F) following 
massive T  cell proliferation (Ikejima et al., 1984; Parsonnet et al., 1985; 
Fast et al., 1989; M arrack et al., 1990; Miethke et al., 1992). Superantigens 
can also enhance the hosts susceptibility to lethal shock by G ram -negative 
endotoxins such as lipopolysaccharide (Sugiyam a et al., 1964; Schlievert 
et al., 1981). Although superantigens have been shown to  be pyrogenic 
and induce B cell proliferation and immunoglobulin secretion (Schlievert 
et al., 1981; M ourad et al., 1989; Wood and Holsapple, 1993), TSST-1
has also been shown to suppress immunoglobulin secretion. This la tte r 
property may result in the growth of Gram -negative bacteria  (Poindex­
ter and Schlievert, 1986) which may in tu rn  enhance the potency of these 
molecules. There are two m ajor differences between superantigens and 
other non-specific mitogens such as concanavalin A (ConA). F irstly  Con A 
binds directly to the TcR  and does not depend on any specific variable 
gene segment; secondly, presentation of non-specific mitogens by the  MHC 
II molecules is not necessary for stim ulation. A sum m ary of some of the 
common properties of the superantigens is shown in Table 1.4.
Studies of monoclonal antibodies to the V/3 gene segment of the  T cR  
have shown th a t almost all T  cells with a particular V/3 element are stim ­
ulated by a specific superantigen (Fleischer and Schrezenmeier, 1988; Choi 
et al., 1989; Uchiyama et al., 1991). The other variable genetic elem ents of 
the TcR: V a, J a ,  D/3 and J/? do not appear to  be involved in this binding. 
The superantigen does not bind in the groove of the MHC II like norm al 
antigens but at other sites on the molecule. There appears to  be confusion 
at present as to the requirem ent for other co-receptors, such as lym phocyte 
function associated antigen 1 and 3, in order to bring about superantigenic 
function. Some researchers suggest th a t they are not required for super­
antigenic activity (Gascoigne et al., 1991), whereas others argue th a t they 
are required for differential involvement (M itrucker et al., 1992; Lagoo et 
a l,  1994).
Although the literature contains much inform ation regarding prolif­
eration of T  cells expressing a/3 TcR  there is little reference to  proliferation 
of T  cells bearing 7 6. The la tte r do appear to  proliferate in a  similar MHC 
II restricted m anner (Fleischer and Schrezenmeier, 1988; Fleischer et al.,
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1989). R ust and co-workers (1990) showed th a t SEA had a specificity for 
the V7 9  molecule.
The toxins may induce the development of num erous T  cell m edi­
ated autoim m une diseases as a consequence of their superantigenic activity 
(K otb, 1992). These include Kawasaki disease, psoriasis and rheum atoid 
arthritis (Palliard et al., 1991; Kotzin et al., 1993). If a  dram atic  in­
crease in T  cell num bers occurs, any ‘loose’ self-T cells which have not 
been deleted in the thym us may proliferate and a ttack  the host. In a  sim­
ilar way superantigens may also be im plicated in o ther diseases such as 
sudden infant death  syndrom e (SIDS) (Telford et al., 1989; M alam et al., 
1992). Staphylococcal enterotoxins have been found in approxim ately 40% 
of SIDS cases at autopsy (Blackwell et al., 1992; M alam  et al., 1992). Most 
SIDS cases occur at a m ean age of three m onths which is a  similar age a t 
which there is m axim al expression of the Lewis blood group antigen. The 
Lewis blood group antigen cells and HEp-2 cells infected w ith respiratory  
syncytial virus have an affinity for strains of Staphylococcus aureus which 
produce enterotoxins. This ‘niche’ binding m ay allow Staphylococcus au­
reus to proliferate and secrete toxins into the  bloodstream . Clearance of 
staphylococcal enterotoxins has been shown to  occur via the kidney which 
may explain their presence in this organ at autopsy (M alam  et al. 1992). 
In such cases death  may have been due to  a com bination of lack of suitable 
superantigen antibodies, renal im m aturity  and poor toxin clearance.
The mitogenicity of the SE has been appreciated for some tim e ever 
since SEB was dem onstrated to be mitogenic for hum an cells in vitro (Peavy 
et al., 1970). SEA is the m ost potent microbial superantigen invoking cy­
tokine release a t concentrations as low as 10-12M (Carlsson et al., 1988;
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Uchiyama et al., 1989). The in vivo effect of SEA and SEB, has been 
dem onstrated  when the toxins were given intravenously to  prim ates, re­
sulting in vom iting and diarrhoea within minutes (Zehavi-W illner et al., 
1984). This was followed by a dram atic decrease of around 65% in the 
circulating lym phocytes which lasted for 24 h. These peripheral lym pho­
cytes were found to  have norm al or decreased [3 H]thymidine incorporating 
activity. This lym phopenia was followed within 48 hours by lym phocytosis 
and the resulting cells were found to incorporate [3 H]thymidine norm ally 
w ithout the  need for any external stimuli.
1.7 M ajor H istocom patib ility  C om plex Class II  M olecules
N um erous studies have been perform ed to show th a t superantigens 
need to bind specifically and with high affinity to MHC II molecules before 
they in teract w ith the  T cR  (Fraser, 1989; Mollick et al., 1989; Scholl et 
al., 1989a; K arp et al., 1990). For example, monoclonal antibodies to  
MHC II (HLA-DR) molecules which prevent whole superantigen-H LA-D R 
complex form ation have as a  result, prevented T cell stim ulation (Carlsson 
et al., 1988; Fleischer and Schrezenmer, 1988; Fraser, 1989; Janew ay et 
al., 1989; Yagi et al., 1990). Furtherm ore, the use of m u tan t cell lines 
deficient in MHC II molecules, which are unable to stim ulate T  cells, have 
shown unequivocally the absolute requirem ent for each molecule to  present 
superantigens to  the T cR  (H erm an et al., 1991a). Given this requirem ent 
for MHC II molecules it is perhaps not surprising th a t the  superantigens 
have been shown to  have a high affinity for hum an MHC II molecules, w ith 
TSST-1 having a kd of 3 x lO -8 M (M ourad et al., 1989).
Recent vrork on the in vitro binary and ternary  complex form ation
between soluble SEB, MHC II (as HLA-DR1) and the TcR  molecules, has 
cast doubts as to  the necessity of the trim olecular complex requirem ent 
(Seth et al., 1994). These workers used native gel electrophoresis and 
plasm on resonance affinity m easurem ents, to  show th a t SEB could complex 
directly to  the  T cR  w ithout the need for MHC II. However the  sam e workers 
were also able to  dem onstrate  the binding of SEB sim ultaneously to  both  
MHC II and the  TcR.
Hewitt et al. (1992) have explored the possibility th a t the MHC II 
molecule m ay be redundan t under certain circum stances. These workers 
m ade use of a T cR  V(33 region of HA1.7, which is a  hum an HLA-DR re­
stricted T  cell clone specific for influenza haem agglutinin. In  com petition 
experim ents using SEB and SEC2, they dem onstrated  unresponsiveness in 
HA1.7 by SEB even in the presence of SEC2. To confirm th a t SEB bound 
directly to  the  T cR  w ithout the need for MHC II molecules, they used an 
MHC II negative T cell line. A lthough addition of SEB to  the  transfected 
cells caused an increase in intracellular calcium ions and subsequent lym- 
phokine production, the cells also showed a down-regulation of the  TcR 
expression. F urther challenge of these cells w ith SEB indicated a decrease 
in responsiveness. From  these results Hewitt et al. deduced th a t SEB could 
in teract directly w ith the TcR without the need for any MHC II molecules 
and as a consequence induce a state  of unresponsiveness in HA1.7.
Given th a t all of the SE and TSST - 1  show this ability to  form a 
non-covalent complex w ith HLA-DR, HLA-DQ and HLA-DP (Scholl et 
al., 1989a; Scholl et al., 1990), there is a m arked difference in the capacity 
of the various MHC II isotypes to  present superantigens w ith HLA-DR^* 
HLA-DQ> HLA-DP (Scholl et al., 1989a,b; K arp, 1990; Mollick et al.,
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1991; Ram esh et al., 1992). In contrast, o ther workers have suggested th a t 
SEA binds to HLA-DR only (Fischer et ah, 1989; Fraser, 1989), and SEC2 
to  HLA-DQ only (H erm ann et ah, 1989).
The SE and TSST - 1  appear to  bind to  different sites on the MHC 
II molecules. Kappler et ah (1992) have shown th a t there m ay be two 
quite separate binding sites on the MHC II molecule. Com petitive binding 
experim ents between TSST - 1  and SEB have shown th a t these two toxins 
do not compete for binding on HLA-DR molecules (Scholl et ah, 1989b; 
C hintagum pala et ah, 1991; Herm an et ah, 1991b; Pontzer et ah, 1991; 
Russell et ah, 1992). In contrast SEA, SED and SEE were shown to  com­
pete with both  TSST-1 and SEB for HLA-DR molecules. This indicates 
th a t SEA might bind to a site on the HLA-DR molecule /? chain which 
overlaps with the site(s) required for both  SEB and TSST-1 (See et ah, 
1990; C hintagum pala et ah, 1991). Fraser et ah (1992) dem onstrated  the 
need for zinc ions for SEA and SEE to bind to  MHC II molecules b u t zinc 
or other ions were unnecessary for the proper functioning of TSST-1. Her­
m an and co-workers (1991b), and K arp and Long (1992) determ ined those 
residues on the MHC II molecule responsible for binding to  SEA and SEE. 
Thus residue 81 was m apped to an a  helix of the  (3 chain which pointed 
away from the nominal antigen binding cleft.
Work using chimeric a  and (3 chains of the isotypes HLA-DR and -D P 
molecules, expressed on m urine cells, indicated th a t the TSST-1 binding 
site was on the a  1 domain of HLA-DR molecules (K arp et ah, 1990). The 
TSST-1 molecule was found not to  bind at all to  the -DP fragm ent (K arp 
et ah, 1990). Residues on MHC II molecules th a t have been shown to  be 
im portan t for TSST -1  binding are located on the  a  helices of bo th  the
14
a  and (3 chains (Braunstein et al., 1992; Panina-Bordignon et al., 1992). 
Specifically those residues 36 and 39 which are thought to  bind TSST-1 
have been shown to point away from the a  helices involved in the peptide 
binding cleft.
The observation th a t an antigenic peptide was still capable of binding 
to  the HLA-DR cleft whilst at the same tim e binding TSST-1, suggested 
th a t the V(3 domain of the TC R  could still m ake contact w ith the a  1 
dom ain of the HLA-DR w ithout any apparent interference from  TSST-1 
(Kotzin et al., 1993).
1.8 M ajor H istocom patib ility  C om plex C lass II  Signalling
Superantigens have recently been used to  dem onstrate  th a t the trans­
mem brane MHC II molecules act as signal-transducing elements (Scholl et 
al., 1992; See and Chow, 1992; Palkam a and Hurm e, 1993; Morio et al., 
1994). The superantigen/M H C II complex differentially regulates a num ­
ber of cellular signalling events starting with tyrosine phosphorylation, gene 
transcription and eventually secretion of num erous cytokines (Lagoo et al., 
1994). Enhancem ent of cytokine production using TSST-1 can occur when 
using biotin-avidin to cross-fink TSST - 1  with the  MHC II molecules (Scholl 
et al., 1992). Suppression of tum our necrosis factor (TN F) production by 
TSST - 1  in monocytes was shown using known inhibitors of bo th  tyrosine 
kinase and protein kinase C. Interleukin - 1  production by TSST-1 was to­
tally prevented using a combination of the two previously m entioned in­
hibitors in addition to both  cyclic AMP and cyclic G M P-dependent kinase 
inhibitors.
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1.9 A ntigen P resenting Cells and T Cells
See et al. (1992) showed th a t bo th  monocytes and T  cells are required 
for TSST - 1  -induced TN F and interleukin production. Using either highly 
purified m onocytes or T cells alone in addition to  TSST-1, did not induce 
cytokine release. However, when bo th  cell types were present in a 1 : 1  ra tio  
TSST-1 induced cytokine release. In  the sam e study antibodies against 
interferon - 7  (IFN-7 ) were used to  see if this cytokine had any influence on 
the interaction between the monocyte and T  cell. A nti-IFN - 7  antibodies 
did not appear to  prevent TN F production in this system . See and Chow, 
(1992) dem onstrated th a t direct contact between the  m onocyte and T  cell 
was a prerequisite for cytokine release by using a twin com partm entalized 
culture well containing the highly purified individual cell types. Even after 
introduction of TSST-1 , no cytokines were found in the  surrounding culture 
media.
Recently Lagoo and co-workers (1994) dem onstrated  th a t in the  ab­
sence of monocytes, T cells challenged with SE undergo induction of cy­
tokine gene transcription although there is no subsequent form ation and 
release of interleukins and interferon. Gene transcrip tion  and release of 
these cytokines occurred in the presence of m onocytes which suggests th a t 
perhaps adhesion molecules present on the m onocytes an d /o r T  cell pop­
ulation are required to trigger form ation and release of cytokines from  T 
cells.
1.10 T Cell R equirem ent For Superantigenic A ctiv ity
W hite and co-workers (1989) injected neonatal mice w ith SEB only 
to find near to ta l elimination of all the m ature  and some im m ature  T  cells
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with specific V/3 types (8.1 - 8.3). They concluded th a t this clonal deletion 
resulted in tolerance to  fu rther SEB injections. Direct evidence to  support 
this hypothesis th a t an established T  cell repertoire is necessary to  bring 
about the biological reactions in response to  superantigens was revealed in 
the form of experim ents w ith mice deficient in T  cells (M iethke et al., 1993). 
W hen these mice were injected w ith TSST - 1  they showed no sym ptom s 
characteristic of the superantigen stim ulation. However if these T  cell 
deficient mice were provided with T  cells and injected subsequently with 
TSST - 1  they suffered from shock showing the typical increase in TN F and 
interleukin - 2  (IL-2 ) levels associated with superantigen stim ulation. The 
same series of experiments showed the im portance of TN F in shock, because 
those mice injected with antibodies against T N F did not dem onstrate  any 
of the sym ptom s normally associated with shock.
Further evidence for a T cell requirem ent has come from studies in­
volving the drug cyclosporin A, an active inhibitor of T  cell proliferation, 
which has been used in organ transplantation  work. Cyclosporin A has 
been used not only to  suppress cytokine mRNA expression bu t also to  pre­
vent shock (Bette et al., 1993; Holbrook et al., 1993; Miethke et al., 1993). 
This drug has also been used to  suppress arth ritis  induced by TSST-1 
(Schwab et al., 1993) which is thought to be finked to  the prevention of 
cytokine production in T  cells.
Although SEA and SEE are approxim ately 83% identical, they  acti­
vate quite different V/?s on the TcR  (Table 1.3). For example, SEA binds 
to  V/?3 bu t SEE does not; V/311 binds SEE bu t not SEA. Binding assays 
have been perform ed on a num ber of SE A /SEE hybrids in order to  m ap 
those amino acids responsible for discrim inating between the two different
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V/?s (Irwin et al., 1992; Hudson et al., 1993). The results indicated th a t 
only two amino acid residues 206 and 207, located tow ard the C term inus, 
were responsible for this discrim ination and as a  consequence m ay directly 
interact w ith the TcR V/3 a t this region.
1.11 B Cell Proliferation
TSST - 1  has been shown to bind w ith high affinity to  MHC II 
molecules on B cells isolated from tonsils (M ourad et al., 1989) although 
T cells were found to be necessary for proliferation to  occur. As a result of 
this the B cells changed into immunoglobulin-secreting plasm a cells involv­
ing both  the M H C /T SST - 1  and T cR /C D 3 complexes from  the  T /B  cell 
interaction. Immunoglobulin secretion was found to  be highly dependent 
on the ratio  of T  to B cells; secretion of im m unoglobulins decreased with 
an increase in the to tal num ber of T  cells which m ay partly  explain the 
suppression of immunoglobulin production in patients exposed to  super­
antigens.
1.12 C ytokine P roduction
In 1970 Peavy et al. described massive T  cell proliferation using SEB 
with the concom itant production of the cytokine interferon - 7  (IFN-7 ) from 
hum an lymphocytes. This activity has subsequently been found in TSST-1 
and all the known SE.
Cytokines are a group of low molecular weight glycosylated proteins 
(Mr 10 - 24 kDa) and are norm ally involved in the  immunological response 
to  conventional antigens. The complexity of the  interactions between dif­
ferent species of cytokines makes analysis of their individual roles difficult.
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The pathogenic effects a ttribu ted  to  bo th  TSST-1 and  SE m ay be related 
to  the  massive release of cytokines produced by bo th  T  cells and antigen 
presenting cells, over and above norm al physiological levels. Cytokines such 
as IN F-7 , IL -l, T N F -a  and T N F-/? are known to  be produced in response 
to  the  presence of both  TSST-1 and SE whereas: IL-2, IL-3 and IL - 6  are 
produced on exposure to  TSST - 1  alone. In addition to  the increase in cy­
tokine production in response to  superantigens there  is also an increase in 
the expression of MHC II molecules and also cell adhesion molecules (K otb, 
1992).
One of the sym ptom s of toxic shock syndrom e, hypotension, m ay be 
caused by an increase in capillary leakage and decreased vasom otor tone. 
This is thought to  be directly related to  the  secretion of IL -l and TN F- 
a . Studies on patients suffering from  toxic shock syndrom e have shown 
elevated levels of T  cells expressing V(32 and T N F -a  (Panina-Bordignon et 
a l,  1992).
1.13 Im m unotherapy
Two com pounds, caffeine and pentoxifylline, bo th  from the family of 
chemicals known as m ethylxanthines, have .been used in studies as possible 
therapeutic  agents in connection w ith their ability to  prevent T  cell prolif­
eration (Rosenthal et al., 1992). Such im m unotherapy could potentially be 
directed against autoim m une and inflam m atory diseases. An anti-idiotypic 
antibody coupled to  SEB has been used as a form  of im m unotherapy against 
tum ours in mice (Ochi et al., 1993). The results showed th a t this toxin- 
antibody conjugate resulted in a significant extension of the  life of the  mice 
and also prevented tum our growth.
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Activation of cytotoxic T cells by superantigens including the SEs is 
a ttracting  great interest as a  means of lysing tum our cells containing MHC 
II molecules (Dohlsten et al., 1991; Hansson et al., 1992). Indeed these 
experim ents showed th a t MHC II negative tum our cells in ra ts  did not lyse 
in the presence of SEA or SEB unless IFN - 7  was used to  induce MHC II 
expression in the tum our cells. Such observations suggest th a t in the  fu ture 
SEs could be used to  com bat colonic and ovarian cancers in hum ans.
In an alternative form of cancer im m unotherapy (K alland et al., 1993) 
a hybrid molecule, consisting of a colon carcinom a monoclonal antibody 
(C215) linked to  SEA, bound to and lysed tum our cells. This p reparation  
prevented any further growth of the tum our by secreting TN F and IN F - 7  
in vitro.
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Table 1.1 Current medical criteria used to confirm TSS:
Feature
Fever (>  39°C)
Hypotension (>  90mm Hg)
Diffuse erythem atous rash
Abnormal: liver, heart, kidney and  lung function
C entral nervous system abnorm alities
Subsequent desquam ation on the palm s of the hands 
and soles of the feet on recovery.
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Table 1.2 Immunological Detection Methods for Staphylococcal Toxins.




Single Gel Immunodiffusion 300-1000
Electro-immunodiffusion 500
O ptim um  Sensitivity P late 500
Microslide Technique 1 0 0
Reverse Passive Haem agglutination 0.4
Radioimmunoassay 0.3
ELISA 0 . 1
f Data from Tranter and Brehm, (1994)
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SEA 27,078 233 7.3 1.1, 3, 5, 6 ’s, 
7.3, 7.4, 9.1
SEB 28,336 239 8 . 6 3, 12, 14, 
15, 17, 20
SECl 27,496 239 8 . 6 3, 6.4, 6.9, 
12, 15
SEC2 27,589 239 7.0 3, 5, 12, 
13.2, 14, 
15, 17, 20
SEC3 27,563 239 8 .1 3, 5, 
12, 13.2
SED 26,360 228 7.4 5, 12
SEE 26,425 230 7.0 5.1, 6 ’s, 
8 , 1 1 , 18
TSST -1 22,049 194 7.08-7.22 2
f Data from Alouf et al., 1991; $ Data from Marrack and Kappler, 1990; Choi et al., 
1989; Kotzin et al., 1993.
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Table 1.4 Properties of bacterial superantigens
Feature
Polyclonal mitogen of T  cells 
Bind to MHC II molecules 
Specificity of particular V/3 gene segment on T  cell receptor 
Induce cytokine production 
Enhance host susceptibility to  endotoxic shock 
Enhancem ent an d /o r suppression of im m unoglobulin synthesis.
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SEA 1 SEKSEEINEK DLP.KKSELQG TALGNLKQIY YYNEKAKTEN KESHDQFLQH
SEB 1 . ESQPDPKPD ELHKSSKFTG L . MENMKVLY DDNHVSAINV K.SIDQFLYF
SEC1 1 . ESQPDPTPD ELHKASKFTG L.MENMKVLY DDHYVSATKV K . SVDKFLAH
SEC2 1 .ESQPDPTPD ELHKSSEFTG T.MGNMKYLY DDHYVSATKV M.SVDKFLAH
SEC3 1 . ESQPDPMPD DLHKSSEFTG T.MGNMKYLY DDHYVSATKV K.SVDKFLAH
SED 1 ............... SVKEK ELHKKSELSS TALNNMKHSY ADKNPIIGEN KSTGDQFLEN
SEE 1 . . . S E E I N E K  DLRKKSELQR NALSNLRQIY YYNEKAITEN KESDDQFLEN
T S S T - 1  1 .............................................................................................................................. STNDNIKDL
T S S T - 0  1 ....................................................................................................... ■....................  .....................
SEA 51 TIL FKGFFTD HSWYNDLLVD FDSKDIVDKY KGKKVDLYGA YYGYQCA.. .
SEB 4 8  DLIYSIKDTK LGNYDNVRVE FKNKDLADKY KDKYVDVFGA NYYYQCYFSK
SEC1 4 8  DLIYNISDKK LKNYDKVKTE LLNEGLAKKY KDEWDVYGS NYYVNCYFSS
SEC2 4 8  DLIYNISDKK LKNYDKVKTE LLNEDLAKKY KDEWDVYGS NYYVNCYFSS
S E C 3 4 8  DLIYNISDKK LKNYDKVKTE LLNEDLAKKY KDEWDVYGS NYYVNCYFSS
SED 4 6  TLLYKKFFTD LINFEDLLIN FNSKEMAQHF KSKNVDVYPI F .Y S IN C Y . . .
SEE 4 8  TLLFKGFFTG HPWYNDLLVD LGSKDATNKY KGKKVDLYGA YYGYQCA...
T S S T - 1  10  LDWYSSGSDT FTNSEVLDNS LGSMRIKNTD G S I S L I I F P S  PYYSPAFTKG
T S S T - 0  10  ---------------- A      - - -   T - S - -
SEA 9 6   GGTPNKT ACMYGGVTLH DNNRLTEEKK VFINLWL.DG
SEB 9 8  K .................TND INSHQTDKRK TCMYGGVTEH NGNQLD..KY RSITVRVFED
SEC1 9 8  K ................. DNV G K V T G G .. .K  TCMYGGITKH EGNHFDNGNL QNVLIRVYEN
SEC2 9 8  K ................. DNV G K V T G G .. .K  TCMYGGITKH EGNHFDNGNL QNVLIRVYEN
SEC3 9 8  K .................DNV G K V T G G .. .K  TCMYGGITKH EGNHFDNGNL QNVLVRVYEN
SED 9 3   GGEIDRT ACTYGGVTFH EGNKLKERKK IP IN L W I.N G
SEE 9 5   GGTPNKT ACMYGGVTLH DNNRLTEEKK VFINLWI.DC
T S S T - 1  6 0  EKVDLNTKRT KKSQHTSEGT YIHFQI3GVT NTEKLPTPIE LPLKVKV.HG
T S S T - O  6 0   1 -------------------- W--------------------- --------------------  --------------
SEA 1 3 5  KQNTVPLETV KTNKKNVTVQ ELDLQARRYL QEKYNLYNSD VFDGKVQRGL
SEB 1 4 0  GKNLLSFD. V QTNKKKVTAQ ELDYLTRHYL VKNKKLYEFN . . NSPYETGY
SEC1 1 39  K R N T ISF E .V  QTDKKSVTAQ ELDIKARNFL INKKNLYEFN . . SSPYETGY
SEC2 1 3 9  K R N T ISF E .V  QTDKKSVTAQ ELDIKARNFL INKKNLYEFN ..SSPYETGY
SEC3 1 39  K R N T IS F E .V  QTDKKSVTAQ ELDIKARNFL INKKNLYEFN ..S SPYETGY
SED 1 2 9  VQKEVSLDKV QTDKKNVTVQ ELDAQARRYL QKDLKLYNND TLGGKIQRGK
SEE 1 3 1  KQTTVPIDKV KTSKKEVTVQ ELDLQARHYL HGKFGLYNSD SFGGKVQRGL
T S S T - 1  1 0 9  KDSPLKYG. P KFDKKQLAIS TLDFEIRHQL TQ IHGLYR. .  . . SSDKTGGY
T S S T - 0  1 0 9   . -    K---------  - - T -------- . .  . . ---
SEA 1 8 5  IV FH TSTEPS VNYDLFGAQG Q Y S N . .TLL R  IYRDNKTINS ENMH. IDIYL
SEB 1 8 7  I K F I E . NENS FWYDMMPAPG DKFDQSKYLM MYNDNKMVDS KDVK. IEVYL
SEC1 1 8 6  IKFIENNGNT FWYDMMPAPG DKFDQSKYLM MYNDNKTVDS KSVK.IEVHL
SEC2 1 8 6  IKFIENNGNT FWYDMMPAPG DKFDQSKYLM MYNDNKTVDS KSVK.IEVHL
SEC3 1 8 6  IKFIENNGNT FWYDMMPAPG DKFDQSKYLM MYNDNKTVDS KSVK.IEVHL
SED 1 7 9  IEFDSSDGSK VSYDLFDVKG D FP E. .K Q LR  IYSDNKTLST EHLH. ID IYL
SEE 1 8 1  IVFHSSEGST VSYDLFDAQG Q Y P D . .TLL R  IYRDNKTINS ENLH. IDLYL
T S S T - 1  1 5 4  WKITMNDGST YQSDL.............................. SKKFE YNTEK PPINI D EIK TIEA EI
T S S T - O  1 5 4  --------------------  --------- ----------------------- ----------- --------------------  --------------------
SEA 2 3 2 Y TS.  .
SEB 2 3 5 TTKKK
SEC1 2 3 5 TTKNG
SEC2 2 3 5 TTKNG
SEC3 2 3 5 TTKNG
SED 2 2 6 YEK. .
SEE 2 2 8 YTT. .
T S S T - 1 1 94 N -------














































Figure 1.1 Amino acid sequence alignment of SEs A-E, wild type TSST-1 and TSST-O, 
produced by BESTFIT (GCG; Devereux et al., 1984). Numbers are residue numbers. 














Figure 1.2a Figure 1.2b
Figure 1.2a Represents the interaction of a conventional peptide fragment with both 
the full MHC II molecule and the T cell receptor (TcR). The peptide fragment lies in 
the cleft formed between two a  helices, one each from the a  chain and the 0  chain, 
of the MHC II molecule. The T cell recognizes the peptide-MHC II complex involving 
numerous components within the a  and 0  chain. The numbers within the TcR indi­
cate the individual complementarity determining regions (CDR) involved in Ag-MHC 
II recognition. The most important CDR for peptide recognition is CDR3 from both 
the TcR a  and 0  chains. CDR3 is made up of variations in the junctional regions from 
Va-Ja and the V0-D0-J0.
Figure 1.2b Represents the interaction between the superantigen and the peptide 
fragment-MHC II-TcR complex. As can be seen from this diagram, the superantigen 
does not bind within the cleft of the MHC II molecule as does the peptide fragment. 
The superantigen makes contact with the outer a  helical region of the MHC II molecule
and the solvent exposed face of the TcR V0  region.
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C hapter 2
P rotein  X -ray Crystallography
2.1 Introduction
The molecular structure of a protein by single-crystal X-ray diffrac­
tion consists of a time-averaged molecule, which best fits the scattered 
X-ray intensities. This average structure consists of contributions from 
m any different conformational interm ediate states which arise from  the 
tem peratu re  derived fluctuations and collective m ovements of the protein 
molecule during da ta  collection. The final static  m odel w ith its ‘ideal’ bond 
lengths and angles is a t best only one conform ation from  the m any possi­
ble and it m ust be borne in mind th a t proteins are not static even a t their 
physiological tem perature.
A lthough biological macromolecules function in aqueous solution, the 
final refined structure  of proteins in the crystal form  is still a reasonable 
representation of the protein in solution as dem onstrated  by the  crystal­
lization studies of several enzymes which were still fully active even after 
crystallization (Rossi, 1992). Protein molecules in a crystal pack together 
in such a way as to form a complex network of solvent channels through­
out the  crystal. This solvent, comprising of the m other liquor, bathes the 
protein molecules and perm its the inward diffusion of any reactants to the 
active sites, and the movement of products out. As protein crystals can 
contain anywhere between 30% and 80% solvent, it is thought th a t the 
struc tu re  deduced from the crystalline form is similar to  th a t in aqueous 
solution. This has also been dem onstrated when com paring small protein
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structures determ ined using bo th  X-ray crystallography and nuclear m ag­
netic resonance (NMR) techniques, and also from  crystal structures derived 
from different space groups.
At present, there are only two m ajor experim ental m ethods capable 
of providing a three dimensional structu re  of a biological macromolecule, 
namely X-ray crystallography (Blundell and Johnson, 1976; Methods in 
Enzymology Vol 114 and 115) and NMR. A lthough NM R provides the 3D 
structure  of the biomolecule in solution it can only yield detailed inform a­
tion for lower molecular mass proteins consisting of up to  one hundred and 
fifty amino acids residues in size. The classical technique of single crystal X- 
ray crystallography can provide a wealth of inform ation on macromolecules 
of a wide variety of sizes and also viruses. However, it can only be used if 
suitable crystals can be grown in the first instance.
Chemical reactions involve direct interactions between participating 
molecules, all of which m ust possess a  particular conform ation to  enable the 
reaction to proceed. Hence, inform ation on their three dimensional struc­
ture  could help to  explain how these molecules in teract and bring about a 
chemical change, as in the case of enzymes and their substrates. The atomic 
structure of proteins derived from X-ray diffraction pa tte rn s has led to  a 
wealth of inform ation about patterns in protein folding and protein-protein 
interactions th a t lead to the form ation of large stable biological structures.
2 . 2  B asic  T h e o ry  a n d  P r a c t ic e  o f  X -ra y  C ry s ta l lo g ra p h y
Protein structu re  can be inferred from a crystal by the way it diffracts 
a collimated beam  of m onochrom atic X-rays. A protein crystal consists of 
a periodically repeated assembly of molecules in three dimensions. This
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m eans the protein molecules in a well ordered crystal all possess the sam e 
orientation and local environm ent. The intervening spaces between the 
protein molecules are occupied m ostly by disordered solvent molecules in 
equilibrium with the crystal supernatant. In  this way the crystal diffracts 
the X-rays as a single molecule. If the  protein molecules were orientated  
randomly, as in a powder sample, the resulting diffraction p a tte rn  would 
be impossible to  interpret. X-rays are used to  achieve high resolution, or 
extent of detail, th a t can be recovered from the  crystals which obey the 
laws of diffraction. In order to ‘visualize’ the atom s in a protein molecule, 
the wavelength of the radiation used m ust be similar to  the interatom ic 
separations, for example the C-C single bond length is 1.5A (lA  =  O .lnm ). 
X-rays have wavelengths in the range 0.6 to  2.0A and are therefore suitable 
for work of this nature.
An incident beam  of X-rays will in teract w ith the atom s (or m ore 
precisely their electrons) present in a  crystal resulting in scattered rad ia­
tion, as a result of reflections from the m any planes of atom s. This takes 
the form of discrete spots which form  a diffraction p a tte rn . The periodic 
nature  of the crystals enable it to  act as a three dimensional diffraction 
grating and the resulting diffraction pa tte rn  is characteristic of the crystal 
lattice type and unit cell param eters. The reflected X-rays can reinforce 
one another in certain directions and are characterised by a location on a 
3-D grid or reciprocal lattice. This relates the orientation of the crystal and 
the angle th a t the diffracting plane makes w ith the incident X-ray beam . 
This reflection can be labeled by three integers (hkl), or Miller indices, 
which relates the position of the reflection in the reciprocal lattice using a 
common origin.
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Bragg (1913) showed th a t this reinforcem ent would only occur when 
the  rays diffracted from parallel planes have a p a th  difference of an integral 
num ber of wavelengths ie. when they are in phase w ith one another (F igure 
2.1). This can be expressed m athem atically as:
2  dhkisind = nX  [1]
where:
dhki is the  perpendicular spacing between successive planes,
9 is the Bragg angle,
n  is the order of diffraction (taken by convention to  be 1 ),
A is the wavelength of the incident radiation (in A)
Equation 1 predicts the angular position of a diffracted ray. It also 
illustrates the inverse relationship between the  crystal, in real space, and 
in diffraction space. If the resolution is given as d A, d a ta  have been 
collected to a B ragg angle 9 corresponding to  d = \ /2 s in 9 .  The intensities 
of the reflections relate to the electron density of the  atom s located on 
the Bragg plane. The low angle reflections, ie. those which deviate only 
slightly from th e  m ain X-ray beam , contribute to  the broad features of the  
electron density m ap such as the gross shape of the  protein molecule and 
the solvent; the high angle ones contribute to  the  fine detail or sharpness 
of the final electron density m ap.
2.3 Ewald Sphere
The reciprocal lattice and the Ewald sphere construction (Sphere of 
Reflection) are simple ideas to show the relationship between the planes
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in a crystal exposed to  an X-ray beam  and their potential to  satisfy the 
conditions of diffraction. The reciprocal la ttice is fixed w ith respect to  
the  real crystal lattice. Figure 2.2 describes the  diam etral plane passing 
through the Ewald sphere. The crystal is located a t the centre of the sphere 
of reflection, C, a t a  radius of j .  The point 0  is the point a t which the 
direct beam  leaves the sphere after first passing through the  crystal. 0  
is the origin of the reciprocal lattice of the crystal and this point is fixed. 
B ragg’s law is satisfied ie. a reflection will occur whenever a reciprocal 
lattice point is norm al to the (hkl) plane.
2 .4  T h e  E le c tro n  D e n s ity  E q u a tio n
X-ray crystallography ultim ately describes the electron density within 
a unit cell. Each reflection, which is periodic in na ture , can be approxi­
m ated  by sine and cosine functions. A Fourier synthesis describes such a 
periodic function and can be used to com pute the electron density m ap 
from waves w ith known am plitude and phase. A reciprocal lattice point 
(hkl)  corresponds to  one wave passing through the unit cell. The contri­
bution of the (hk l)  reflection to  the electron density is given by equation 
2 , otherwise known as the  electron density equation:
Phki (xyz)  = l-F (h k l)e ia(kkl'>e-2,'i<-hx+ky+lz'> [2]
where:
V  is the volume of the unit cell
F (h k l)  is the  am plitude of the diffracted wave.
a (h k l)  is the phase angle of the wave relative to  the origin of the cell,
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hkl are the indices of the diffracted wave arising from planes dhkl
In order to  calculate the electron density bo th  the  am plitude and the  phase 
of each reflection m ust be known. The am plitude is calculated from  the 
experim entally determ ined intensities using:
I(h k l)  oc F (h k l)2 [3]
Due to  the technical lim itations of d a ta  collection equipm ent routinely used, 
the phase of the reflections cannot be recorded, and constitutes the ‘phase 
problem ’. Unlike the light microscope, the image cannot be focussed using 
X-rays therefore the ‘phase’ of structure  factor vector has to  be determ ined 
using other techniques, namely isomorphous replacem ent or molecular re­
placem ent. These two techniques are discussed in m ore detail in Sections
2.9.1 and 2.10.
The wave scattered by the contents of the unit cell in the direction 
of the hkl reflection is described by the structure  factor F  (hkl):
F (hkl) = F (h k l)e ic,<-hkl) [4]
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The electron density equation can also be rew ritten  to  involve con­
tributions of the single atom  j  within the unit cell giving reflection (hkl):
N
F (h k l )  =  Y j f j { h M ) e 2*i(hxi+kviJrlzi) [5]
i=1
where:
N  sum m ed over all atom s in the  unit cell 
j  is the jth  atom  with coordinates ( x j , y j , Zj )  
f j  is the atomic scattering factor of the  j th  atom .
This equation indicates th a t the diffraction p a tte rn  can be calculated given 
th a t the coordinates of all the contributing atom s w ithin the  unit cell are 
known.
2.5 Steps in X -R ay Structure D eterm in ation
There are m any stages involved in the X -ray s tructu re  determ ination 
of a  new protein including:
• Protein preparation,
• Crystallization,
• D ata collection,
• D ata processing,
• P reparation of heavy atom  derivative,
• Calculation of phases,
• In terpretation of the electron density m aps,
• Refinement of the structure,
• Analysis of the final structure.
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Figure 2.3 is a flow chart describing the different stages in the elucidation 
of a  protein structure. The rest of this chapter deals w ith the basic stages 
involved in structure  determ ination.
2.6 C rystallization
In order to  determ ine the structu re  of a homogenous purified pro­
tein it is necessary to produce diffraction-quality crystals of the protein. 
Crystallization consists of those precise conditions under which the weak 
interm olecular forces between molecules of the  protein produce a highly or­
dered packing as a  crystal ra ther th an  as an am orphous precipitate. This 
stage is perhaps the rate-lim iting step in the  s tructu re  determ ination of 
any protein.
There are no standardised procedures for obtaining good quality crys­
tals suitable for X-ray diffraction because of the  large num ber of factors 
th a t can be varied eg. tem peratu re, protein concentration and buffer pH 
etc. The classical vapour diffusion hanging drop and sitting drop tech­
niques have been frequently used to  produce crystals of the required qual­
ity (M cPherson, 1990). This procedure requires the supersaturation  of 
a crystallization drop which produces few subsequent nucleation sites for 
crystal form ation and gives steady sustained growth. The advantage of this 
m ethod is th a t it requires only sm all am ounts of m aterial and is suitable 
to  screen large num bers of conditions. Recently a  sparse m atrix  sampling 
system  such as the ‘Magic 50’ (Jancarik  and Kim, 1991) and crystal screen 
I and II (H am pton Research, USA.) have been devised to  screen m any of 
the factors involved in crystal form ation. It involves producing 50 reservoir 
stock solutions containing various salts, precipitants and buffers.
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The hanging drop m ethod usually consists of mixing small am ounts 
of the reservoir solution with equal volumes of the  protein stock solution 
at a concentration of 15-20mg/ml on a plastic or siliconized coverslip. This 
is then  inverted and sealed over a greased well of a Linbro plate (Flow 
Labs) containing 0.7ml of the reservoir solution. The drop is allowed to 
equilibrate with the reservoir at different tem peratures. Visual inspection 
of the drop is perform ed using a microscope at least once every three or 
four days. For exposing to X-rays, the crystal is then  carefully drawn up 
into a  quartz capillary tube and the ends sealed w ith beeswax.
2.7 D ata  Collection and Processing
The first stage in solving the X-ray struc tu re  of a  protein molecule is 
d a ta  collection and processing in order to  characterise the unit cell param ­
eters (lengths a , 6 , c and angles a , /? ,7 ), determ ine the  internal sym m etry 
and find out to w hat spacing the crystal will diffract on an X-ray detector. 
The second stage is to systematically record as m any reflections in as short 
a tim e as possible because of the sensitivity of biological macromolecules 
to  the destructive free radicals produced by X-rays (Helliwell, 1992). In 
any d a ta  collection run, m any thousands of reflections will be generated 
and each m ust be indexed (hkl) and its intensity determ ined.
The crystal is m ounted on a goniometer which is then  m ounted onto 
the stepper m otor of the diffraction apparatus. T he distance between the 
crystal and detector face has to be altered to  produce a clear and unam bigu­
ous separation of the adjacent diffraction spots on the diffraction image. If 
the unit cell param eters are unknown, this distance has to  be determ ined 
by trial and error but once the prelim inary param eters have been deduced
35
the empirical form ula used for setting this distance is to  divide the largest 
unit cell param eter by eight and then  give it units of m m .
Once the unit cell param eters are known it is necessary to  determ ine 
the swing angle (20) of the area detector w ith respect to  the incident X-ray 
beam . Using a steady increm ental increase in 29 the  m axim um  resolution 
can be determ ined. The exposure tim e per oscillation range given for each 
fram e of da ta  m ust also be determ ined. Using too short an exposure may 
prevent accurate detection of any reflections; too  long an exposure will 
inevitably lower the lifetime of the crystal by the  form ation of free radicals. 
Normally the crystal tends to  be oscillated a  num ber of tim es w ithin each 
oscillation range, to  sm ooth out any fluctuations caused by variations in 
the X-ray beam.
Once the reflection positions and intensities have been recorded, op­
erations such as statistical corrections for absorption, scaling and merging 
of the da ta  have to  be perform ed. The ability to  collect and process da ta  
is directly related to the increase in sophistication in not only the software 
and algorithms bu t also in com puting capacity available to  the crystallog- 
rapher.
2.8 P h oton -D etection  Equipm ent
2.8.1 Area D etector
The area detector is an electronic device used to detect photons 
diffracted by a crystal. The monochrom atic X-ray beam  is generated by a 
ro tating anode em itting C uK a radiation with a  wavelength of 1.5418A. The 
selected wavelength is obtained by use of a graphite  m onochrom ator. The 
diffracted X-rays cause ionization of the  high pressure (4 a tm ) xenon gas
contained within the unit. This ionization event occurs once the diffracted 
rays have passed through the beryllium window. The electrons thus pro­
duced are then accelerated to  the anode wires found within the cham ber, 
thereby causing secondary ionization and hence amplification of the signal. 
The precise 2  D position of the ionization event is determ ined by a set of 
m utually perpendicular wires within the cham ber. The photon position is 
then  determ ined on a 512 x 512 grid and stored in the com puter.
2.8.2 Im age P late
The MAR Research image plate is a fully autom atic  high perform ance 
electronic device which tem porarily stores the X-ray reflections on a  fixed 
phosphorescence screen, in the form of colour centres. The screen is then 
‘read ’ by a scanner (M AR Research M anual; Helliwell, 1992) consisting 
of a  H e/N e laser light which then converts the reflections into a  digital 
signal in the form of a 1200 x 1200 pixel m atrix . The intensity of the 
luminescence is proportional to the num ber of absorbed X-ray photons. 
This read-out system is highly efficient, with a high signal to  noise ratio, 
and takes only ~90s between successive images to  read and then  erase the 
image. Com pared to film, the image plate is free from  chemical fog and 
spatial distortion and is reusable. This detecting device has an extremely 
low intrinsic noise level and coupled w ith its high spatial resolution is useful 
when processing data. As a result of im provem ents in the m aterials used, 
the exposure times have been reduced by a t least a factor of 1 0  when 
com pared to  film (Helliwell, 1992).
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2.9 Phase D eterm ination
2.9.1 Isom orphous R eplacem ent
Isomorphous replacement is an ab initio  m ethod to  obtain  initial es­
tim ates of phases for a novel protein ie. the first protein in a family (Green 
et al., 1954; Bailey et a l ,  1988; Wolf et al., 1991). All atom s within a 
protein contribute to  the diffraction p a tte rn , and this technique relies on 
the fact th a t the introduction of one or two heavy m etal ions a t identical 
sites throughout the crystal will subtly change the  resu ltan t diffraction p a t­
tern. From these slight changes in the  diffraction p a tte rn  the heavy atom  
positions can be calculated using a P atterson  function from  which initial 
estim ates of the phases can be determ ined.
This process involves soaking native protein  crystals w ith a  heavy 
m etal, such as Hg, U or P t (Petsko, 1985). It is generally accepted th a t 
m ercury ions bind to disulphide bonds in proteins. D ata  collection sim­
ilar to th a t for the native protein m ust then  be perform ed for the heavy 
atom  derivative to verify th a t the heavy atom s do not alter the unit cell 
param eters determ ined for the native crystal, ie. they  rem ain isomorphous.
2.9.2 H eavy A tom  D erivative Preparation
Native crystals surrounded by a m inim um  am ount of m other liquor 
are placed on a glass plate inside a hum id cham ber to  prevent dessication 
of the crystals. This process is usually visualized by use of a light m i­
croscope. Next, the crystal plus the ‘derivitized’ artificial m other liquor 
are transferred to  a microbridge (Harlos, 1992), which is then  placed in a 
well containing 0.7ml of the artificial m other liquor, sealed w ith a  coverslip
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and stored at 16°C. Inspection of the derivitized crystals can be perform ed 
after one hour and then for regular intervals thereafter. Any potential 
heavy atom  derivative crystals thought suitable for continued isomorphous 
replacem ent m ust then be carefully transferred  to  a  quartz  capillary tube, 
sealed and m ounted on a detector/im age plate  for d a ta  collection.
2.9.3 C alculation o f P hases From  D erivative D ata
The first stage in calculating the phases is to  determ ine the structure  
factor contribution for a particular reflection from  the native data, heavy 
atom  derivative and the heavy atom , which are F p  F p h  5 F h  respectively. 
Assuming ‘ideal’ isomorphism they are related by the equation:
Fph = Fp + F h  [6]
This shows th a t they are additive vectors and can be represented 
graphically by Figure 2.4. F h  cannot be directly m easured b u t it comprises
of only a few atom s in the unit cell and can be calculated providing th a t
its refined coordinate positions are known.
2.9.4 H eavy A tom  Positions in the U nit Cell
To determ ine the positions of the heavy atom  within the unit cell 
use is m ade of the P atterson  function P (u v w ), a variant on the electron 
density equation using structu re  factors:
P (uvw )  =  ^ £ E E F L e~2’ri('‘U+fc',+‘“’) [7]
h k I
The coordinates (u v w ) locate the heavy a tom  positions in a Patterson
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m ap. It uses as coefficients the squares of the m easured s tructu re  factor 
am plitudes only ie. it does not require any phase inform ation. The posi­
tions of the m axim a represent the vector end points between the particu lar 
atom s referring to a common origin. In this instance a difference P atterson  
function is calculated ie. (Fp h  — F p )2. The result of this is a  contour m ap 
with peaks a t positions of the vectors between atom s.
2.9.5 M ultiple Isom orphous R eplacem ent
This classical m ethod is still widely used to  solve the phase problem . 
It requires a second isomorphous heavy atom  derivative w ith the heavy 
atom s binding at different sites to the first derivative. The phase prob­
lem can be solved by collecting two heavy atom  derivative d a ta  sets w ith 
struc tu re  factor am plitudes F p h i  and F p h 2 (where P H I is from  the  first 
derivative and PH2 from the second) and determ ining the  contributions 
of the separate heavy atom s within their refined positions F h i  and  F h 2 
(Figure 2.5). This construction w ith the origin a t 0  has a  circle of radius 
Fp  drawn around it. Two vectors — F # i  — F jf 2 are draw n from 0  and 
form the origin of two other circles w ith radii F p h i  and F p h 2 respectively. 
Assuming the two derivative crystals are perfectly isom orphous w ith the 
native crystal, the three circles drawn in Figure 2.5 should intercept exactly 
a t one point, X. The vector OX will therefore coincide w ith the struc tu re  
factor of the protein. From this the initial phase angle can be estim ated.
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2.9.6 E stim ation  o f  the Isom orphous D ifferences
The next stage of d a ta  processing is to  scale the  derivative d a ta  to  
th a t of the native d a ta  using the Wilson scaling equation:
( K Z ' i f  = [8 ]
where the factor k is chosen to minimize the  sum  of the squares of the 
differences between the native and scales derivative intensities and B  is the 
tem perature factor.
E rror estim ates for the rms isom orphous error E  m ay first be deter­
mined using the equation:
E 2 =  X)(I-Pph ±  e h  I f / N  [9]
using the centric refinement on all the  sites. The occupancies for the  heavy 
atom s can be estim ated using the param eters of centric refinem ent. Using 
small intervals, the phase probabilities can be calculated and any m easure­
ments deemed im probable rejected. The E  values can be reassessed during 
refinement using the equation:
E 2 =  y ^(EpH(gba) — FpH( Calc))2 / N  [10]
2.9 .7  Interpretation  o f  the D ifference P atterson  M aps
W hen the positions of the heavy atom  sites in a crystal have been 
accurately located protein phase inform ation can be determ ined by the
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m ethod of isomorphous replacem ent. The P atterson  function is based on 
the squares of the differences in the am plitudes between two sets of data. 
The difference Patterson  m ap consists of the peaks corresponding to  vectors 
between heavy atom  sites given bo th  the native and heavy atom  derivative 
data. A significant m ean fractional isom orphous difference (M FID) value 
w ith one or two heavy atom  sites per asym m etric unit should result in a 
few strong peaks which are visible on the Harker sections of the difference 
m ap. From these peaks, the heavy atom  positions can be in terpreted. If 
m ore th an  this num ber of heavy atom  sites were present per asym m etric 
unit then  inspection of the peaks found a t the  general positions in the 
difference Patterson  m ap would correspond to  the  cross vectors between 
the non crystallographically related sites.
2.9.8 H eavy A tom  P aram eter R efinem ent
If the heavy atom  structure  factors F h  are known, then  the protein 
phase angles a p  can be estim ated from  the m agnitudes of bo th  the native 
and derivative structure  factors F p  and F p h -  In. order to  calculate these 
heavy atom  structure factors, their positions, degrees of substitu tion and 
therm al param eters should be accurately known for all the bound heavy 
atom s.
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2.9.9 P hase R efinem ent
The initial multiple isomorphous replacem ent protein phases can be 
calculated from a trial set of heavy atom  param eters. E rror estim ates for 
the rm s isomorphous error E  can be determ ined using the equation:
=  £ ( ! * « *  ± J ! jH ) j /W  [1 1 ]
using the centric refinement on all sites. T he occupancies for the  heavy 
atom s can be estim ated using the param eters of the centric refinement. 
The E  values are reassessed during the refinem ent using the  equation:
E 2 = YXFpHiobs) — FpH(caic))2 / N  [12]
2.9.10 P hase Im provem ent
The initial phases derived from multiple or single isom orphous re­
placem ent are usually not of sufficient quality to  produce an in terpretable 
m ap. This is due in part to  errors present in the  phase estim ates. Therefore, 
techniques such as solvent flattening and m olecular averaging are used to 
improve and extend the low resolution m ultiple isom orphous replacem ent 
phases, to  give an interpretable m ap.
2.9.11 M olecular Averaging
M any proteins crystallize in such a way th a t the  asym m etric unit 
contains more th an  one molecule. In this instance there is a redundancy of 
d a ta  which can be processed using a m ethod known as molecular averaging
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(Bricogne, 1976). This technique requires a m atrix  to  ro ta te  one copy of the 
molecule onto the others within the asym m etric unit. Using the unphased 
d a ta  requires analysis of the interatom ic vectors of the  P atterson  m ap. 
Although this technique is very useful in reducing the  phase errors when 
there are multiple copies of the molecule available it does often result in a 
ra ther high noise level complicated by the interm olecular vectors.
If the d a ta  is of sufficient quality, phases can be extended to  a res­
olution beyond those used to  determ ine the initial electron density m ap. 
This involves using phases derived from a small band  of struc tu re  factors 
ju st beyond the resolution limit used in the previous cycle of refinement. 
They are then combined with their corresponding experim entally deter­
mined am plitudes during the next cycle in the procedure.
2.9.12 The Solvent F latten ing P rocedure
In order to  improve the molecular averaging technique, a  solvent en­
velope or m ask is required (W ang, 1985). This envelope, surrounds the 
protein molecule around the molecular boundary between the ordered pro­
tein molecule and the disordered solvent. The envelope is exploited to 
reduce the noise by averaging out, am ongst the  other molecules in the 
asym m etric unit, and thereby sm oothing the m ap for a low resolution im ­
age of the protein. This technique assumes th a t even if noise is present, 
the density of the protein molecule will be m uch higher th an  th a t found 
within the solvent region. This region outside the protein density can then  
be set to zero and any negative density truncated . Each point w ithin the 
protein envelope, as designated by the density in a  sphere of known radius 
is averaged and the actual value for th a t point is then  replaced by the  av­
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eraged value. This results in the generation of a  new electron density m ap 
where the density at each point is now proportional to  the sum  of the  high 
density level in the sphere surrounding it. The molecular boundary of the 
molecule can be determ ined by setting a density level which is based on 
the experim entally estim ated solvent content of the  protein crystal.
This m ethod, which works best for high solvent content crystals 
(>55% ), entails generating a molecular boundary or envelope around each 
molecules’ electron density within the asym m etric unit of the initial m ul­
tiple isom orphous replacement m ap, ie. the  ‘p ro te in ’ region. Next the 
electron density outside this boundary, the solvent region, is set to  a con­
stan t value ie. solvent flattening (W ang, 1985). This newly modified elec­
tron  density m ap is then inverse transform ed to  generate a modified set 
of intensities and phases. The original m ultiple isom orphous replacem ent 
phases are then  combined with those of the modified m ap in order to  gen­
erate  a new ‘im proved’ electron density m ap. Making the solvent region 
‘red u n d an t’ can reduce some of the spurious noise and discontinuous re­
gions generated from the original multiple isom orphous replacem ent m ap 
thus im proving the quality of the electron density m ap. This procedure 
would then  be repeated a num ber of times in com bination w ith the molec­
ular averaging procedure to  produce a good quality electron density m ap 
which could be used for m ap in terpretation.
2 . 1 0  M olecular R eplacem ent
Molecular replacem ent can also be used to  determ ine the initial 
phases of an  unknown structure  (Rossm ann, 1972; M achin, 1985; D od­
son et al., 1992; Navaza, 1994). This knowledge-based technique requires
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a well refined search model which is similar to  the  unknown. Molecular 
replacem ent depends on optimizing bo th  the  orientation (ro tation  func­
tion) and position (translation function) of the  search model in the unit 
cell of the unknown to provide the best correlation between the  observed 
and calculated diffraction data. This is perform ed using a P atterson  search 
technique. In the case of the ro tation function the  search m odel orientation 
is altered until its calculated Patterson  function is ‘identical’ to  th a t of the  
unknown. The translation function is similarly determ ined and when this 
is complete a rigid body refinement is perform ed on these positional pa­
ram eters. There are m any problems with this technique, such as obtaining 
a sufficiently similar or homologous search m odel to  th a t of the unknown. 
This will eventually lead to a list of possible peak solutions, and requires 
a significant am ount of in terpretation to  obtain the correct solution.
It is im perative to obtain a good search m odel based not necessarily 
in term s of amino acid sequence b u t on the s truc tu ra l identity between 
two molecules. It is necessary to use a refined protein struc tu re  a t the 
highest resolution possible because the m ethod of molecular replacem ent 
constantly makes comparisons between observed experim ental d a ta  and 
predicted d a ta  calculated from the refined search model. If a  protein s truc­
ture  is obtained using a poor search model then  the  subsequent phases will 
be poor estim ates of the actual phase. These phases will be heavily bi­
ased towards the search model and therefore potentially difficult to  refine. 
A part from not using a sufficiently good search model, another reason for 
the failure of this technique may result from using poor quality da ta . This 
technique is powerful enough to use only a  p a rt of the search m odel in 
order to get initial phase estim ates.
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In order to  correctly superim pose a known structu re  in the  unit cell 
of the unknown and obtain a good m atch, the  search m odel m ust undergo 
a six-dimensional search. This can be split in to  two parts . The first is a 
rotation function perform ed by use of three variables in order to  correctly 
orientate the molecule. Secondly, a  translation function is perform ed, using 
three o ther variables, the distances, in order to  correctly position the  search 
model in the unit cell of the unknown. W hichever direction the search 
model is ro ta ted  and translated  it always requires these six variables to 
completely describe the operation in moving one set of coordinates over to 
the unknown. Simply stated , if X orjs represents the  vectors describing the 
atom s of the search model and X  the transform ation:
X  =  [C]Xorig +  T
where:
[C] is the rotation m atrix  X o r , 5 determ ined in the first stage of molec­
ular replacement into its new orientation,
T  is the translation vector determ ined in the  second stage.
Equation 13 will therefore minimize the difference when a comparison is 
m ade between the F0 and Fc. At present this function cannot occur in one 
move and it m ust be split into two parts: the  ro tation  function and the 
translation function. The action of splitting the transform ation into two 
parts enables a potential solution to  be determ ined whilst simultaneously 
being more frugal with com puter tim e and can be achieved by use of the 
P atterson  function. Only two functions are necessary to  define the position 
of proteins because amino acids usually exist in the  L-form and only by the
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introduction of m irror planes would create the  D-form. Once the search 
model has been optim ally orientated and positioned in the unit cell, the 
initial phases can be calculated for subsequent crystallographic electron 
density m ap fitting.
2 . 1 0 . 1  T h e  R o ta t io n  F u n c tio n
The rotation function is used to  locate common vectors w ithin a 
crystal. The rotation search is perform ed over all possible rotations in 
order to highlight any overlap between the two functions:
R (C ) =  P ( uviu) P i (ut;u;) [14]
where:
P ( u v w ) is the Patterson  function to be exam ined,
Pa- the Patterson  function corresponding to  the  sam e P atterson  func­
tion having been related by the necessary angles.
Patterson  functions use experim entally derived data , in the form  of 
intensities w ithout the need for any phase inform ation and as such repre­
sent the vectors between elements of the scattering density. The Patterson  
function consists of two parts. Firstly those vectors within one protein 
molecule ie. intram olecular vectors which are confined to  a  sphere centred 
on the origin of the P atterson  m ap and secondly those vectors between 
identical molecules within the asym m etric unit ie. the interm olecular vec­
tors.
By carefully choosing the P atterson  radius, and thereby reducing 
the interm olecular vectors, the chances of obtaining a good ro tation  peak
48
search can be increased. One other variable to  be considered is the  choice of 
resolution ranges. High resolution (> 3 .5A) reflections describe the actual 
conformation of the residues while low resolution reflections ( 1 0 —3.5A) 
describe the general relationship between secondary structu re  elements to  
be found within the molecule. The ro tation  function will have a  m axim um  
when all the self vectors of one P atterson  exactly coincide w ith those of the 
second. The fast ro tation function can also be considered as a sum m ation 
of intensities and the strongest reflections contribute significantly when 
com pared to the weak ones. It is therefore advantageous to  include all 
the strong reflections and reduce or omit the  weak ones. This will allow 
enough reflections to be used to represent the  d a ta  set collected without 
the function being dom inated by only a few strong term s.
2.10.2 The Translation Function
The quality of the rotation function heavily influences th e  quality of 
the translation function. Once the orientation of the  search m odel has been 
established in the unknown unit cell, the next three variables to  determ ine 
are the relative positions of the m odel coordinates. Once the search model 
has been correctly positioned, all the rem aining sym m etry related molecules 
can be generated. From this the calculated P a tte rson  cross vectors can be 
com pared with the observed P atterson  vectors. Self vectors can be ignored 
due to the fact th a t they are insensitive to translation  bu t do form  p art of 
the background.
The initial step in molecular replacem ent is to determ ine the centre 
of mass of the search model, place it a t the  origin of an artificial unit 
cell P I  and calculate its structu re  factors which will then  be used for the
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ro tation  function search. The search model is ro ta ted  in small increm ents 
so as to cover as much volume as possible about the space group of the 
unknown structure. After each small increment a system atic inspection is 
m ade of the m atch between the  search model and the  P atterson  m ap of 
the  unknown. A peak list is then  provided which indicates the agreement 
relative to the origin. Evidence for a good agreement m ight consist of a 
single large peak above background.
A num ber of factors need to be taken into consideration when deci­
phering the output. If no obvious peaks are produced then  the resolution 
range should be altered. Should this again fail, an a ttem p t should be 
m ade on an alternative search model. Altering the original search model 
m ay hold the key in determ ining the correct rotation function solution. For 
instance, assuming the search model has its complete am ino acid sequence 
m ay help. Reducing all the side chains to its 0(3 a tom  m ay reduce any 
unw arranted bias providing m ore detail in emphasising similarities in the 
secondary structure elements.
2 . 1 1  Interpretation  o f  the E lectron D ensity  M ap
After the initial electron density m ap has been produced the protein 
m ain chain may be m anually added to the available density w ith sufficient 
fit to  produce an atomic model using a dedicated com puter graphics system  
(Jones, 1985). The ease a t which the model building can be achieved, to  
give reasonable stereochem istry, is determined by the  accuracy with which 
the phase estim ates have been generated by either isom orphous or molec­
ular replacement. If the d a ta  are of sufficient quality and the resolution 
is high then features like a  helices or (3 strands m ay be discernable. The
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continuous nature  of the electron density m ay allow a significant portion 
of the m ain chain to be built.
2.12 R efinem ent
The first atomic model obtained from an initial electron density m ap 
usually contains a num ber of errors which do not closely follow the  ex­
perim entally determ ined structure factors and thus m ay not be sterically 
correct (Briinger and Nilges, 1993). This is because m axim um  resolution 
is not high enough to position individual non-hydrogen atom s bu t only 
the gross m ain and side chains. The purpose of refinement is to  im prove 
the overall chemistry of the molecule with respect to  the  agreem ent be­
tween the observed structure  factors and those calculated for the  m odel by 
minimizing the energy. (Briinger et al., 1987).
The conventional refinement protocol of a  proposed model m ade use 
of a m ethod known as least squares. This technique required m any cycles 
of refinement followed by an extensive m anual rebuilding on a dedicated 
com puter graphics system. One disadvantage w ith this m ethod was th a t it 
required extensive reinterpretation of the m odel w ithin its electron density 
m ap. Furtherm ore the small radius of convergence prevented good resolu­
tion of any residues lying at a distance > lA  from  their correct positions. 
Such residues rem ained trapped  in a local m inim a and required m anual 
intervention.
In recent years, a technique known as sim ulated annealing (K irk­
patrick et al., 1983) has superseded the least squares m ethod of refin­
ing protein molecules, which only allows a downward descent in energy. 
This new technique simultaneously uses m olecular dynamics and crystal-
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lographic refinement to  explore a  greater conform ational space th an  could 
ever be achieved using the old m ethod (Briinger et al., 1987; K arplus et 
ah, 1987; Goodfellow et ah, 1989; Brunger and Nilges, 1993). The m ain 
advantage lies in the fact th a t the local m inim a problem  is overcome.
One such refinement program  is X PLO R  (B runger, 1988; Version 
2.1). This program  perform s least squares refinem ent in addition to  the  
sim ulated annealing refinement via molecular dynamics which increases 
the radius of convergence. The surface potential energy of the protein 
can be expressed as a function of the atom ic coordinates of the model 
(Karplus et ah, 1987). Refinement using molecular dynamics and sim ulated 
annealing are perform ed by solving Newton’s equations of m otion in order 
to  determ ine the change in atomic position w ith respect to  tim e.
Empirical energy functions are required in order to  establish the 
global m inim a of the model using the following equation:
E iota l = Eem pirical “H E xra y  [1 ]^
where:
Eem pirical includes empirical energy inform ation on all chemical in­
teractions of the model,
E xray denotes the squared differences between all observed and cal­
culated diffraction d a ta  using an appropriate weight.
This empirical energy function (or geometric term ) can be fu rther broken 
down into the atomic coordinates describing the  covalent interactions as 
well as the non-bonded interactions (hydrogen bonds, electrostatic and
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Van der W aals), in the form of Cartesian coordinates.
Eempirical = K t (b  -  b#)2 +  K ) ( 9  -  0o) +  K j (  1 +  COs(n<j> — S))
, (  A  C  , ?192\ r1fil
+  [i6 l
where:
b is the internal coordinates for the bonds,
A ,C  are Lennard-Jones param eters, 
q the atomic charge,
D  dielectric constant,
0 is the bond angle,
(f> are the dihedral angles,
r is the interatom ic distance for any given geom etry R
The E xray is the crystallographic residual which is form ed from  the  squared 
differences between the observed F0 and calculated Fc struc tu re  factor am ­
plitudes sum m ed over all reflections:
Etray = (Fa -  kF cf  [17]
where:
fc is a scale factor used to minimize the residual.
Having got the coordinates of the atom s, X PL O R  assigns random  veloci­
ties to each atom . The refinement then  proceeds by using an energy m in­
imization program  which relieves bad contacts and  stresses caused by any 
non-bonded contacts.
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2 . 1 2 . 1  Sim ulated A nnealing
Sim ulated annealing uses molecular dynam ics and can prevent prob­
lems associated with local minima. It has been described as being similar 
to  a process in which a protein, in a  ‘heat b a th ’, can be heated to  ex­
trem e conditions (around 4000AT) which allows all the constituent atom s 
to  move random ly in the liquid phase. The next step is for a  ‘slow cool­
ing’ (or annealing) of the protein in the b a th  to  prevent the model from 
remaining in an incorrect state. This allows all the  atom s to  rearrange 
themselves into the lowest energy sta te  by having access to  smaller re­
gions of conformational space and have a lower global m inim a th an  before. 
This im provem ent over previous m ethods allows for a  global exploration of 
conformations even in an ‘upw ard’ direction.
2.13 A nalysis
The final stage in the structure  determ ination of a protein molecule is 
to  assess the quality of the final model. The m odel m ust be chemically, con- 
formationally and stereochemically correct. The bond angles and lengths 
should contribute to  a chemically acceptable model. The conformationally 
reasonable model m ust have planar peptide bonds and residues th a t (usu­
ally) exist in the trans conformation; the side chain torsional angles m ust 
be in the staggered conformation.
A num ber of techniques exist to  judge the  quality of a  model, which 
include the R am achandran plot (R am achandran and Sasisekharan, 1968) 
and the crystallographic reliability index or R-factor. The R am achandran 
plot dem onstrates the allowed pairs of angles (<£,-0 ), for each amino acid 
residue in the model. The plot then indicates w hether the specific backbone
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conform ational angle exists in an ‘allowed’ or ‘disallowed’ region. By sys­
tem atically determ ining those residues th a t lie outside the  allowed region 
from the plot and then locating th a t residue on the  model, subtle changes 
can be m ade to  these residues in order to  bring them  back into the allowed 
region and hence improve the overall accuracy of the model.
The m ain system  used to assess the accuracy of a model is the  R-  
factor which can be calculated from the following equation:
j-£ _  XXI Fob* 1 1 Fcalc 1) ^gj
X) I Fobs I
where:
F0ba are derived from the experim entally m easured reflection in ten­
sities,
Fcaic are the am plitudes derived from the  latest model.
The 5-factors can have values ranging from  0 to  1 w ith a value of 
0  indicating a perfect agreement between the observed and calculated am ­
plitudes. A value of 0.5 suggests a ra ther poor m odel w ith little hope for 
im provem ent even with alterations m ade to  the structure . In a well re­
fined s tructu re  to  2.5A one would expect an 5 -fac to r of ~20%. It has been 
shown th a t poor search models can in fact be refined with apparently  good 
5-factors (Branden and Jones, 1990). The root m ean square deviation 
from the  ideal for bond angles and bond length should be less th an  4° and 
0.02A respectively. Another analysis param eter used is the  tem peratu re  
factor or 5 -fac to r for each atom . This is a m easure of the ‘m ovem ent’ of 
the atom  about a fixed point. Therefore side chains would be expected to  
have m ore freedom of movement th an  say a m ain chain atom . If there are
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multiple copies of the molecule within the asym m etric un it, a comparison 
should be m ade between these molecules. In this instance, the differences 
in the atomic coordinates should be less th an  0 .2 A.
2.14 A im s o f  th is S tudy
Toxic shock syndrom e toxin-1 and the SE possess several properties 
th a t are of clinical interest both  in causing disease and as potential thera­
peutics. The initial aim of this project was to  produce enough pure toxin 
(TSST-1 , SEA, SEB and SEC2) to initiate crystallization trials. Having 
produced good quality crystals, s tructure  determ ination was carried out. 
The structural aspects of these molecules determ ined by X-ray crystallog­
raphy are im portan t in identifying regions on these molecules which are 
involved in binding to  MHC II and TcR. Such a study  m ight form a basis 
for detailed protein engineering experim ents in an  a ttem p t to  understand  
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F ig u r e  2 .4  A n idealised phase triangle used to  re la te  b o th  th e  native  (Fp) and  heavy 
atom  derivative (Fppr) s tru c tu re  factors for each reflection, assum ing perfect isom or­




F ig u r e  2 .5  A construction  for phase de term ination  by th e  m ethod  of m ultiple isom or- 
phous replacem ent. T he heavy atom  derivative con tribu tions are given by -F jy . T he 
unequivocal phase F p  is given by O X .
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C hapter 3
3.1 Purification, C rystallization and S tructure D eterm in ation  o f  
Toxic Shock Syndrom e Toxin-1
Toxic shock syndrom e toxin- 1  (TSST-1 ) and  all of the staphylococcal 
enterotoxins (SEs) have been purified to homogeneity. Since the first en- 
terotoxin (SEB) was purified (Bergdoll et al., 1959) the protocols used have 
been simplified. Early procedures tended to  contain m any tim e consuming 
steps which add to the complexity of the purification routine and  reduced 
the yields of toxin (Rosten et al., 1989; Schlievert, 1989; B rehm  et al., 
1990). More recently a simplified procedure for the  purification of TSST - 1  
(Passalacqua et al., 1992) and SE has been devised using dye-ligand chro­
m atography (Reynolds et al., 1988; Brehm  et al., 1990). To purify these 
toxins for X-ray crystallographic work a tw o-step purification procedure 
was used which was suitable for bo th  sm all and large-scale production. 
This was based on dye-ligand chrom atography using the triazine textile 
dye known as ‘Red A’ (Amicon Ltd.). Toxin prepared in this way was 
subsequently cleaned up by fast protein liquid chrom atography (FPLC ). 
The following section contains detail of the production and purification of 
TSST - 1  and its subsequent crystallization and analysis.
3.2 Strains U sed  for Toxin P roduction
Staphylococcus aureus strain  MN8  (kindly supplied by Professor M.S. 
Bergdoll, Food Research Institu te , D epartm ent of Food Science and Indus­
try, University of W isconsin, M adison, USA.) was used for the production 
of TSST-1 . Cultures producing TSST - 1  were stored in growth m edium
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(see below) containing 50% v /v  sterile glycerol (BDH; 121°C / 15 min) and 
frozen in liquid nitrogen. W hen required stock cultures were thaw ed and 
subcultured through growth m edium  prior to  being m aintained on nutrient 
agar (Oxoid Ltd.) slopes at 4°C, for 1-2 days.
3.3 G rowth M edium
Staphylococcus aureus stra in  MN8  was grown in culture m edium , pre­
viously sterilized by autoclaving a t 121 °C for 20 m inutes. The m edium  
consisted of 20.0 g/1 N-Z amine A (Sheffield P roducts) and 20.0 g/1 pro- 
tease peptone no.3 (Difco Laboratories) a t a pH of 7.0. In addition, 50% 
(w /v) glucose, sterilized by autoclaving (121°C / 15 m in), was added to 
give a final concentration of 2  g / 1  in the  m edium .
3.4 P roduction  o f Toxic Shock S yn d rom e Toxin - 1
To provide an initial inoculum , 1 m l of sterile (121°C/15 min) phos­
phate buffered saline pH 7.4 (A ppendix A) was washed over an agar slope 
culture of S. aureus and 0.7 ml of the  resulting suspension used to  inoculate 
50ml of growth m edium  in a 300ml Ehrlenm eyer flask (Passalacqua et al., 
1992). The culture was shaken for 16 h  - 20 h a t 300 rpm  in an orbital 
incubator (INR-200; Gallenkamp) a t 37°C. A fter grow th of this culture 10 
m l was used to  inoculate 500 m l of the  sam e m edium  in a 2 1 flask and 
shaken for 16 h - 2 0  h at 37° C. Finally, this seed culture (500 ml) was used 
to  inoculate a 35 1 bioreactor (C hem ap AG) which contained 25 1 of growth 
m edium  sterilized in situ (121°C/15 m in), and  0.03% w /v  (final concen­
tra tion) polypropylene glycol 2000 antifoam  (KW ; Revai Chemicals Ltd.) 
previously sterilized by autoclaving (121°C /20 m in) and added im m edi­
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ately prior to inoculation. To enhance production of T SST - 1  an O 2 /C O 2 
(1:1) m ixture (British Oxygen Co.) was filtered (Emflon; Pall) and sparged 
through the culture at 2 1/min. The stirrer speed of the ferm enter vessel 
was set to 280 rpm  and the culture grown for 16 h - 20 h a t 37°C.
After growth the bacterial cells were removed from  the culture 
m edium  using the Millipore Pellicon cassette system (Millipore UK Ltd.) 
containing ten 0.45 /m i m em branes (HVLP-OMP50) and the spent culture 
supernatan t fluid concentrated to  1 1 using the sam e Pellicon cross-flow 
filtration system fitted with two 1 0 , 0 0 0  molecular weight cut-off m em brane 
cassettes (PLGC OMP05). To prevent growth and protease degradation 
of toxin during the rem aining downstream  processing, 0.5M EDTA (BDH) 
was added to the concentrated culture medium to give a final concentration 
of 0.2 mM . The concentrated culture supernatant fluid was placed in dialy­
sis sacs (Scientific Instrum ents L td.) and dialysed overnight a t 4°C against 
20 mM  potassium  phosphate buffer at pH 6.5 and a final concentration of 
0.2 mM  EDTA.
3.5 Purification o f Toxic Shock Syndrom e Toxin-1
3.5 .1  D ye Ligand Affinity C hrom atography
Five hundred millilitres of Red A gel (Amicon L td) was placed in 
a large Buchner funnel, w ashed with 3 1 of 8 M urea (BDH) solution con­
taining 0.5M NaOH (BDH) and loaded into a 4.5 cm x 31 cm column 
(W right-Amicon Ltd.). The gel was allowed to  settle and then washed 
w ith 8  volumes of 20mM potassium  phosphate equilibration buffer, pH 6.5. 
The toxin was eluted from the  Red A column using a stepwise increase in 
m olarity of the phosphate buffer. Ten ml fractions were collected (Super-
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perFract 2211; Pharm acia) at a flow rate  of 40 m l/h  during binding and 80 
m l/h  during elution. The protein content of the  fractions was estim ated 
by m easuring the A 280 using a Pye-Unicam PU  8600 UV/V IS spectropho­
tom eter while the presence and concentration of toxin was m easured using 
the single radial immunodiffusion assay (Section 3.6).
3.5.2 Fast P rotein  Liquid C hrom atography
The Red A column fractions containing toxin were pooled and puri­
fied further using fast protein liquid chrom atography (FPLC ; Pharm acia 
Ltd.) to produce toxin for crystallization. Toxin samples were placed 
in dialysis sacs (Scientific Instrum ents L td .), dialysed overnight in  50mM 
sodium acetate buffer pH 5.0 at 4°C and loaded in batches of approxim ately 
20 ml onto a FPLC  HiLoad S Sepharose high perform ance 16/10 column 
(Pharm acia) previously equilibrated with dialysis buffer. The column was 
eluted at room tem peratu re  using a 150ml linear gradient (0-250 mM) of 
NaCl at a flow ra te  of 2 m l/m in . Fractions were collected using a P h ar­
macia fraction collector (SuperFract 2211) and the  toxin usually eluted as 
a  single peak. All fractions which gave an A 28O of greater th an  0.2 units 
were collected and tested  by single radial immunodiffusion for the presence 
of toxin. After elution both  the Red A and the  S Sepharose columns were 
regenerated according to the m anufacturers instructions. Finally, the pu­
rified toxin was dialysed a t 4°C for 16 h - 20 h  against MilliQ (Millipore 
Ltd.) or E lgaStat (E lgaStat Ltd., High W ycom be) w ater (conductivities: 
>18 m fl and >15 m fi respectively). The concentration of the purified 
TSST-1 was determ ined using the extinction coefficient of 0.95 a t 280 nm  
(Reiser et al., 1983). The equivalent of 1 mg am ounts of the freshly purified
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toxin solution were added to small freeze-drying vials and lyophilized. The 
freeze-dried toxin was stored at 4°C until required.
3.6 Toxin A ssay
Toxin concentrations were determ ined using a single radial im m un­
odiffusion assay (Meyer & Palm ieri, 1980). This was perform ed by mixing 
4ml of 1 % (w /v) agarose (BDH) in barbitone buffer pH 7.4 (Appendix A) 
th a t had been previously melted by steam ing and  incubated at 60° C with 4 
ml of barbitone buffer containing 80 fil of rabb it anti-toxin antiserum . The 
solution was poured into a Merrid single rad ial immunodiffusion (SRID) 
plate (M ercia Brocades L td.), cooled to room  tem peratu re  and 5m m  di­
am eter wells cut into the gel using a gel punch (LKB Ltd.). Ten microlitre 
samples containing toxin were placed in the well and the SRID plates in­
cubated overnight in a moist cham ber at 37° C. Toxin concentrations in 
the unknown samples were determ ined by m easuring the diam eters of the 
precipitin rings formed and com paring them  to  standards 1 0  p g /m l to 1 0 0  
/xg/ml of purified toxin solutions which were present on the sam e plate.
3.7 Criteria o f  Purity
The purity  of toxin preparations was determ ined using sodium  dode- 
cyl sulphate-polyacrylam ide gel electrophoresis (SDS-PAGE) on gradient 
gels (PAA 4/30; Pharm acia Fine Chemicals). After electrophoresis the 
gels were stained for 1 h in ethanol/acetic acid (3:1, v /v ) containing 0.1% 
coomassie blue R250 (Pharm acia) and destained by diffusion overnight in 
accordance w ith the m anufacturers instructions (Instruction M anual; P h ar­
macia). The toxin preparations were also loaded, in accordance with the
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m anufacturers instructions (Instruction M anual; Pharm acia), onto an iso­
electric focussing gel (Pharm acia). Isoelectric focussing was perform ed on 
an Ampholine PAG plate gel (pH 3.5 to 9.5; LKB Instrum ents L td.) us­
ing an LKB M ultiphor II system  (P harm acia  LKB Biotechnology). The 
anode solution comprised 1M H3 PO 4  and the  cathode 1M NaOH. Sample 
volumes (15 fil) containing 1.0 to  2.0 m g /m l of protein were applied to  the 
gel and electrophoresis perform ed at 1500 V and 50 mA for 1.5 h. The pH 
gradient across the gel surface was determ ined after electrophoresis using 
a surface electrode (Pye Ingold). The staining and destaining procedures 
were perform ed as with the SDS-PAGE described above.
3.8 G el F iltration  Studies on Toxic Shock Syndrom e Toxin - 1
Gel filtration studies on TSST-1 was carried out a t 4°C using two 
different buffer system s on a column (1.5 cm  x 75 cm) containing 120 
ml of Bio-Gel P-100 gel beads (Bio-Rad). In  an initial experim ent 0.1M 
acetate buffer pH 4.6 was used to sim ulate crystallization conditions. In 
a separate  experim ent 0.1M Tris-HCl buffer pH 7.2 was used to  sim ulate 
physiological conditions. For each experim ent, the  column was initially 
washed w ith the appropriate  buffer until the A 280 read zero and the eluant 
pH was equal to th a t of the reservoir buffer used.
The column was calibrated for each buffer separately using blue dex- 
tra n  (M r 2,000kDa) followed by low m olecular weight calibration proteins 
(Pharm acia) in accordance with the m anufacturers instructions (P harm a­
cia). After the molecular weight m arkers were loaded onto the top of the 
gel under gravity, the buffer reservoir was connected and 1.2 m l fractions 
collected, a t a flow ra te  of 5 m l/h , using a P harm acia  fraction collector
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(SuperFrac 2211). The A28O for each fraction was recorded using a CECIL 
CE6600 M ultim ode Com puting UV Spectrophotom eter. Fractions were 
collected until the A280 reached the baseline and  the  pH reached th a t of 
the reservoir buffer. After calibration, 1 m g of lyophiiized TSST-1 was dis­
solved using 950 pi of the appropriate buffer and  loaded onto the  column. 
The column was eluted with the suspension buffer and 1.2 m l fractions 
were collected. The protein in the fractions was estim ated by m easuring 
the A280 •
3.9 C rystallization Studies
3.9.1 N ative Toxic Shock Syndrom e Toxin - 1
For crystallization toxin stock solutions (20 m g /m l) were prepared by 
dissolving the lyophiiized toxin preparations in 50 p i of MilliQ or ElgaStat 
water. Unless otherwise stated  all the chemicals used in crystallizations tr i­
als were of analytical grade and obtained from  Sigma Ltd. All of the stock 
solutions contained a final concentration of 0.02% sodium  azide as a  bacteri­
cide. The initial crystallization trials for TSST-1 were perform ed at room 
tem perature  by the hanging drop m ethod (M cPherson, 1982) using the 
sparse m atrix  sampling protocol of Jancarik & Kim  (1991). The individual 
drops (approxim ately 6 pi) consisted of equal volumes of reservoir stock 
solution and toxin stock solution. The drops were mixed on either plastic 
(Therm anox) or siliconized glass coverslips, 22 m m  diam eter (Chance Prop- 
per L td.), which were then inverted over individual wells in a 24 well tissue 
culture plate (Linbro, Flow Labs) and sealed w ith high vacuum silicone 
grease (Dow Corning). Later crystallization trials were perform ed using the 
sitting drop technique in microbridges (Harlos, 1992) a t 16°C. Over 1000
68
crystallization trials were perform ed to obtain  good quality crystals suit­
able for crystallographic work. For diffraction analysis, the crystals were 
carefully m ounted, by conventional m ethods (D ucruix and Geige, 1992), in 
fine quartz capillary tubes 0.7-1.0 m m  diam eter (Q uartzkapillaren; Glas) 
along with a small am ount of m other liquor to  prevent crystal dessication.
3.9.2 M utant Toxic Shock Syndrom e Toxin-1 (K 105E )
Two m utan t TSST -1  toxins were used during this project. The first, 
K105E, in which the lysine residue at position 105 had  been m uta ted  to a 
glutam ate was purified by D r.C .P.Q uinn and M rs.R .B rehm  from the Cen­
tre  for Applied Microbiology and Research (CA M R), Salisbury. The second 
H135A, in which the histidine residue had been converted to  alanine, was 
supplied in the form of a crude E.coli shockate by Professor P. Bonventre 
(D epartm ent of Microbiology and Molecular Genetics, University of Cincin­
nati Medical Centre, Cincinnati, Ohio, USA.). H135A was subsequently 
purified by Dr.D .Beer, CAMR. Crystallization trials for bo th  of these m u­
tan t toxins were carried out using the same set of conditions which were 
used for the wild type protein.
3.10 H eavy A tom  D erivatives
W ith no obvious structures similar to  TSST-1 available in the 
Brookhaven D ata  Bank, molecular replacem ent m ethod could not be used 
to determ ine the structure  of this toxin. Instead , isom orphous replacement 
m ethod by preparing heavy atom  derivatives (Petsko, 1985) of TSST-1 was 
perform ed at the Laboratory of Molecular Biophysics, Oxford University.
Using a light microscope, small am ounts of heavy atom  solutions was
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carefully added to the native crystals suspended in a m inim um  am ount 
of m other liquor inside a hum id cham ber to  prevent dessication. Native 
TSST -1  crystals were transferred to  an artificial m other liquor containing 
a range of heavy atom s (Table 3.5; Results Section). The artificial m other 
liquor was prepared to  stabilize the  crystals and  to prevent them  from 
dissolving on introduction of the heavy atom  salt. This liquor was similar 
in composition to th a t used for crystallization except for the polyethylene 
glycol 3350 concentration, which was increased to  30%, prior to  addition of 
the heavy atom  compound. The ‘derivitized’ crystal and the new artificial 
m other liquor were transferred to  a m icrobridge (Harlos, 1992), placed in 
a well containing 0.7 ml of the artificial m other liquor and sealed w ith a 
coverslip before storage at 16°C. The derivitized crystals were inspected 
after one hour using a light microscope and  then  daily thereafter. Any 
heavy atom  derivative crystals which looked suitable for diffraction (by 
initial inspection under the microscope) were carefully transferred  to  a 
quartz capillary tube, sealed and m ounted on the  imaging plate for d a ta  
collection.
During these trials careful consideration was given to the  pH em­
ployed during the native crystallizations to  decrease the probability of 
heavy atom  derivatives failing due to  precipitation in the artificial m other 
liquor (Petsko, 1985), Wolf et al., 1991 and Blundell and Johnson 1976). 
As TSST -1  does not possess any cysteine residues, m ercury com pounds 
were not used for a potential derivative search.
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3.11 Toxic Shock Syndrom e Toxin-1 D a ta  C ollection
3.11.1 W ild T ype Toxic Shock Syndrom e Toxin-1
Diffraction da ta  were collected from  native TSST - 1  crystals a t 3.5A 
and 2.5A resolution and from num erous heavy atom  derivatives a t 3.5A. 
Heavy atom  derivative d a ta  were collected a t 3.5A because the phase errors 
obtained at higher resolution may be quite high due to non-isomorphism. 
D ata  were collected using a MAR Research im age plate system  (Fuji Photo  
Film Co. Ltd.) with Cua X-rays (A=1.5418A) generated by a Rigaku 
RU200 ro tating  anode w ith a graphite m onochrom ator operating a t 60 
kV and 70 mA. The 3.5A data  were collected at 1.5° oscillation at 30 
m in/im age, and the 2.5A data  a t 1 .0 ° oscillation a t 60 m in/im age. To 
achieve a complete native data  set to  m edium  resolution, the most effec­
tive m ethod was to collect approxim ately ten  images and then  to  skip 7°. 
During d a ta  collection the crystals were tran sla ted  to  minimize radiation 
dam age and to  record the  best diffraction d a ta  (Figure 3.1).
The native and heavy atom  imaging p late  d a ta  were processed sepa­
rately (Figure 3.2; Appendix B) including the  M OSFLM  com puter package 
(A.Leslie, MRC Cambridge.). The d a ta  were scaled and m erged using the 
program s ROTOVATA and AGROVATA (Love, 1993). The unit cell pa­
ram eters were m onitored during d a ta  collection. If the unit cell param eters 
of the  heavy atom  derivative rem ained very close, ie. ~5%  (isomorphous), 
to th a t of the native crystal dimensions after a  prelim inary analysis, d a ta  
collection was continued. Otherwise d a ta  collection was abandoned and 
the whole exercise repeated for a different derivative.
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3.11.2 M utant Toxic Shock Syndrom e Toxin-1 (K 105E )
Initial d a ta  collection was perform ed at am bient tem peratu re  on a 
Siemens area detector m ounted on a Siemens ro ta ting  anode X-ray source 
using CuK a radiation (A=1.5418A) and operating  between 44-50 kV and 
76-80 mA. Two crystals of m utan t TSST-1 K105E were found to  be suitable 
for diffraction studies bu t they were poorly ordered w ith high mosaicity. 
The crystal to  detector distance was 17.0 cm w ith a 29 angle of 20°. Os­
cillation range was 0.25°/fram e and 150 s/fram e. F urther crystallization 
trials are required to improve the quality of these crystals. All d a ta  from 
the initial diffraction studies were processed on a VAX w orkstation using 
the XDS package of program s (Kabsch, 1988; Figure 3.3 and A ppendix B). 
Further characterization of these crystals a t the  Synchrotron Radiation 
Source, D aresbury showed possible diffraction to  2.5A.
3 .12  E s t im a t io n  o f  th e  Is o m o rp h o u s  D iffe re n c es
The first stage in the elucidation of the s truc tu re  of TSST-1 was the 
processing and scaling of the derivative d a ta  to  th a t of the 3.5A native 
data. This was perform ed using the program  D IF F E R  (S tuart et al., 1979; 
Appendix B). An im portan t feature of the D IF F E R  analysis is the  m ean 
fractional isomorphous difference value which is expressed as a percentage 
and describes the difference in scattering betw een the native and heavy 
atom  derivative am plitudes resulting from in troduction  of the heavy atom . 
A value between 15% and 30% suggests a  good derivative assum ing all 
other unit cell param eters remain isom orphous w ith the native.
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3.13 Interpretation  o f  the D ifference P a tterso n  M aps
After accurate location of the heavy atom  sites in a  derivative crystal 
protein phase angles for each reflection can be estim ated. However, it may 
be necessary to  have more than  one derivative in order to  estim ate the 
phase angles w ith m inim um  errors. The P a tte rson  function is based on 
the squares of the differences in the am plitudes between two sets of data. 
Quite often the heavy atom s do not bind at the  sam e sites on the protein. 
The binding will depend on the heavy m etal and  the n a tu re  of the  protein. 
The difference Patterson  m ap consists of peaks corresponding to  vectors 
between heavy atom  sites given bo th  the native and  heavy atom  derivative 
data. Given a significant m ean fractional isom orphous difference value with 
one or two heavy atom  sites per molecule in the  asym m etric un it, the heavy 
atom  positions can be interpreted  from a few strong peaks which can be 
located on the Harker sections of the difference m ap. Difference m aps are 
needed to  identify additional sites if there is m ore th an  one derivative.
3.14 H eavy A tom  Phasing
Using the heavy atom  structure  factors (Section 2.9.3) F h  can be 
calculated and the protein phase angles a p  can then  be estim ated from 
the size of bo th  the native and derivative s truc tu re  factors F p  and Fpj*. 
Lower resolution (6.0A) studies of TSST -1  gave approxim ate param eters 
for the uranyl fluoride derivative. The binding sites for the  uranyl acetate 
derivatives were obtained by difference Fourier analysis.
Phase refinement was initiated within the  resolution range 10A to 6A 
for 8  heavy atom  sites after their coordinate positions were determ ined from 
the difference Patterson  m aps. The initial m ultiple isom orphous replace­
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m ent protein phases were calculated from a tria l set of heavy atom  param e­
ters using the program  PHASE (P.Shaw, unpublished; Appendix B). These 
heavy atom  param eters were refined in tu rn  using the least squares phased 
refinement based on the program  R EFIN E for each derivative (P.Shaw, 
unpublished; Appendix B).
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R esults and D iscu ssion
3.15 P roduction  and Purification o f  W ild  T ype Toxic Shock Syn­
drom e Toxin-1
After ferm entation of S.aureus MN8  for 16 to  20 h  at 37°, TSST -1  
was purified from concentrated culture su p ern a tan t fluid to  >99% purity  
by chrom atography on Red A (Figure 3.4) and  FPL C  (Figure 3.5). The 
concentration of toxin in the final ferm enter culture was estim ated to  be 
0.044 m g/m l. Table 3.1 indicates the recovery of TSST-1 during the Red 
A and FPLC stage of purification. A lthough the  purified TSST-1 prepa­
rations m igrated as a single band on an SDS-PAGE gel (Figure 3.6), the 
purified toxin preparation did not give a single band when assessed by 
isoelectric focussing (Figure 3.7). This phenom enon has been noted from 
previous purification protocols used (Alouf et al., 1991). Although the pi 
values for the m ajor bands may be a ttrib u ted  to  the  different systems used 
to  determ ine the pi, an explanation for the m ultiple forms is more difficult 
to  ascribe. It may be due to deam idation during the  purification protocol 
(Alouf et al., 1991).
3.16 C rystallization o f  Toxic Shock Syndrom e Toxin-1
3.16.1 N ative Toxic Shock Syndrom e Toxin-1
In general, single parallelepiped crystals of T SST - 1  formed within one 
week, using either hanging or sitting drop m ethods under the conditions 
described in Table 3.2. However, subsequent crystals grown at 16°C were 
bo th  larger and of superior quality when com pared to  those grown at room  
tem peratu re  (Figure 3.8). They appeared to have a hexagonal cross-section
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of 0.3 to 0.4 m m  with a length of up to 1.0 m m .
3.16.2 M utant Toxic Shock Syndrom e Toxin-1 (K 105E )
Crystals of recom binant T SST -1  (rTSST-1) m u tan t K105E but not 
H135A were obtained using similar conditions to  wild-type TSST -1  (Table 
3.2). Small crystals of rT SST - 1  H135A were obtained at 16°C when the 
buffer was changed to HEPES pH7.5 (Table 3.2). These crystals had a 
different morphology com pared to  th a t of the  native TSST-1 crystals in­
dicating th a t they may have a different packing arrangem ent within the 
crystal lattice. Due to  tim e constraints, fu rth er analysis of these H135A 
crystals was not perform ed.
3.17 Prelim inary C haracterization o f  C rystals
3.17.1 W ild T ype Toxic Shock Syndrom e Toxin-1
These crystals belonged to the orthorhom bic space group C222i (a  =  
108.6A, b =  177.6A, c =  97.5A; Table 3.3) and, assum ing th a t there were 
three molecules in the asym m etric unit, the specific volume of the protein 
was 3.55A3/D a  which falls within the range norm ally observed for protein 
crystals, in accordance with M atthews (1968), and corresponds to  a  65% 
(v /v ) solvent content. Initial investigations a t the  SRS D aresbury (Beam 
line 7.2) showed th a t they diffracted to a m axim um  resolution of 1.9A.
The TSST-1 crystals also appeared to  possess pseudo-hexagonal sym­
m etry with space group P 6 3 2 2  and cell dimensions of a =  b =  104.1 A and 
c =  97.5A, 7  =  117° containing one molecule in the  asym m etric unit. Even 
though the y  angle was close to 1 2 0 °, ‘forcing’ these pseudo-hexagonal val­
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ues during d a ta  processing failed to  fit a hexagonal space group. However, 
an equivalent orthorhom bic space group C 222 \ , in a  lower sym m etry, could 
account for all the system atic absences and was found to  be the  alterna­
tive space group which gave good merging statistics (Table 3.4). This 
pseudo-hexagonal sym m etry was la ter confirmed by careful observation of 
the packing of molecules in the asym m etric units during isom orphous re­
placement m ethod structure  determ ination. These units contained one half 
of a  crystallographic dimer and one non-crystallographic dim er arranged 
on a pseudo-hexagonal net.
3.17.2 M utant Toxic Shock Syndrom e Toxin-1 (K 105E )
Prelim inary d a ta  processing of two crystals of TSST-1 K105E using 
XDS (Kabsch, 1988) indicated th a t it had identical space group and unit 
cell param eters as the wild type (Table 3.3). These d a ta  gave an Rmerge 
of 14.6%. This high 72-factor suggested underlying high mosaicity and 
poor internal order. These d a ta  gave 19,834 unique reflections to  2.5A 
with a to ta l completeness of 53.2%. These d a ta  were used for subsequent 
refinement using X PLO R  (Brunger, 1988).
3.18 D eterm in ation  o f  the M ultim eric S ta te  o f  W ild T ype Toxic 
Shock Syndrom e Toxin-1
It has been reported in the  literatu re  th a t TSST-1 exists in the 
monomeric state  in solution (Naidu et al., 1989). However, in the  crystal 
form of TSST -1  reported here, there were three molecules in the asym m et­
ric unit. In order to  address this question, purified preparations of TSST-1 
were applied to  a gel-filtration chrom atography colum n of Bio-gel P-100 in
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an a ttem pt to  separate any m ultim eric forms under gravity (Section 3.8). 
In each case TSST -1  eluted as a single sharp peak with bo th  TRIS-HC1 and 
acetate buffer (Figures 3.9 and 3.10 respectively). From  the plot of k av vs. 
log M r (Figure 3.11), in accordance w ith the m anufacturers instructions, it 
was estim ated th a t the M r of TSST - 1  was 25.9 kD a in acetate buffer, and 
28.5 kDa in Tris-HCl buffer. These results suggest th a t w ithin experim en­
ta l error, at these two pH values, TSST -1  exists as a monomer. The M r 
of TSST -1  from the nucleotide sequence is 22,049 Da (B lom ster-H autam aa 
and Schlievert, 1988). Therefore, the three molecules in the asym m etric 
unit of the crystallized toxin are probably an artefact of protein packing 
w ithin the crystal and as such are not expected to  fulfil any physiological 
function.
3.19 H eavy A tom  Derivative Trials
Twenty seven heavy atom  solutions a t concentrations ranging from  1 
mM to 10 mM were used to  soak native T SST -1  crystals for varying lengths 
of tim e (Table 3.5). Many of these com pounds (Table 3.5) reacted with 
the native TSST -1  crystals and caused the cracking of the crystal. O ther 
derivatives actively dissolved the crystals as seen by the obvious loss of 
the very sharp long edges characteristic of TSST-1 crystals. Despite this, 
m any derivatized crystals m aintained their m orphology during heavy atom  
soaking (Table 3.5) and were m ounted and placed on the  M AR Research 
imaging plate and da ta  collected at 3.5A. D ata  from the native crystals 
and all the heavy atom  d a ta  were processed using the program s illustrated 
in Figure 3.2.
Table 3.6 indicates th a t bo th  the uranyl acetate and uranyl fluoride
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gave a m ean fractional isomorphous difference (M FID ) value of 29.9% and 
17.1% respectively. These two were therefore chosen as potential derivatives 
to estim ate the prelim inary phases for the TSST-1 structure . A sum m ary 
of the M IR and solvent flattening statistics can be seen in Tables 3.7 and 
3.8 respectively.
3 .20  I n te r p r e ta t io n  o f  th e  D iffe ren ce  P a t t e r s o n  M a p s
The uranyl acetate/native difference P a tte rso n  m aps were perform ed 
in the resolution range 1 0 A to 6 A and calculated using the native d a ta  
to 3.5A. Phase extension to 2.5A was perform ed using the technique of 
molecular averaging with the program  GAP (D .S tuart and J.G rim es, un­
published), by a 3-fold real space averaging. This resulted in an R-factor 
and correlation of 0.31 and 0.91, respectively, between the observed d a ta  
and da ta  obtained by inversion of the averaged solvent flattened m ap.
3.21  E le c tro n  D e n s ity  M a p  o f  W ild  T y p e  T oxic S h o ck  S y n d ro m e  
T o x in - 1
The background noise in the initial (2| F0 \ — \ Fc |) electron density 
m ap produced at 3.5A was generally low. A significant portion of strands 
and the m ajor a  helix were identifiable in the  3.5A electron density m ap. 
Although it was possible to follow the  polypeptide chain some regions were 
unclear due to occasional breaks in electron density.
After the 2.5A m ap was calculated there  was a significant improve­
m ent in the electron density and the secondary structu re  elements were 
well defined with clearly visible side chains. Initially location of the N 
and C term ini was difficult. However, after establishing the first and last
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residues, the trace from the N to C term ini was very clear w ith few breaks 
in connectivity in the m ap. W hen this was com pleted, segments of the 
polypeptide backbone were identified and fitted  to  the electron density 
m ap of one TSST -1  molecule. In order to  com plete the  structu re  in ter­
pretation  and to  obtain the atomic coordinates for T SST-1 , the /3 strands 
of the cell adhesion molecule CD 2 , refined to  2.8A (Jones et a l ,  1992), 
were im ported into the com puter for subsequent m anipulation. These /? 
strands were transposed over and into the TSST-1 density. M anipulation 
of these newly inserted strands fitted  the density b e tte r and ensured the 
correct position for the residue side chains. The (3 tu rns were then added 
and linked with the /? strands already in place. F itting  the a  helices was 
easier th an  th a t for the {3 strands due to  the  ordered na tu re  all a  helices 
display. Finally the loops between the secondary s tructu re  elements were 
then carefully added.
Almost all of the amino acid side chains h ad  well defined density and 
were clearly visible. The sequence for the m ore obvious large side chains like 
Trp, Phe and His residues were identified and positioned in the m ap from 
knowledge of their general shape. It was easy to  identify prom inent features 
such as the location of tyrosines Tyr 51 and Tyr 52 and Lys 121 and Lys 122. 
The amino acid sequence was then  checked in th e  forward and backward 
direction for fitting into the electron density available. Throughout m anual 
rebuilding, local least squares energy m inim ization for the  segments of the 
struc tu re  were perform ed using the  program  FR O D O  (Jones, 1985) and 
the side chain sequence was then incorporated using the program  CALPHA 
(R.Esnouf, unpublished), and reordered from  1 th rough to  194 (Blomster- 
H autam aa and Schlievert, 1988). In to ta l 1559 protein atom s were fitted
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into one molecule of TSST-1.
3.22 R efinem ent o f W ild T ype Toxic Shock Syndrom e Toxin-1 
Structure
The 2.5A starting  model was refined using the  package X PLO R (Ver­
sion 2.1; Brunger, 1988). Initially strict non crystallographic sym m etry 
(NCS) restraints were employed as described in the X PLO R  m anual (Ver­
sion 2 .1 ; Brunger, 1988) for the refinement of the three  TSST -1  molecules 
found within the asym m etric unit. X PLO R  contains a facility which utilises 
the non-crystallographic sym m etry found w ithin the unit cell during simu­
lated annealing refinement. It can also allow ‘s tr ic t’ or ‘restra ined’ refine­
m ent. The former makes use of a  designated m onom er, which is assumed 
for the purposes of the refinement to  be sim ilar to  the  rem aining molecules 
within the asym m etric unit, and th a t any alterations to  this monom er are 
reflected in identical changes to the two rem aining m onom ers. The non- 
crystallographic sym m etry operators, which represent the  ro tation  matrices 
and also the translation vectors, generate the  rem aining molecules of the 
asym m etric unit and are subsequently applied to  the  m onom er. Indeed, the 
Fcalc for the entire asym m etric unit is generated from  this single molecule. 
The advantage of this strict refinement is th a t any noise present is reduced 
by averaging it over the whole asym m etric un it. The restrained refinement 
option allows for the contents of the asym m etric unit to  be refined inde­
pendently, The non-crystallographic sym m etry related atom s within each 
molecule are restrained about their average position. A flow diagram  of 
the program s used can be seen in Figure 3.12.
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Round 1
W ith strict NCS restraints applied, a new electron density m ap was 
calculated and all 194 m ain and side chains were system atically adjusted as 
necessary using the program  FRO D O  on an Evans and Sutherland graphics 
system  (ESV 10), for one molecule only.
Round 2
Refinement continued as in round 1 using the  same protocol, includ­
ing strict NCS restraints. At the end of round 2, a detailed analysis was 
m ade of the molecule using a R am achandran plot. This plot describes the 
<j>,Tj> angles found in the present m odel with the  experim entally ‘allowed’ 
values (R am achandran and Sasisekharan, 1968). These angles were moni­
tored for each residue for any unacceptable geom etry and adjustm ents to 
the model were m ade accordingly.
R ound 3
After round 2  the strict NCS restraints were relaxed. By the  end of 
round 3, refinement of all 3 molecules was checked individually.
Round 4
The final R -factor was 21.3% for all reflections in the range 8.0 to 
2.5A. A portion of the final 2 | F0 | — | Fc | electron density m ap for TSST-1 
is shown in Figure 3.13 contoured at \<r.
The present 3-D model, refined to 2.5A resolution, contains all 194 
amino acid residues and includes 4677 non-hydrogen atom s for all three
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molecules in the asym m etric unit. The overall s truc tu re  has a  crystallo- 
graphic R-factor of 21.3% for all d a ta  to  2.5A (15.6% for F  >  3<t). It 
has good geometry as exemplified by rm s deviations in bond lengths of 
0.011 A and in bond angles of 2.64°. W ith the  exception of Ser 86 all of 
the non-glycine residues, have <j>^  angles which lie w ithin the allowed zone 
of the R am achandran plot (R am achandran and  Sasisekharan, 1968) w ith 
<j> =  61°, V’ =  —157° (Figure 3.14). The Ca coordinates for each molecule 
were superim posed in a pairwise m anner w ith one another which gave an 
rm s difference of 0.13A, 0.15A and 0.15A for the  molecules 1-2, 1-3 and 
2-3 respectively, indicative of a high degree of sim ilarity between the three 
molecules.
3.23 D escription o f  W ild T ype Toxic Shock Syndrom e Toxin-1 
Structure
The structure of a single TSST -1  molecule is illustrated in Figure
3.15 referred to as its ‘s tan d ard ’ orientation. The molecule has approxim ate 
dimensions 45A x 45A x 58A. It can be divided in to  two distinct structu ral 
domains both  of which contain a significant num ber of (3 strands. The two 
domains are linked through a long a  helix which is functionally im portan t. 
Overall, 17% of the structure exists as a  helices, 46% as (3 strands and the 
rem aining 37% as (3 tu rns and loops. The secondary structure  assignment 
was based on the program  DSSP (Kabsch and Sander, 1988; Figure 3.16).
3.23.1 D om ain  1
Domain 1 comprises of the N term inal residues 1 to 95 and includes 
five (3 strands ((31 to (35) and one a  helix ( a l ;  Figure 3.17). After a short
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N term inal portion, which is sterically adjacent to  dom ain 2 and includes 
the first a  helix a l  (7 to 15), this dom ain is dom inated by a distinctive 
antiparallel /? barrel comprising of two (3 sheets ((3 1 , /?4 and (32 (33 (34 (35). 
The (3 strands are all connected by loops w ith no a  helices. This (3 barrel is 
elliptical in cross-section (Figure 3.18) and has a criss cross p a tte rn  (Figure 
3.19). The (3 barrel has a core of hydrophobic residues: Phe 20, Val 25, 
Met 33, He 35, lie 45, Phe 47, P ro  54, Phe 56, Val 62, Leu 64, lie 81 and 
Val 8 8 . The concave region of dom ain 1 is delineated by strands /31 (32 
and (33 and is noticeable for its clustering of hydrophobic solvent accessible 
residues.
This overall feature comprises five (3 s trands forming a (3 barrel with 
the addition of a small a  helix finking strands (3 3 and /? 4, is not unique 
having been observed in SEB (Sw am inathan et al., 1992) and other struc­
tures including two toxins, verotoxin -1  (Stein et al., 1992) and heat labile 
enterotoxin (B subunit; Sixma et al., 1992), and  also staphylococcal nu­
clease (Hynes and Fox, 1991). None of these proteins share high sequence 
homology with one another, yet they all show very similar tertiary  struc­
ture. All of these proteins apart from  SEB have been shown to bind either 
oligosaccharides or oligonucleotides. The binding sites are located to one 
side of the (3 barrel called the ‘OB fold’ (M urzin, 1993).
3.23.2 D om ain  2
The C term inal dom ain 2 , consists of residues 96 to  194 which consti­
tu te  seven (3 strands ((36 to (312), one m ajor a  helix (125 to  140) and two 
single tu rn  3io helices (173 to 177 and 183 to  185). This dom ain is dom­
inated by the m ajor helix a 2 , which has five f3 strands cupped around it
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forming a (3 barrel. This (3 barrel is slightly tw isted w ith a less pronounced 
concave surface on one side. The upper p a rt of the  a2  helix in teracts with 
a l  helix from dom ain 1 ; the lower p a rt of the a 2  helix in teracts w ith a 3io 
helix. Unlike dom ain 1 , the distribution of am ino acid residue types within 
this domain shows no distinctive features.
The C term inal dom ain of T SST -1  appears to  be unique am ongst the 
bacterial superantigens but could nevertheless be considered a variation 
of the l(3 grasp’ m otif (M urzin, 1992; O verington, 1992). This has been 
seen in a num ber of other proteins with an a  helix tightly surrounded by 
4 /3 strands. These proteins include chloroplast ferredoxins (T sukihara et 
al., 1981), immunoglobulin G-binding dom ain of streptococcal protein  G 
(Achari et al., 1992) and ubiquitin (V ijay-K um ar et al., 1987).
3.23.3  Interm olecular C ontacts
Wild type TSST -1  packs into the C222i unit cell w ith approxim ately 
65% solvent. There are three molecules in the asym m etric unit which are 
governed by crystallographic and non-crystallographic (local) sym m etry as 
shown in Figure 3.20. Molecules designated 1 and 3 constitute p a rt of the 
dimer on the crystallographic 2 -fold axis and molecule 2  forms one half of 
the non-crystallographic dimer.
These interm olecular interactions in TSST-1 involve residues from 
dom ain 1 on the ‘to p ’ surface of bo th  molecules (w ith respect to  its s tan ­
dard orientation), which seem to he at 45° to  one another. The m ain 
contributions are from a l  helix and strands (3A and j3h which participate 
in dimer interactions. There are only 16 unique hydrogen bond contacts 
between the three molecules in the asym m etric unit of less than  3.5A, 15
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of which He at the interface between molecules 1 and 3 (Table 3.9).
3.24 C om parison o f  Toxic Shock S yndrom e Toxin-1 and SEB  
Structure
The crystal structu re  of SEB has recently been determ ined (Swami- 
n a than  et al., 1992). The overall topology of TSST-1 is clearly similar to 
th a t exhibited by SEB (Sw am inathan et al., 1992), w ith dom ain 1 of SEB 
consisting of a j3 barrel structu re  based on five /? strands forming two (3 
sheets (1 , 4 and 5 and 2 , 3, 4 and 5 ), and dom ain 2  of SE containing a 
m ajor helix (o4) tightly covered by 5 (3 s trands (6 , 7, 9, 10 and 12). De­
spite the lack of any significant sequence sim ilarity (approxim ately 24%) 
between these two toxins (Figure 1.1), they possess similar secondary struc­
ture  features (Figure 3.21). A conservation of the  global fold is perhaps 
not unexpected considering their similar biological properties and their in­
teraction with both  MHC II and T cR  in vivo.
The evolutionary relationship of these enterotoxins is quite evident 
from the preservation of the distinct two-dom ain fold and it is possible th a t 
they diverged from a common ancestor. However when the structures are 
com pared in more detail, they are not strictly conserved because the  whole 
TSST -1  molecule is smaller than  SEB by 45 am ino acid residues (M r 2 2  
kDa and SEB 28 kDa respectively). As such, a num ber of differences m ust 
occur which can be a ttribu ted  to secondary s tru c tu re  deletions in TSST-1. 
Domain 1 of TSST -1  comprises 96 amino acid residues com pared w ith SEB 
which contains 1 2 0  residues.
There are three m ain regions in dom ain 1 where the struc tu re  of 
TSST -1  and SEB differ to a great extent, and two in dom ain 2 . W hen the
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TSST -1  dom ain 1 p a tte rn  is com pared w ith th a t of SEB (Table 3.10), the 
equivalent a l  helix in SEB is replaced in TSST-1 by an extended region 
of six amino acid residues. The SEB a2  helix is equivalent to  the TSST -1  
a l  helix. The short a  helix (a3) of SEB linking strands 03  and /?4, has 
been replaced with a short loop of 12 residues (48 to  59) in TSST-1 . The 
equivalent disulphide loop of SEB is not present in TSST -1  per se bu t is 
replaced by a much shorter loop of three residues between 0  strands 4 and 5 
(residues 75 to  78), In the reported s tructu re  of SEB (Sw am inathan et al., 
1992) residues 99 to  105, were missing. This was a ttrib u ted  to  the increase 
in flexibility of these residues beyond the disulphide. In all the loop regions 
between the 0  strands in TSST -1  there are variations to  be found in the 
num ber of residues when com pared with SEB (Table 3.10). For example 
there are only two residues between 01  and 02  and three residues between 
02  and  03  in TSST -1  bu t there are 8  and 1 2  residues respectively between 
similar strands in SEB.
3.25 R efinem ent o f M utant Toxic Shock Syndrom e Toxin-1 
(K 105E ) Structure
As the m utan t TSST-1 K105E unit cell param eters were isomorphous 
w ith the wild type (Table 3.3). It was decided to  use the wild-type TSST-1 
model for refinement against the m utan t da ta . Table 3.11 illustrates the in- 
house d a ta  collection. The refinement consisted of several steps using the 
X PLO R  (Brunger, 1988) com puter package (Figure 3.22). For refinement 
purposes the original residue Lys 105 in the wild type TSST-1 was replaced 
with an alanine. This was done to prevent any side chain bias from the 
original lysine in the electron density for this region. After one round of
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refinement the final R -factor for the model was 21.3% (Table 3.12) for 
15389 reflections (F  > 3cr(F)) between 8.0 and  2.8A. The final TSST -1  
K105E model had an rm s bond length 0.006A and an rm s bond angles 
of 1.454°. Figure 3.23 dem onstrates the g lu tam ate  105 modelled in the 
electron density. There were still a num ber of breaks in the electron density 
m ap along both  the m ain chain and side chains. This m ay have been due 
in p a rt to  the lack of completeness of the d a ta  used in the refinement.
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T ab le  3.1 Purification o f TSST-1 by ‘Red A 1 and fast protein liquid chro­





















FPLC 660 80 60
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T ab le  3 .2  A comparison of the final crystallization conditions employed 









P E G f
3350
(%)
TSST -1 2 0 0.1M Acetate 4.6 0.2M




2 0 0.1M Acetate 4.6 0.2M




2 0 0.1M HEPES* 7.5 1 0 %
2 -Propanol
2 0
f Polyethylene glycol; * H E PE S, 4-(2-hydroxy e thy l)-l-p iperazineethanesu lphon ic  acid.
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Table 3.3 Crystal data for wild type and mutant TSST-1
Feature TSST-1 K105E








Solvent Content 65% 65%






Time (s) per 
Oscillation
200-300 150
No. of Crystals 
Used
8 2
d m i n  (A) 2.5 2 .8
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Table 3 .4 . Summary of TSST-1 Imaging Plate Diffraction Data.
Feature Native 1 Native 2 Native














189.1 124.2 124.1 189.1 189.1
No. of 
Reflections




11,231 29,155 30,009 9,186 10,536
%
Complete
94 87 89 77 8 8
R m e rg e 7.5 7.5 8 .6 8.4 4.5
MFID - - - 29.9 17.1
Rmerge =  Yli/^obs — I / )  ^ 2 1 • MFID- Mean fractional isom orphous difference.
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D1 EM P 1 0 2 2 h Cracks
D2 Lead Acetate 1 0 46h V .poor diffraction
D3 M ercury Iodide 5 6 h
D4 Bakers 9.3 5h Ruined
D5 Bakers 9.3 Cracks (30 mins)
D 6 M ercury Iodide 5 C rystal redissolves
D7 Bakers 0.93 Cracks (lOmins)
D8 EM P 1 25h C rystal redissolves
D9 EM P 5 3h
DIO Platinum  Cyanide 5 3h
D ll Lead Acetate 5 2 1 Cracks
D12 Platinum  Cyanide
D13 Uranyl Acetate 1 0 16h Yellow crystal
D14 Gold Chloride 5 16h
D15 Platinum  Chloride 5 16h
D16 Sam arium  Acetate 5 2 0
D17 EM P 5 24h
D18 Lead Acetate 1 0 24
D19 Platinum  Cyanide 5 24h
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D20 Uranyl Acetate 1 0 1 2
D21 Gold Chloride 5 1 0 Poor diffraction
D22 Uranyl Acetate 1 0 1 2 h Small cracks
D23 Gold Chloride 5 lOh Poor diffraction
D24 Gold Cyanide 1 0 37h
D25 Uranyl Fluoride 1 0 23h
D26 Uranyl Acetate 1 0 13
D27 Gold Chloride 5 3h Yellow crystal
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Table 3.6. TSST-1 derivative data collection to 3.5A.




MFIDf R m e r g e
D1 ND
D2 ND
D3 2 1 57 15.34 10.3
D5 ND
D13* 2 2 77 29.86 8.4
D14 60 76 34.47 8 .8
D15 34 72 16.03 6 .6
D16 35 74 16.05 6 .6
D17 7 17 15.69 4.1
D18 5 15 13.0 10.5
D19 5 15 9.3 6.3
D21 ND
D22+R13 52 90 30.43 7.2
D22 30 6 8 26.43 8 .0
D23 ND
D24 4 2 0 7.24 3.5
D25* 40 8 8 17.06 4.5
D27 9 39 33.4 16.3
f M FID , m ean fractional isom orphous difference; ND, no t determ ined .
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Table 3.7. A summary of MIR phasing.
Feature Uranyl Acetate Uranyl Fluoride
No. Sites 5 3
R c  to 6 .0 A 0.55 0.49
(3 .5 A) (0.56)
Phasing Power 1.9 2.1
to 6 .0 A (3 .5 A) (1.7)
i2<7:Cullis R-factor for centric reflections. P hasing  pow er: m ean  value of th e  heavy atom  
s tru c tu re  factor am plitudes divided by th e  residual lack-of-closure error.
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Table 3.8. A summary of TSST-1 solvent flat tening.











6 .0 0.60 65 26.3 41.3° 0.78
3.5 65 2 2 .6 50.5° 0.77
(55) (18.7) (48.3) (0.80)
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T ab le  3 .9 . Intermolecular hydrogen bond contacts in the TSST-1 asym ­
metric unit, f
Molecules Donor Acceptor Distance (A) f
1-3 Ser 001 N T hr 038 O 2.73
Asn 003 N Asp 039 O 3.11
Asn 005 N D 2 Gly 078 O 3.27
Lys 007 N Z Asp 039 O 3.02
Arg 068 N H 2 T hr 011 O 2.93
Ser 072 O G Asp 011 O D 2 2.94
Tyr 080 O H T hr 008 O D 2 3.31
Ser 080 O H T hr 011 O D 2 3.37
3-1 Ser 001 N T hr 038 O 2.71
Asn 003 N Asp 039 O 3.15
Lys 007 N Z Asp 039 O 2.90
Arg 068 N H 2 T hr 011 O 2.91
Ser 072 O G Asp 011 O D 2 2.93
Tyr 080 O H T hr 008 O D 2 3.43
Ser 080 O H T hr 011 O D 2 3.21
1-2 Ser 034 N H 1 Asp 160 O 3.17
f D ata  com piled using D SSP and H ERA  X Residues listed  m ake pro te in -p ro te in  contacts 
w ithin a 3.5A cut-off d istance.
98
T ab le  3 .10 . Secondary structure comparison between TSST-1 (this study) 







— — a l 12-17
a l 7-15 a2 21-29
01 18-29 (31 33-39
(32 32-37 (32 48-52
03 41-47 £3 63-68
— — a3 70-78
(34 60-75 (34 81-89
(3b 79-89 (35 112-120
06 101-106 (36 127-138
(37 109-111 (37 141-151
08 119-124 (38 1154-156
a  2 125-140 a4 157-172
(39 152-158 (39 182-190
(310 161-166 (310 195-200
3io-l 173-177 a5 210-217
0 1 1 181-182 (311 222-225
3io-2 183-185 — —
(312 186-193 (312 229-236
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oo-15.00 186 186 37 37 19.8
15.00-10.00 397 583 326 363 82.1
10.00-8.00 518 1101 439 802 84.7
8.00-6.00 1435 2536 1268 2070 88.3
6.00-5.00 1774 4310 1546 3616 87.1
5.00-4.50 1550 5860 1306 4922 84.2
4.50-4.00 2411 8271 2019 6941 83.7
4.00-3.50 3969 12240 3135 10076 78.9
3.50-3.20 3695 15935 2739 12815 74.1
3.20-3.00 3351 19286 2241 15056 66.2
3.00-2.80 4309 23595 2416 17472 56.1
2.80-2.70 2680 26275 1233 18705 46.0
2.70-2.60 3102 29377 1042 19747 33.5
2.60-2.50 3605 32982 87 19834 2.4
Total 32982 19834 53.2
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Figure 3.1 A typical diffraction pattern of TSST-1 to 2.5A to show the quality of 
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F ig u r e  3 .2  Flow diagram  to  show the  program s used  in  d a ta  collection and  processing 




F ig u r e  3 .3  Flow diagram  for XDS d a ta  processing (K absch , 1988).
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F ig u re  3 .4  Dye ligand chrom atography  of TSST-1 from  25 1 of cu ltu re  su p e rn a ta n t 
using Red A. T he  colum n (4.5 x 31 cm ) was equ ilib ra ted  in 20 mM  phosphate  buffer, 
pH 6.5, and elu ted  w ith a stepw ise increase in m olarity  of ph o sp h a te  buffer pH 6.5, as 
indicated . F ractions (10 ml) were collected a t a flow ra te  of 40 m l/h  (during binding) 
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Figure 3.5 Final purification of TSST-1 by FPLC, after previous chromatography using 
Red A. The 20 ml HiLoad S Sepharose high performance 16/10 column (Pharmacia) 
was equilibriated with 50 mM sodium acetate buffer (pH 5.0). Toxin was eluted using 
150 mM linear gradient of increasing NaCI concentration (up to 250 mM) at a flow rate 
of 2 ml/min.
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Figure 3.6 An SDS-polyacrylamide gradient (8 to 18%) precast gel (Pharmacia) anal­
ysis of stages in the purification of TSST-1. Lane A, pooled fractions from fast protein 
liquid chromatography. Lane B, pooled fractions eluted from Red A. Lane C, concen­
trated culture supernatant fluid. Lane D, molecular mass markers (Pharmacia; kDa): 
phosphorylase 6, 94; albumin, 67; ovalbumin, 43; carbonic anhydrase, 30; trypsin in­
hibitor, 20.1 and a-lactalbumin, 14.4. Lanes A to C were loaded with 10 fil of sample 




Figure 3.7 Isoelectric focusing of TSST-1 purified by FPLC. Lanes A and C, pi markers: 
trypsinogen, 9.30; lentil lectin (basic band), 8.65; lentil lectin (middle band), 8.45; lentil 
lectin (acidic band), 8.15; myoglobin (basic band), 7.35; myoglobin (acidic band), 6.85; 
human carbonic anhydrase B, 6.55; bovine carbonic anhydrase B, 5.85; /3-lactalbumin 
A, 5.20; soybean trypsin inhibitor, 4.55 and amyloglucosidase, 3.50. Lane B, TSST-1.
108
Figure 3.8 Orthorhombic crystal of native TSST-1. The crystal dimensions are 0.3 mm 
X 0.4 mm X 0.8 mm.
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Figure 3.9 Gel filtration using 0.1M Tris-HCl buffer, pH 7.5, showing the separation of 
standard proteins superimposed with TSST-1 using P-100 gel (Bio-Rad) and column (1.5 
x 75 cm) under gravity at a flow rate of 5 ml/h. The calibration proteins (Pharmacia) 
are (kDa): ribonuclease A, 13.7; chymotrypsinogen A, 25.0; ovalbumin, 43.0; bovine 
serum albumin, 67.0.
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Figure 3.10 Gel filtration using 0.1M acetate buffer, pH 4.6, showing the separation 
of standard proteins superimposed with TSST-1 using P-100 gel (Bio-Rad) and column 
(1.5 x 75 cm) under gravity at a flow rate of 5 ml/h. The calibration proteins are 
(kDa): ribonuclease A, 13.7; chymotrypsinogen A, 25.0; ovalbumin, 43.0; and bovine 
serum albumin, 67.0.
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Figure 3.11 A graph to show Kav against log Mr for both the TRIS-HCI and acetate 





S lo w co o l
Prepstage
F ig u re  3 .1 2  Flow d iagram  for wild type  TSST-1 refinem ent th ro u g h  th e  X P L O R  pack­
age of program s (B runger, 1988).
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Figure 3.13 A 2F0 — Fc electron density map of a typical region in the fully refined 











Figure 3.14 A Ramachandran plot of the fully refined TSST-1 structure using 
PROCHECK (Laskowski et al., 1994). Glycine residues are indicated as triangles.
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Figure 3.15 A ribbon diagram to illustrate the polypeptide fold of TSST-1 in its 
‘standard’ orientation. Helices are coloured red (3io helices are drawn more thinly than 
normal helices), the (3 strands are coloured green and loops yellow. The N and C termini 




Figure 3.16 A secondary structure hydrogen-bonding diagram of toxic shock syndrome 
toxin-1. The secondary structure was defined using the program DSSP (Kabsch and 
Sander, 1993). All main chain hydrogen bonds are indicated as small arrows , from the 
donor to the acceptor. Residues involved in a  helices are indicated as elipses and those 
contributing to the f3 sheets are boxed. The larger bold arrows indicate the direction of 
the (3 strands.
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NFigure 3.17 Identification of secondary elements of TSST-1 in its standard orientation. 
N and C termini are indicated. Figure produced with MOLSCRIPT (Kraulis, 1991).
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Figure 3.18 Diagram to illustrate the /3 barrel in domain 1 of TSST-1. This figure has 
been rotated approximately 100°, topside backward, about a horizontal axis running 
through the molecule in its standard orientation. Figure produced with MOLSCRIPT 
(Kraulis, 1991).
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Figure 3.19 Diagram to illustrate the criss cross pattern of the /3 strands in domain 1 
of TSST-1. This figure has been rotated approximately 35°, right side forward, about a 
vertical axis from its standard orientation. Figure produced with MOLSCRIPT (Kraulis, 
1991).
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Figure 3.20 The packing of 3 TSST-1 molecues in the asymmetric unit. Molecule 1 
is coloured blue, molecule 2 orange and molecule 3 in yellow. Figure produced with 
FRODO (Jones, 1985).
121
Figure 3.21 A ribbon diagram of SEB. Regions implicated in MHC II binding are 
identified. Region 1 (residues 9 to 23) in red, region 2 (residues 40 to 53) in blue and 
region 3 (residues 60 to 61) in white. Residues implicated in TcR binding: residues 90 
to 92 in dark blue and residues 208 to 217 in light green. The disulphide loop is yellow. 








F ig u r e  3 .2 2  Flow diagram  for refinem ent of m u ta n t T SST -1 K105E using X P L O R  
package of p rogram s (B runger, 1988).
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Figure 3.23 A 2F0 — Fc electron density map of the mutated residue 105 in the structure 
of mutant TSST-1 K105E after one round of refinement. During refinement residue 105 




Purification o f  SEA  and C rystallization o f  S taphylococcal Entero- 
toxins A , B and C2
4.1 P roduction  and Purification o f  SE A , SE B  and SEC2
Staphylococcal enterotoxins B and C2, purified by affinity chrom atog­
raphy on Red A (Brehm  et a i, 1990), were a gift from  Mrs. R .D .Brehm , 
Developmental Production D epartm ent, Centre for Applied Microbiologi­
cal Research, Salisbury.
4.2 Strains U sed  for SEA Production
Staphylococcus aureus strain  FRI-722 (kindly supplied by Professor 
M.S. Bergdoll, Food Research Institu te , D epartm ent of Food Science and 
Industry, University of Wisconsin, M adison, USA) was used for the pro­
duction of enterotoxin SEA. Stock cultures were stored frozen, in liquid ni­
trogen (BOC), in growth m edium  (see below) including 50% v /v  glycerol. 
W hen required the stock cultures were thaw ed and subcultured through 
growth m edium  prior to being m aintained on nu trien t agar (Oxoid Ltd.) 
slopes a t 4°C for up to 3 days.
4.3 G row th M edium
Staphylococcus aureus strain FRI-722 (SEA) was grown in culture 
m edium , previously sterilized by autoclaving at 121°C for 20 m inutes. The 
m edium  consisted of 20.0 g/1 N-Z amine A (Sheffield P roducts) and 20.0 
g/1 proteose peptone no.3 (Difco Laboratories) and was adjusted to  a pH
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of 6.8. After the m edium  had cooled to room  tem perature, 0.5% (w /v) 
thiam ine and 1% (w /v) niacin grow th factors, previously sterilized by fil­
tra tion  using a 0.2 fim  pore filter (Millex; Millipore L td.) were added to  the 
growth medium. In addition, 50% (w /v) glucose, sterilized by autoclaving 
(115°C /15 mins), was added to give a final concentration of 2 g/1 in the 
growth medium.
4.4 P roduction  o f  SEA
To provide an initial inoculum , 1ml of sterile phosphate buffered 
saline (Appendix A) was washed over an agar slope culture of S. aureus 
FRI-722 and 0.7 ml of the suspension used to  seed 50 m l of growth m edium  
in a 300 ml Ehrlenm eyer flask. The culture was then shaken at 300 rpm  
in an orbital shaker (INR-200; Gallenkam p), for 16 h to  20 h a t 37°C. Af­
ter growth of this culture, 10 ml was used to  inoculate 500 ml of the same 
m edium  in a 2 1 flask, and shaken (300 rpm ) overnight a t 37°C. Finally this 
seed inoculum (500 ml) was used to  inoculate a 15 1 Biostat E bioreactor 
(B .Braun Medical Ltd.) which held 15 1 of grow th m edium  sterilized in situ  
(121°C/20 m in), containing 0.03% (final concentration) sterile (121°C/15 
min) polypropylene glycol 2000 antifoam  (KW ; Revai Chemicals L td.). The 
air into the ferm enter vessel was filtered (Emflon; Pall), and the dissolved 
oxygen concentration set to  20% and controlled using bo th  agitation and 
aeration (10 1/min). The stirrer speed was initially set to  280 rpm  and the 
culture grown overnight a t 37° C.
After growth the bacterial cells were removed from the culture 
m edium  using a Millipore Pellicon cassette system  (Millipore UK Ltd.) 
containing 10 x 0.45 /m i m em branes (HVLP OM P50) and the culture fil­
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tra te  concentrated down to 1 1 using the sam e Pellicon cross-flow filtration 
system  fitted with two 10,000 molecular weight cut-off m em branes (PLGC 
OM P05). To prevent growth and degradation of toxin occurring during 
the remaining dow nstream  processing, 0.5M EDTA (BDH) was added to 
the concentrated culture m edium  to give a final concentration of 0.2 mM. 
The concentrated culture supernatan t fluid was dialysed overnight a t 4°C 
in 20 mM potassium  phosphate, buffer pH 6.8.
4.5 Purification o f SEA
4.5.1 D ye Ligand Affinity C hrom atography
Purification of SEA by dye-ligand chrom atography was essentially the 
same as th a t used for the purification of TSST-1 as described in Section 
3.5.1.
4.5 .2  Fast P rotein  Liquid C hrom atography
Those Red A column fractions containing SEA were pooled and pu­
rified further using fast protein liquid chrom atography (FPLC; Pharm acia 
Ltd.). Also, samples of SEB and SEC2, previously purified by Red A 
chrom atography and stored frozen in 60 mM  potassium  phosphate buffer 
(SEB) or 35 mM potassium  phosphate buffer (SEC2) bo th  a t pH 6.5, were 
thawed and placed in dialysis tubing (Scientific Instrum ents L td.). All 
toxin samples were individually dialysed overnight in 50 mM sodium ac­
e tate  buffer pH 5.0 at 4°C and loaded in separate batches of approxim ately 
20 m l onto an FPLC HiLoad S Sepharose high perform ance 16/10 column 
(Pharm acia) which had previously been equilibrated w ith dialysis buffer. 
The column was eluted at room  tem perature  using a 150 m l linear gradient
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(0-250 mM ) of NaCI at a flow ra te  of 2 m l/m in . Fractions were collected 
using a Pharm acia fraction collector (SuperFrac 2211) and those giving an 
A280 >0.2 units were collected and tested  for the  presence of toxin using 
single radial immunodiffusion (Section 3.6). A fter elution bo th  the Red 
A and the S Sepharose columns were regenerated according to  the m anu­
facturers instructions. Finally the purified toxins were all dialysed against 
MilliQ or ElgaStat water. The concentration of the  purified toxin samples 
was determ ined using the relevant extinction coefficient a t 280 nm  (Table 
4.1). The equivalent of 1 mg am ounts of the  freshly purified toxin solu­
tion were added to small vials and lyophilized before storage a t 4°C until 
required.
4.6 Toxin A ssay
Enterotoxin concentrations were estim ated  using single radial im m un­
odiffusion (Meyer and Palmieri, 1980) as described in Section 3.6.
4.7 Criteria o f  Purity
The purity  of the toxin samples was determ ined using sodium dodecyl 
sulphate -polyacrylamide gel electrophoresis (SDS-PAGE) on precast gra­
dient gels (M ini-PROTEAN II, BioRad) a t 150 V for 1.5 h. The gel was 
stained for 1 h on ethanol/acetic acid (3:1, v /v )  containing 0.1% coomassie 
blue R250 (Pharm acia) and destained overnight by diffusion. Isoelectric 




The toxin stock solution was prepared by resuspending the lyophilized 
toxin preparations in MilliQ or E lgaS tat w ater. Unless otherwise stated  all 
chemicals used were of analytical grade from  Sigma. All of the stock solu­
tions contained a final concentration of 0.02% sodium  azide as a bactericide. 
The initial crystallization trials for SEA, SEB and SEC2 were perform ed 
at room tem perature  by the hanging drop m ethod  (M cPherson, 1982) us­
ing the sparse m atrix  sampling protocol of Jancarik  and Kim (1991). In 
the crystallization of SEA, a new sparse m atrix  protocol called Crystal 
Screen II (H am pton Research, USA.) was also used. The individual drops 
(6^1) consisted of equal volumes of reservoir stock solution and toxin. The 
drops were mixed on either plastic (Therm anox) or glass coverslips (Chance 
Propper L td.), which were then  inverted over wells in a  tissue culture plate 
(Linbro, Flow Labs) and sealed w ith high vacuum  silicone grease (Dow 
Corning). The crystals were m ounted in quartz  capillaries as described in 
Section 3.9.1.
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R esults and D iscussion
SEA, SEB and SEC2 were all purified using a com bination of Red 
A (Figure 4.1) and FPLC  (Figures 4.2, 4.3 and  4.4 respectively). The 
concentration of SEA in the culture m edia after large scale culture was 
estim ated to be 0.028 m g /m l and after purification the overall yield for SEA 
(Table 4.2) was 34% from  the ferm enter culture. This yield was less than  
th a t previously reported to be 49% by Brehm  et al. (1990). The difference 
in these yields can be explained by loss resulting from the final FPLC clean 
up step Despite these losses, the simplicity of the  purification protocol 
enables it to  be used to  prepare large am ounts of toxin for crystallography. 
SDS-PAGE gels of SEA, SEB and SEC2, purified to the FPLC  stage were 
all shown to exist as a single band, with a purity  >99% (Figure 4.5). 
However, these same samples on an IE F  gel indicated th a t these toxins all 
existed in multiple isoelectric forms (Figure 4.6).
4.9 C rystallizations
4.9.1 SEA
Crystals of SEA were not obtained despite the extensive use of both  
the Magic 50 and C rystal Screen II (H am pton Research) protocols over a 
range of different tem peratures (13°C to 25°C) and protein concentrations 
(2 m g /m l to  20 m g/m l).
4.9.2 SEB
SEB crystallized as ‘rosette-like’ plates when a 20 m g/m l protein 
stock solution was mixed with an equivalent volume of 0.1M TRIS buffer
130
pH8.5 containing 0.2M lithium  sulphate and  28-32% polyethylene glycol 
3350.
4.9 .3  SEC2
Small crystals of SEC2 appeared after four weeks when a 2 m g /m l 
protein stock solution was mixed w ith an equivalent volume of 0.1M cacody- 
late buffer pH6.5 containing 0.15M am m onium  sulphate and 26% polyethy­
lene glycol 3350. These crystals reached a m axim um  size of 0.3 m m  x 0.4 
m m  x 0.8 m m  (Passalacqua et al., 1993) after eight weeks (Figure 4.7).
4.10 D ata C ollection and P rocessin g  o f  SEC 2
For diffraction analysis, crystals of SEB and SEC2 were carefully 
m ounted as described in Section 3.9.1. Initial d a ta  collection for SEC2 were 
perform ed at ambient tem perature  on a Siemens area detector m ounted on 
a Siemens ro tating anode X-ray source using C uK a radiation and operating 
between 44-50 kV and 76-80 mA w ith a wavelength of 1.518A. Crystals of 
SEC2 were found to be well ordered and suitable for diffraction studies. 
However, crystals of SEB were highly disordered and even after extensive 
a ttem pts to produce ordered crystals by varying crystallization conditions, 
they diffracted to only 5A and were not considered for fu rther analysis. All 
the d a ta  from these studies were processed on a VAX workstation using 
the XDS package of program s (Kabsch, 1988).
Two SEC2 crystals were used to  collect this in-house d a ta  and gave 
an Rmerge of 7.5% with a total completeness of 86.6%. The 20 angle was 
25° and the tim e per frame of 420 s. Table 4.3 illustrates the in-house 
d a ta  collection for SEC2. Initial results from XDS (Kabsch, 1988) indi­
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cated th a t the SEC2 crystals belonged to the  te tragonal space group P i22 
with unit cell param eters of a=b=43.2A and c=290.9A (Passalacqua et 
al., 1993). Assuming a m onom er per asym m etric un it, the specific volume 
of the protein was 2.46A3/D a  and corresponds to  50% (v /v ) solvent con­
tent (M atthew s, 1968). Prelim inary d a ta  processing of the  SEC2 crystals 
showed th a t the large c edge was 290A which suggested th a t d a ta  collec­
tion would best be perform ed at the SRS. T he crystal to  detector distance 
on the in-house equipm ent was approaching its lim it for d a ta  collection a t 
28.5 cm.
Native SEC2 d a ta  were also collected at th e  SRS D aresbury (PX 9.5) 
(A=0.92A) and processed to 3.4A using the program  DENZO (Otwinowski, 
1993) which has the facility for interactive indexing of the  diffraction spots. 
The crystal to detector distance was 325 m m , 60 s /° , 0.75°/ oscillation and 
2 oscillations per image. Only one SEC2 crystal was required to collect this 
da ta  (Table 4.4). The final Rmerge was 5.5% b u t analysis of the num ber 
of reflections per shell indicated th a t 83.2% of the  d a ta  was collected to 
3.4A. In the event it was decided to  use the SRS D aresbury da ta  with 3927 
unique reflections for subsequent molecular replacem ent analysis.
4.12 Structure Solution o f SEC2 U sing M olecular R eplacem ent
4.12.1 M ER LO T M olecular R ep lacem ent
During this study the 3-D structu re  of TSST-1 was found to  resemble 
th a t of SEB (Sw am inathan et al., 1992). The homology between SEB and 
SEC2 is reported to be 86% hence TSST-1 was initially regarded to be a 
good search model for the structure  determ ination of SEC2 by molecular 
replacement.
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Patterson  functions of the complete TSST-1 structu re  were used in 
the initial ro ta tion  searches. These were based on the calculated s tructu re  
factors for TSST-1 in an artificial unit cell of 80 x 80 x 80A. The Crow ther 
ro tation  search (Crow ther, 1972) was carried out over the resolution range 
8 to  4A. Harmonic coefficients were calculated using a P atterson  cut-off 
radius of 24A to reduce the problem  of interm olecular vectors. Figure 4.8 
shows the program s used in M ERLO T m olecular replacem ent (Fitzgerald, 
1988; Appendix B). Refinement of the value given from ROTATION was 
carried out using ROTATION-FINE. The L a ttm an  ro ta tion  function using 
the program  LAT was used to refine this peak and from  this the translation 
search was perform ed (L attm an  and Love, 1970).
4.12.2  S tructure R efinem ent o f  the M E R L O T  Solution
Initial R -factor refinement was carried out on the TSST-1 search 
model after it was first converted to  a polyalanine structure . A polyalanine 
structure  was used reduce any bias given by any incorrect side chains in 
TSST-1. It was then orientated and positioned in accordance w ith the 
M ERLOT solution. The initial R-factor was 55% for d a ta  from 8 to  4A. 
Refinement was perform ed using a com bination of the  molecular dynamics 
and sim ulated annealing from the X PLO R  package of program s (Brunger, 
1988), with m anual rebuilding. An overview of the  protocol is given in 
Figure 4.9. The final R-factor for this polyalanine model was 37%.
Using the  polyalanine model a (2 | F0 | — | Fc |) m ap was calcu­
lated which was assessed against the density using FRODO (Jones, 1985). 
The electron density m ap was initially very difficult to  in terpret w ith a 
significant am ount of ambiguous density. This was due to  the size differ­
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ential between TSST-1, with 194 am ino acids, and the m uch larger SEB 
molecule with 239 amino acids. Several a ttem p ts  were m ade to  manually 
alter certain m ain chain connectivity and to  include any side chains when­
ever possible. From the secondary s tructu re  alignm ent of TSST-1 with 
SEB (Table 3.10), it was possible to  add the  entire SEC2 a2  helix in one 
a ttem pt (Figure 1.1). W hen the a2  helix was added  to  the  m ap m ore scat­
tering m atte r was available for phase calculation. The polyalanine a l  and 
a3  helices were incorporated into the m ain chain ready for further refine­
m ent. From a visual inspection of the SEB stru c tu re , (Sw am inathan et al. 
1992), a polyalanine ‘disulphide loop’ was incorporated , in addition to the 
first 17 amino acid residues.
Three further rounds of refinement were perform ed on the model 
including addition of the other side chains to  try  and increase the scattering 
m atte r available to provide phases for the calculation of struc tu re  factor. 
It was obvious however by the end of round 4, th a t there were significant 
problems with the new T SST/SEC 2 model (/2-factor of 58.5%). These 
problems included significant num bers of bad  side chain contacts which 
could not be relaxed during sim ulated annealing refinem ent. These side 
chain clashes were extremely difficult to rem edy using m anual rebuilding 
in an a ttem pt to establish an improved agreem ent between the model and 
the available da ta . The final electron density m ap  generated was poor.
A second a ttem p t to  determ ine a correct molecular replacem ent so­
lution using the  same sequence of program s resu lted  in the generation of a 
different potential ro tation function peak. The top  peak was used for the 
subsequent molecular replacem ent trial and the  m odel was converted to its 
polyalanine equivalent and repositioned according to  this potential solution
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ready for refinement. After round 1, SEC2 side chains were added to the 
search model using FRODO. The m ajor a  helix was the first secondary 
structure  element to be added which resulted in an im proved .R-factor of 
39.6%. An inspection of the results from  the second round of refinement af­
ter the sym m etry operators were included however revealed several internal 
intram olecular clashes which prevented struc tu re  solution.
4.12.3 A M oR E  M olecular R eplacem ent
Due to the poor results of m olecular replacem ent w ith the  M ERLOT 
package, a new package called AM oRE (Navaza, 1994) was used in a final 
a ttem pt to solve the SEC2 structure  using the  refined TSST-1 structure 
as the search model. AMoRE is a new m olecular replacem ent com puter 
package which has been improved over previous m ethods by involving more 
powerful algorithm s (Navaza, 1994). It is a m uch quicker au tom ated  pack­
age of program s which explores a great m any potential solutions. AMoRE 
makes use of a correlation coefficient as its m ain selection criteria for peaks 
as well as an R-factor value. This improved algorithm  is used to  calculate 
the structu re  factors of the ro tated  and translated  search model.
The TSST-1 m onom er was used as the first search model and the da ta  
processed using the series of program s which m ake up this package, (Figure 
4.10; Appendix B). The final correlation coefficient as defined in AMoRE 
(Navaza, 1994) was 24 with an associated R -factor of 54.2% (Table 4.5), 
suggesting th a t this first solution was not correct. W hen this procedure 
was repeated using a different resolution range, w ithout changing the other 
values, the molecular replacem ent solution was still found to  be incorrect. 
The difficulty associated with using this technique is th a t any correlation
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coefficient value approaching 60% is in effect a random  solution. Although 
the whole process was repeated after changing the sphere of radius there 
was still no sufficiently acceptable solution. Having used the whole TSST-1 
molecule as a search model, molecular replacem ent was a ttem p ted  using a 
polyalanine TSST-1 search model by converting the  side-chains to  their (3 
carbons thus reducing any bias given by incorrect side chains.
The individual TSST-1 domains (1-96 and  97-194) were used in an­
other a ttem p t a t molecular replacem ent. O n the  first run  w ith domain 
1 ie. residues 1 to  96, AMoRE failed. A com parison of the structures 
of TSST-1 with SEB showed th a t there were significant differences be­
tween the  secondary structure elements at the  very beginning of the two 
molecules. However, analysis of the m olecular replacem ent ou tpu t pro­
vided no genuine solution. Repeated a ttem p ts  to  vary the resolution range 
and the  sphere of radius for domain 1 were unsuccessful. The sam e result 
was obtained during a ttem pts to solve the SEC2 structu re  using the full 
TSST-1 sequence for domain 2, although there  was no need in this case to 
remove any residues from the dom ain. Even conversion of the two individ­
ual dom ains to the polyalanine model and altering param eters such as the 
sphere of radius failed to provide any peaks; all the  correlation coefficients 
were >50% (Table 4.5).
In  a final a ttem p t to solve the SEC2 s truc tu re  the whole TSST- 
1 model was converted to  a polyalanine s tru c tu re  replacing only those 
residues known to  be in the secondary s truc tu re  elements of SEC2 from 
the SEB d a ta  (Sw am inathan et al., 1992). The SEB d a ta  was extrapolated 
to  the SEC2 sequence (both  SEB and SEC2 have 239 amino acid residues; 
Table 1.1) and assuming tha t the secondary elements are identical, all
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‘known’ residues of SEC2 were replaced (not inserted) into the TSST-1 
search model. This resulted in 120 residues being replaced in the polyala­
nine TSST-1 model with SEC2 residues. Despite this the new search model 
in its entirety or even its individual dom ains failed once again to  produce 
any noticeable peaks above background.
Having tried a num ber of different strategies to  solve the structure 
of SEC2, none of them  gave a solution. After all these efforts it was clear 
th a t it was ra ther difficult to obtain a clear solution for the SEC2 structure 
using molecular replacem ent and TSST-1 as the  starting  structure.
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D ata  from  fS chan tz  et al., 1972; {Borja and  Bergdoll, 1967; *Schantz et al., 1965
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T ab le  4 .2  Purification of SEA by ‘Red A ’ and fast protein liquid chro­





















FPLC 143 81 34
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oo-15.00 71 71 41 41 57.7
15.00-10.00 149 220 129 170 86.5
10.00-8.00 185 405 172 342 92.9
8.00-6.00 478 883 447 789 93.5
6.00-5.00 588 1471 567 1356 96.4
5.00-4.50 508 1979 505 1861 85.5
4.50-4.00 759 2738 758 2619 99.8
4.00-3.50 1269 4007 1266 3885 99.7
3.50-3.40 334 4341 333 4218 99.7
3.40-3.30 386 4727 384 4602 99.4
3.30-3.20 437 5164 437 5039 100.0
3.20-3.10 461 5625 459 5498 99.5
3.10-3.00 585 6210 573 6071 97.9
3.00-2.90 609 6819 601 6672 98.6
2.90-2.80 735 7554 716 7388 97.4
2.80-2.70 809 8363 791 8179 97.7
2.70-2.60 980 9343 850 9029 86.7
2.60-2.50 1112 10455 26 9055 2.3
Total 10455 9055 86.6
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1 2 3 4 5
oo-15.00 71 71 44 44 61.9
15.00-10.00 149 220 124 168 83.2
10.00-8.00 185 405 163 331 88.1
8.00-6.00 478 883 414 745 86.6
6.00-5.00 588 1471 526 1271 89.4
5.00-4.50 508 1979 470 1741 92.5
4.50-4.00 759 2738 696 2437 91.6
4.00-3.90 201 2939 190 2627 94.5
3.90-3.80 230 3169 209 2836 90.8
3.80-3.70 252 3421 238 3074 94.4
3.70-3.60 253 3674 239 3313 94.4
3.60-3.50 333 4007 316 3629 94.8
3.50-3.40 334 4341 298 3927 89.2
Total 4341 3927 83.2
Colum n 1, num ber of possible reflections; 2, cum ulative num ber of possible reflections; 
3, num ber of reflections; 4, cum ulative num ber of reflections; 4, percentage possible.
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Whole 28 15-4 24 54.2
TSST-1 28 10-4 22 53.0
24 15-4 25.9 55.2
Polyalanine 24 10-4 34.2 54.3
TSST-1
Domain 1 24 10-4 19.7 54.6
TSST-1
Domain 2 24 10-4 28.4 56.1
TSST-1 24 20-4 25.3 55.2
24 15-4 26.1 55.8
Polyalanine 24 10-4 26.1 53.8
Domain 1 24 15-4 27.1 55.7
TSST-1
Polyalanine 24 10-4 26.1 55.8
Domain 2 24 15-4 25.9 56.4
TSST-1
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Figure 4.1 Dye ligand chromatography of SEA using Red A. The column (4.5 x 31 cm) 
was equilibrated in 20 mM phosphate buffer, pH 6.8, and eluted with a stepwise increase 
in molarity of phosphate buffer, pH 6.8. Fractions (10 ml) were collected at a flow rate of 
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Figure 4.2 Final purification of SEA by FPLC, after previous chromatography using 
Red A. The 20 ml HiLoad S Sepharose high performance 16/10 column (Pharmacia) 
was equilibriated with 50 mM sodium acetate buffer pH 5.0. Toxin was eluted using 150 
















Figure 4.3 Final purification of SEB by FPLC, after previous chromatography using 
Red A. The 20 ml HiLoad S Sepharose high performance 16/10 column (Pharmacia) 
was equilibriated with 50 mM sodium acetate buffer pH 5.0. Toxin was eluted using 150 


























Figure 4.4 Final purification of SEC2 by FPLC, after previous chromatography using 
Red A. The 20 ml HiLoad S Sepharose high performance 16/10 column (Pharmacia) 
was equilibriated with 50 mM sodium acetate buffer pH 5.0. Toxin was eluted using 150 










Figure 4.5 An SDS-polyacrylamide gradient 10 to 20% precast gel (Mini-PROTEAN 
II, BioRad) showing analysis of the final purity of SEA, SEB and SEC2 after FPLC 
purification. Lane A, SEA. Lane B, SEB. Lane C, SEC2. Lane D, molecular mass 
markers (kDa): phosphorylase b, 94; albumin, 67; ovalbumin, 43; carbonic anhydrase, 
30; trypsin inhibitor, 20.1 and a-lactalbumin, 14.4. Lanes A to C were loaded with 10 
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Figure 4.0 Isoelectric focusing of SEA, SEB and SEC2 after final purification by FPLC. 
Lanes A and E, pi markers: trypsinogen, 9.3; lentil lectin (basic band), 8.15; horse myo­
globin (basic band), 7.35; human carbonic anhydrase B, 6.55; bovine carbonic anhydrase 
B, 5.85 and /3-lactalbumin, 5.2. Lane B, SEA. Lane C, SEB. Lane D, SEC2.
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F ig u r e  4 .8  Flow diagram  for SEC2 m olecular rep lacem ent th ro u g h  th e  M E R L O T  pack­







F ig u r e  4 .9  Flow diagram  to show SEC2 refinem ent th ro u g h  X P L O R  package of pro­






F ig u r e  4 .1 0  Flow diagram  to  show SEC2 m olecular rep lacem ent th rough  th e  A M oR E 
package of program s (Navaza, 1994).
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C h a p te r  5
S tr u c tu re - F u n c t io n  S tu d ie s  o f  th e  S ta p h y lo c o c c a l E n te ro to x in s  
a n d  Toxic S h o ck  S y n d ro m e  T oxin-1  in  R e la t io n  to  th e i r  B io lo g ica l 
A c tiv ity
5.1 E m e s is
One feature common to all of the SEs is the centrally located disul­
phide loop (Swam inathan et al., 1992; Figure 3.21). A lthough there is 
some evidence to  suggest th a t this region may be responsible for emesis, 
there does not appear to be a complete dem arcation of this function and 
the T cell stim ulatory effects of the SE. Thus, it is still unclear w hether 
emesis is a result of T  cell stim ulation or w hether these two biological phe­
nom ena are unrelated. Site-directed mutagenesis of residue Leu 48 in SEA 
and Phe 44 in SEB have been shown to reduce T  cell proliferation b u t the 
toxins m aintained their emetic properties when fed to  monkeys (Harris et 
al.} 1993). This study suggested th a t these two activities are located at 
two different sites on the toxin. M utants residues th a t form  the disulphide 
bridge in SEA, Cys 106 to  Ala (G rossm an et al., 1991), and SE C l Cys 110 
to  Ala (Hovde et a l ,  1994) both  prevented emetic activity. However, when 
another SECl m utan t, Cys 110 to Ser was prepared there was no appre­
ciable loss in emetic capacity (Hovde et al., 1994). It was noted th a t there 
was a 100-fold reduction in the ability of SEA m utan ts  Cys 96 and  Cys 
106 to  induce T  cell proliferation while still binding to  MHC II molecules 
(Grossm an et al., 1992). Unlike the SEs, TSST-1 does not possess any 
disulphide bridges and does not appear to prom ote emesis in individuals 
suffering from TSS (Spero and Morlock, 1978).
5.2 S taphylococcal E nterotoxin  B inding S ites for M H C  II
A num ber of studies have been perform ed to  dem onstrate  the  sites 
on the SEs responsible for binding to  MHC II. As SED and SEE are pro­
duced only in sm all am ounts and there is a  difficulty in obtaining sufficient 
pure protein to  carry out meaningful studies, the  m ajority  of this work has 
been perform ed on SEA and SEB. These include the  use of enzymatically 
and chemically prepared peptide fragm ents and  site directed mutagenesis 
of the toxin molecules. Deletion m utan ts  of SEA have indicated problems 
associated w ith protein instability. For exam ple, Hufnagle et al, (1991) 
dem onstrated  th a t removing the last C te rm inal am ino acid of SEA did 
not appear to  affect the biological activity of th e  toxin. However, deletions 
of three m ore SEA residues from  the C term ina l did show a loss of bio­
logical function, ie. it abrogated T  cell activity, associated w ith molecule 
instability ie. a  change in conform ation. F raser et al. (1992) dem onstrated 
the need for Zn2+ ions to be present for SEA, SED and SEE for efficient 
binding to  MHC II. This Zn2+ ion appears to  be necessary to  stabilize the 
SE/M H C II complex.
N term inal peptide fragm ents alone from  SEB (residues 1 to 138) 
were shown to possess mitogenic activity (Buelow et al., 1992). In  a differ­
ent experim ent, the  mitogenic activity of whole SEB was inhibited when a 
num ber of short SEB peptide fragm ents were in troduced  separately to  holo- 
toxin SEB which prevented binding to  MHC II (K om isar et al., 1994). One 
of these peptide fragm ents (90 to 114), which covered the entire disulphide 
loop, was shown to be the m ost effective in preventing MHC II binding. 
Sw am inathan et al. (1992) m ention two regions thought to  be involved in 
MHC II binding. They are region 1 which include residues 9 to  23 and
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region 2 which include residues 40 to  53. In the event, the crystal structure  
of SEB complexed to DR1 confirmed the role played by the dom ain 1 (3 
barrel and f35 helix of dom ain 2 of SEB in binding to  MHC II (Jardetzky 
et al., 1994). The loop between f3 strands 1 and 2 and a portion of strand  
3 were found to  be the most im portan t binding regions of SEB for MHC 
II. Bohach et al. (1989) dem onstrated in SEC1 th a t removal of the N te r­
m inal 59 amino acid residues by trypsin, did not affect the superantigenic 
properties of the toxin. This C term inal fragm ent of SEC1 was still pyro- 
genic, mitogenic and in the rabbit model caused enhanced suceptability to 
lethal endotoxin shock. Using random  m utational studies, K appler et al. 
(1992) identified SEB residues 13 to 17 and 41 to  55 as im portan t in MHC 
II binding.
Hoffmann et al. (1994) characterised a num ber of synthetic peptide 
fragm ents of SEC1 to determ ine those residues of the prim ary sequence 
which may be involved in MHC II binding. They deduced th a t three pep­
tides 74 to  86, 148 to 162 and 156 to  171 were involved not only in T cell 
proliferation bu t also MHC II binding. From  their SEC3 structure  (Hoff­
m ann et al., 1994) they noted th a t these peptides are located around a 
structure  called the a5  groove. They suggest th a t this groove could easily 
provide a potential binding site for the a  helix of the MHC II molecule.
5.3 Toxic Shock Syndrom e Toxin-1 B inding Sites for M H C  II
Early experim ents on the localization of biological function, m ade use 
of internal cyanogen brom ide-generated fragm ents of TSST-1 and neutral­
izing monoclonal antibodies prepared against these fragm ents (Blomster- 
H autam aa et al., 1986c). These workers m anaged to  produce three IgG
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monoclonal antibodies which blocked bo th  th e  TSST-1 induced mitogenic 
activity and the immunoglobulin suppression in mice cells. One of these 
fragm ents (14kDa), consisted of residues 33-158, which spans bo th  domains 
of TSST-1.
Chemical modification of histidine and tyrosine (Kokan-Moore and 
Bergdoll, 1989a) or m ethionine (Kokan-M oore and Bergdoll, 1989b) 
residues showed th a t modification of four of the  five histidine residues, 
with diethylpyrocarbonate, reduced its m itogenic effect by 50%. Although 
a monoclonal antibody was not able to  react w ith the modified toxin, bind­
ing to  polyclonal antibody preparations was not affected. The lack of re­
activity with the monoclonal antibody together w ith far-UV CD studies, 
on the modified toxin molecule, indicated an increase in the a  helical con­
tent after modification, suggested th a t there was a  change in the tertia ry  
structure  of the toxin at a crucial antigenic site. M odification of only one 
or two of the nine tyrosines of TSST-1, using te tran itrom ethane was found 
to  inhibit up to 85% of the mitogenic activity. C ircular dichroism analysis 
of this modified protein showed a m arked change in secondary structure 
elements which may explain the decrease in activity. Unfortunately these 
experim ents were unable to precisely identify those residues which are in­
volved in the mitogenic activity of the  toxin. A lkylation of the m ethionine 
residues, using iodoacetic acid, revealed no change in the mitogenic ac­
tivity or change in tertiary  structu re  as dem onstrated  by no alteration of 
the binding of polyclonal antibodies, this suggested th a t the two m ethion­
ines, located at residues 33 and 158, are not solely involved in this activity 
(Kokan-Moore and Bergdoll, 1989b).
Many N term inal protease-generated peptide fragm ents from  TSST-1
156
have been im plicated in MHC II binding. One problem  associated w ith in­
terpreting the d a ta  is th a t contam ination of these peptide fragm ents with 
nanogram m e quantities of the holotoxin m ay m ask the true  location of 
active epitopes on the peptides. To circum vent this problem  such studies 
have been repeated w ith chemically synthesised peptide fragm ents. Syn­
thetic peptide fragm ents located w ithin dom ain 1 of TSST-1 th a t have 
been im plicated in MHC II binding are: 34 to  43 (M urphy et al., 1988), 
58 to 78 (Edwin et al., 1991) and 39 to 68 (Pontzer et al., 1992; Soos et 
al., 1993). Figure 5.1 illustrates the location of these sites on the TSST-1 
molecule. Com petitive binding studies between individual fragm ents and 
radiolabelled 125I-TSST-1 for whole cell-bound MHC II molecules, revealed 
th a t a N term inal region of TSST-1 (fragm ent 39 to  68) m ay be involved 
in binding to  MHC II molecules (Pontzer et al., 1992; Soos et al., 1993). 
Another fragm ent 58 to 78 (Edwin et al., 1991) was itself capable of pro­
m oting in vitro proliferation of hum an peripheral m ononuclear cells with 
concom itant induction of TN F secretion and as a  result was im plicated as 
binding directly to MHC II molecules. The range of these fragm ents, 34 to 
78, are all located around strands (32, (33 and (34 in the concave region of 
the N term inal (3 barrel.
In contrast other workers have dem onstrated  th a t a  significant por­
tion of dom ain 2 is also involved in MHC II binding. For example fragm ents 
88 to 158 (Edwin and Kass, 1989) and also 155 to  194 (Soos et al., 1993) 
have been shown to possess superantigenic properties (Figure 5.1). The 
reasons for this la tte r observation may be the  result of residues 170 to  180 
which are sterically adjacent to the concave region in dom ain 1.
Edwin and Kass (1989) used papain generated fragm ents of TSST-1,
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and reported th a t a C term inal fragm ent residues 88 to  158, could bind 
to  monoclonal antibodies known to  prevent m itogenic activity. From the 
structure  of TSST-1 reported here, this peptide fragm ent represents an 
interface between domains 1 and 2 finishing a t the  end of s trand  j39. It is 
not clear how this fragm ent alone could contain all the  elem ents necessary 
for superantigenic activity.
Using monoclonal antibodies to  TSST-1 and  site directed m utagen­
esis of the toxin, Bon ventre and colleagues (1988) tried  to  elucidate the 
regions of reactivity and more specifically the  residues involved in TSST- 
1-caused mitogenicity. In their early studies they  showed th a t some mono- 
clonals could reduce mitogenesis in a  dose dependent m anner; others could 
prevent TSST-1 induction of interleukin-1 from  hum an m onocytes. Most 
significant was the ability of one m onoclonal antibody, 8-5-7, to  prevent 
the death  of rabbits given a constant supply of TSST-1 by intravenous 
adm inistration. The protected rabbits showed no obvious clinical signs of 
the renal and hepatic disorders characteristic of the controls. They used 
this toxin neutralizing monoclonal 8-5-7 as a probe to fu rther investigate 
regions in TSST-1 th a t were responsible for the  sym ptom s of toxic shock 
syndrome.
Site directed mutagenesis studies of TSST-1 have been based mainly 
within the region covering residues 34 to 158 as a result of the peptide 
studies described above. W hen the m utan ts which do not appear to  influ­
ence m itogenicity are plotted on the TSST-1 m odel it is possible to identify 
regions which may be discounted as being crucial for superantigen activity. 
For example single m utants His 74 (which lies a t the top of /?4 strand  of 
the dom ain 1 f3 barrel and is exposed to the solvent) and Tyr 153 (located
158
within domain 2 on (39) and double m utan ts T yr 51.Tyr 52 (bo th  located 
in the loop linking strands (33 and (34) and T yr 80.His 82 (bo th  located 
on (35), all of which were m uta ted  to  Ala, still retained full mitogenicity. 
They were all indistinguishable from the native toxin when tested  in rabbits 
(Blanco et al., 1990; Bonventre et al., 1993).
5.4 T Cell R eceptor B inding Sites on th e  S taphylococcal Entero- 
toxins
For T cell proliferation to occur the SE m ust first bind to  the  MHC 
II molecule. Therefore, any experim ents to  locate the TcR  binding sites on 
a SE m ust not effect the MHC II binding. L ittle inform ation is available in 
term s of SE generated peptide fragm ents, to  suggest possible TcR  binding 
sites. Confusion has arisen from experim ents which describe bo th  domains 
as necessary for TcR  binding. Spero and Morlock (1978) dem onstrated  th a t 
the N term inal fragment (6.5 kDa) of SEC1 was responsible for mitogenic 
activity. They showed th a t the C term inal (28 kD a) fragm ent was inactive. 
This is in contrast to work by Bohach et al. (1989) which indicated th a t the 
C term inal fragm ent (21 kDa) of SEC1 m ain tained  the characteristics of 
the holotoxin. SEB has been studied via site directed m utagenesis studies 
to reveal the putative TcR binding sites. K appler et al. (1992) showed th a t 
regions 1 and 3 (residues 9 to 25 and 60 and 61 respectively) had  influence 
on the T cell activation. Asp 25 was shown to  be the m ost im portan t 
residue involved in T cell activation. This Asp residue has been conserved 
in all the SE (Figure 1.1) but not TSST-1.
Irwin et al. (1992), in a series of hybrid molecules of SEA and SEE, 
identified just two residues in SEA which could discrim inate between V(33
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and  Y/311. Briefly, the SEA and SEE molecules were split into th irds and 
the  generated hybrids tested to see how they bound to MHC II and  for T 
cell activation. SEA binds to V/93 molecules and SEE to Y/311 molecules. 
These hybrid molecules m aintained similar nanom olar binding affinities to 
the  MHC II as well with ‘norm al’ T  cell binding characteristics. From 
these d a ta  the hybrids were assum ed to have m aintained their s truc tu ra l 
integrity. Eventually, SEA residues 220 and 221 were shown to be respon­
sible for discrim inating between the two Y/3 molecules. If extrapolated  to 
the  SEB structure , these two residues are located on the loop leading to 
the  c*5 helix.
Hoffmann et al. (1994) recently dem onstrated  potential T cR  binding 
sites by producing a num ber of deletion m u tan ts  in the highly conserved 
N term inal region of SEC1. The first m u tan t lacked residues 6 to  13 with 
the result th a t it induced norm al T  cell proliferation. However, the  second 
m u tan t w ith deleted residues 19 to  33 was rendered non-mitogenic. In ter­
estingly, this second m utan t was capable of inhibiting native SEC1 binding 
to  MHC II and native SE C l induced T cell proliferation.
5.5 T C ell R eceptor B inding Sites on  Toxic Shock Syndrom e  
T oxin-1
Recent work involving a num ber of site directed m utan ts of TSST- 
1 have been used in a rabbit infection m odel for toxic shock syndrom e 
(Bonventre et al., 1993). The prim ary objective of these studies was to 
com pare the toxicity, mitogenic potential and also the structure-function 
analysis of the  native toxin to th a t of the m u tan t toxins. One such m utan t 
generated  by a single point m utation  at His 135 which was converted to
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Ala in the m utan t toxin, (H135A; Figure 5.1), which was adm inistered to 
rabbits using an im planted subcutaneous cham ber. The m u tan t retained 
only 10% of the mitogenic activity present in  the  native toxin. W hen 
two other m utan t toxins were prepared by m aking related single conserved 
m utations at residue 135, one to glutam ine the  o ther to  asparagine, neither 
had any mitogenic activity (Bonventre et al., 1993).
In  addition to the work by Bonventre et al. (1988; 1993), a num ­
ber of other workers have carried out sim ilar m utation  experim ents and 
dem onstrated changes in the mitogenicity of recom binant toxins (Blanco 
et al., 1990; M urray et al., 1994). Single m utations of Tyr 115, and dou­
ble m utations His 141.Tyr 144 and E132.I140, which were all converted to 
Ala, were found to have decreased m itogenicity bu t were found to be un­
recognizable by monoclonal antibodies due possibly significant alterations 
of their 3D structure. Tyr 115 for example is located between the strands 
(37 and (38 and is exposed to the solvent. This residue m ay form part of the 
epitope recognised by the monoclonal 8-5-7. B oth  of the  residues affected 
by the double m utant 141.144 are buried inside the molecule and like the 
115 m utan t are thought to be crucial to m aintain ing the tertia ry  structure 
as a monoclonal produced against the native toxin cannot recognize the 
m utan t toxin. This m utation lies in the loop between the C term inal end 
of the m ajor helix a2  and the (39 s trand  following it.
The residues 132, 135 and 140 are all found on the m ajor helix of 
domain 2 (Figure 5.1). and are positioned in the  region of the molecule 
thought to be crucial for superantigenic activity. The m utations E132K 
and I140T were selected after a comparison was m ade between hum an wild 
type TSST-1 and ovine TSST-1 (Figure 1.1), where there are seven amino
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acid changes. Ovine TSST-1 is not lethal and only slightly mitogenic when 
repeatedly injected in the rabbit (Lee et al., 1992a).
A m ore recent study of site directed m u tan ts  and hybrid proteins 
(Deresiewicz et al., 1994; M urray et al., 1994) has throw n m uch light on 
w hat is considered to  be the likely sites in TSST-1 responsible for m ito­
genicity and lethality. These workers used wild type TSST-1, a variant 
of wild type TSST-1 called T S S T -0  found in sheep suffering w ith m asti­
tis (Ho et al., 1989; Lee et al., 1992b), a gene fusion product containing 
the N term inal region of wild type TSST-1 and containing the C term inal 
end of TSST-O , and  finally two site directed m utagenesis proteins TSST- 
0  K132E. The T S S T -0  toxin is differs from  wild type TSST-1 by seven 
residues (Asn 19, T h r 55, Ser 57, lie 69, Trp 80 in the N term inal domain 
and Lys 132 and lie 140 in the C term inal dom ain (Figure 1.1). TSST- 
O is only weakly mitogenic and does not cause TSS in (the mini osmotic 
pum p) rabb it model. Furtherm ore T S S T -0  is not pyrogenic and does not 
enhance endotoxic shock. The gene fusion protein  which contained the N 
term inal hum an TSST-1 sequence together w ith the C term inal ovine se­
quence differed from  wild type TSST-1 by only two residues a t 132 and 
140. This protein was not mitogenic nor did it produce the sym ptom s of 
TSS in rabb its . Subsequently M urray et al. (1994) produced single point 
m utan ts of the full T S S T -0  by changing residue 132 from  a Lys to a Glu 
similar to  th a t found in wild type TSST-1 and in a  separate experiment 
changing residue lie 140 in the fusion protein to  a  T hr. In the la tte r case 
the toxin resem bled wild type TSST-1 differing at residue Lys 132 only. 
Both of these two m utants clearly caused TSS in rabbits and were also 
capable of enhancing endotoxic shock bu t were only partially mitogenic.
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M urray et al. (1994) concluded th a t they had  identified unequivocally 
th a t the  C term inal dom ain of TSST-1 is involved in m itogenicity and 
th a t the  loss of the mitogenicity of the hybrid proteins was not due to  an 
alteration in its 3D conform ation because it still reacted  w ith bo th  poly and 
m onoclonal antibodies. However they did not rule out th a t subtle changes 
in the  side chain residue could have dram atically  altered the T cR  an d /o r 
the MHC II binding region on TSST-1. Indeed their d a ta  suggested th a t 
the hybrid fusion protein was in fact less mitogenic th an  wild type T S S T -0 . 
Finally M urray et al. (1994) concluded th a t the  five N term inal residues of 
T S S T -0  m ust somehow be involved in m itogenicity and th a t the mitogenic 
activity of TSST-1 is not just located in the  C term inal region.
It is perhaps not coincidental th a t residue His 135 and o ther residues 
located on this m ajor helix a2  are extrem ely accessible to solvent (Figure 
5.1). Such direct availability to the solvent, m ay be im portan t to  allow 
the  reactions involved w ith superantigenic m itogenicity to  proceed. If the 
concave region of dom ain 1 as involved in MHC II binding, it is entirely 
possible th a t the T cR  may bind on or near to  residue His 135 whilst the 
TSST-1 molecule simultaneously binds the MHC II molecule.
5.6 P rop osed  M odel for the T S S T -1 /M H C  I I /T c R  C om plex
As a result of this study a model has been proposed (A charya et al., 
1994) for the trim olecular complex of TSST-1, MHC II and T cR  based 
on site directed mutagenesis studies and crystallographic d a ta  from  both  
TSST-1 and SEB (Sw am inathan et al., 1992). This model identified two 
regions of the TSST-1 molecule, region 1 (residues 39 to  78 and 170 to 
180) and region 2 (residues Tyr 115, Glu 132, His 135 and He 140), th a t
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could interact with the MHC II and TcR  respectively (Figure 5.2). This 
model related only those gross struc tu ra l features involved in superantigen 
interaction.
It has been suggested th a t region 1 of TSST-1 binds to  one site on 
the DR1 molecule, at the end of the peptide binding cleft on DR1. This 
binding site is positioned exactly opposite to a  site on the DR1 /9 chain 
(residues 49 to 55) which itself has been im plicated in DR1 dim erization 
(Brown et al., 1993). The TSST-1/D R1 m odel was still com patible with 
the idea of DR1 dimerization. This hypothetical assembly allowed region 2 
on TSST-1 to rem ain accessible to  the TcR. It has been postulated  th a t the 
superantigens bind to the solvent exposed /? sheet (BDE) of the V/9 region, 
as deduced from immunoglobulin modeling (Pullen et al., 1990; Pullen et 
al., 1991; W hite et al., 1993). In addition the  dimerized DR1 molecules 
are still available for potential binding to  the  CD4 coreceptor (Brown et 
al., 1993).
5.7 Verification o f the Proposed  M odel
Since this study was completed the 3D s tru c tu re  of the D R1/TSST-1 
complex, to a resolution of 3.5A, has been elucidated by the technique of X- 
ray crystallography (Figure 5.3; Kim et al., 1994). The complex structure  
clearly illustrates the TSST-1 binding regions for MHC II. Figure 5.3 shows 
th a t TSST-1 binds DR1 via its N term inal (3 barre l and confirms bo th  the 
model proposed by Acharya et al. (1994; this study) and peptide fragm ent 
studies (Section 5.3). The C term inal dom ain of TSST-1 is tilted up and 
away from the DR1 molecule on binding thereby allowing access for TcR 
binding to  TSST-1. Domain 1 of TSST-1 entirely covers the a  helix of
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D R la  domain, makes a small num ber of contacts w ith the a  helix of DR1/? 
and most interestingly, makes contact w ith the  bound peptide fragm ent. 
TSST-1 covers almost half the ‘to p ’ surface of the  MHC II molecule.
Kim et al. (1994) report three m ajor con tact regions associated with 
D R1/TSST-1 binding. TSST-1 region I involves two loops between f3l 
and (32, and (33 and (34 which contact two loop regions of DR1 (between 
/? strands 1 and 2, and 3 and 4). Region II constitutes four (3 strands 
of TSST-1 (2, 3, 4 and 5) which lie above th e  a  helix of D R la  domain. 
Finally region III involves interaction between TSST-1 strands /?4 and (35 
and the bound peptide fragm ent. Table 5.1, based on Kim et al. (1994) 
illustrates the main residues involved in the D R 1/T SST-1 interactions.
The crystal s tructure  of D R 1/SEB  has also been determ ined to a res­
olution of 2.7A (Jardetzky et al., 1994). T he D R 1/TSST-1 and DR1/SEB 
structures are broadly similar w ith bo th  superantigens binding to  the side 
of the a  helix of DR1 via their N term inal /? barre l domains. However, 
closer inspection of these two structures reveal quite different modes of 
binding. TSST-1 binds DR1 at three regions (see above), and SEB binds 
to only two. The bound peptide fragm ent appears to  play no part in SEB 
binding to DR1. In addition, when the struc tu res  of D R 1/TSST-1 and 
D R1/SEB are com pared, 11 of 17 DR1 residues bind both  TSST-1 and 
SEB even though the complexed toxin orientations are different. Also, of 
24 contacts m ade by TSST-1 with DR1, 13 are structurally  identical with 
SEB in its DR1 complex (Jardetzky et al., 1994).
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5.8 Structural D ifferences O bserved in Toxic Shock Syndrom e
Toxin-1 D ue to D R l B inding
Wild type TSST-1 coordinates (this study) were superim posed over 
the TSST-1 coordinates from the D R 1/TSST-1 complex (Don Wiley, per­
sonal communication). This was undertaken to  highlight any conforma­
tional changes th a t may occur on TSST-1 binding to  D R l. The TSST-1 
coordinates from the D R 1/TSST-1 complex were superim posed over the 
wild type coordinates using the program  ASH (S tuart et al., 1979). The 
rms deviation for all 194 C a atom  pairs was 1.89A. Substantial C a rms 
changes (>3.5A ) from wild type occurred in four m ain regions: between N 
term inal residues 1 to 6, 76 to 79 (a loop between (33 and /?4), 107 and 109 
(a loop between (36 and (31) and 144 to 145 (a  loop between a2  and (39). 
These C a shifts are all rem ote from  the MHC II binding site and do not 
appear to play a role per se in the binding of TSST-1 to  the D R l molecule. 
The rm s deviation for all atom s, including side chains, was 2.4A. Table 5.1 
illustrates the most im portan t residues located a t the D R 1/TSST-1 in ter­
face. The apparent lack of gross (C a) conform ational change in TSST-1 
on binding indicates th a t m ajor changes in TSST-1 need not occur for it 
to  bind to the D R l molecule.
Residues 1 to 6 in the wild type TSST-1 molecule are m ore closely 
associated w ith dom ain 2 than  dom ain 1. In  the  wild type, the C a  of 
Ser 1 is 5.14A away from C a of Ser 147. However, significant changes are 
seen when TSST-1 is complexed to  D R l. Complexed TSST-1 residues 1 
to 6 now move away from residue Ser 147 and towards the D R l peptide 
binding site. The C a  residue 1 in the complexed s ta te  moved approxim ately 
10A away from its original position. The wild type TSST-1 R-factors for
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this region reveal ra ther high values all of which are greater th an  40.0A2, 
with a m axim um  of 71.10A2 for Ser 1. This implies significant freedom of 
movement for this region. It is not clear w hether this radical shift of 10.0A 
is directly due to TSST-1 binding to D R l or perhaps an artifact of crystal 
packing.
The shift in C a positions for residues 107 to  109 does not imm ediately 
suggest a potential site for TcR  binding being rem ote from the  m ain a2 
helix. The H-factors for these residues are betw een 35.31 A2 and 61.75A2. 
This region, located in a loop between /36 and /?7, m ay be involved in as yet 
unidentified binding to form a stabilization complex between the different 
cell types.
W ith residues 1 to 6 moved away from  dom ain 2 on binding D R l, 
this makes residues Tyr 144 and Arg 145 exposed to  the solvent. The wild 
type H-factors for these two residues range from  18.56A2 to  27.5A2. These 
low values are not indicative of flexibility. However, this may, in tandem  
with the shift of residues 1 to 6, provide the accessibility necessary for the 
binding of the TcR  to the ‘preform ed’ T SST-1/D R 1 complex. Section 5.5 
m entioned a double m utan t H141A.T144A which appeared to  decrease not 
only mitogenicity but was also unrecognisable by the m onoclonal antibody 
8-5-7. The residue His 144 in the D R l/T S S T -1  complex was shown to 
alter its C a position by a significant am ount (rm s deviation 4.0A) when 
compared with wild type TSST-1 in the ASH study. This Tyr 144 located 
at a loop and not forming part of a ‘regular’ secondary s tructu re  element 
may play a role in TcR recognition of the D R 1/TSST -1 complex. As with 
the other regions shown to possess significant changes in C a  coordinates 
on TSST-1 binding to D R l, further site directed mutagenesis studies are
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necessary to ascertain their exact role in complex form ation.
It is obvious th a t the peptide fragm ent itself plays an im portan t role 
in altering the local conformation of the TSST-1 molecule around residues 
76 to 79 (the loop between /33 and  /?4). T he wild type TSST-1 molecule 
would make very close contacts w ith the peptide  fragm ent (p l3 ) bound 
to  the D R l, a t approxim ately 0.72A2 at Gly 77. However, when TSST- 
1 is in its complexed state , this sam e residue Gly 77 moves ‘away’ from  
the peptide fragment by 3.83A. The J?-factors for the wild type TSST-1 
residues 76 to 79 he in the range 31.9A2 to 66.29A2.
The very im portan t natu re  of the peptide fragm ent in superantigenic 
activity has only recently been acknowledged. This has been especially 
highlighted in respect of the D R 1/TSST-1 crystal structure. Also, the 
charge of the peptide fragm ent has influenced the  crystallization of the  
D R1/TSST-1 complex (Kim et a l,  1994) as dem onstrated  by the require­
m ent of isoelectric focussing to purify the D R l/p e p tid e  complex. In ad­
dition to this, the size of the bound peptide fragm ent may also influence 
the ability of the superantigen to bind to the  D R l molecule (Vignali and 
Strominger, 1994).
Having taken into consideration the fact th a t  the secondary structu re  
elements have been reduced an d /o r deleted in TSST-1 when com pared w ith 
SEB, the way in which the TcR  binds to  the S A g/D R l complex m ust also 
differ. W hereas SEB can interact w ith 6 hum an  V/?’s (Table 1.3) and 
TSST-1 with only V/52 (Table 1.3), it may be possible to rationalize this 
from the D R 1/SEB  and D R 1/TSST-1 complexes. In D R1/SEB structure , 
the ‘open’ na tu re  of both  the bound peptide fragm ent and the  a  helix 
from DRl/? m ay allow an additional form of contact with the various V(3
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elements from the T  cells. This is in contrast w ith  the top surface of D R l 
in the D R1/TSST-1 complex which is ‘partia lly  open’ (Figure 5.3). This 
partially open D R l surface could prevent o ther, as yet unknown receptors, 
from interacting directly with the bound peptide  fragm ent an d /o r to  the  a  
helix from D Rl/?. This may account for only V/?2 to  in teract w ith TSST-1 
when bound to  D R l. However, all these possibilities m ay be resolved w ith 
a detailed structu re  of the SAg/M HC II /T c R /p e p tid e  complex.
It is not possible at present to  make a direct com parison of the B - 
factors from wild type TSST-1 with the com plexed TSST-1. This is due to 
the D R 1/TSST-1 complex being refined to 3.5A with all 5 -fac to rs set to 
20.OA2. The details of binding modes could be substan tia ted  in the future 
when the higher resolution (at least 2.5A) s tru c tu re  becomes available for 
D R 1/TSST-1 complex.
5.9 Future W ork
Further work on TSST-1 would involve site directed mutagenesis 
studies of potential sites for both  MHC II and  T cR  binding sites. In addi­
tion to this, production of individual TSST-1 dom ains would be of benefit 
to elucidating their functional roles. Co-crystallization studies of TSST-1 
and monoclonal antibodies known to prevent superantigenic activity could 
also be pursued. Finally, a complete trim olecular complex consisting of 
SAg/M HC II /T c R  would enhance our understand ing  of structure-function 
relationships.
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T ab le  5 .1 . Comparison of intermolecular distances between wild type 








W ild Type 
TSST-1 
D istance 
to  D R l 
Residue




to  D R l 
Residue
( A ) t
D27 01 aY13 4.50 3.60
aQ 18 3.62 4.23
aK 67 2.16 4.46
S29 131(32 loop a Q l8 4.07 6.62
aK 67 2.76 3.89
L30 (31(32 loop aM 36 3.86 3.95
S32 (32 aA 64 4.23 3.97
R34 (32 aA68 1.82 3.53
<*E71 3.23 3.03
146 (33 aQ 57 4.50 4.10
F47 (33 aK 39 2.94 3.03
P48 (33(34; loop aL60 4.28 3.78
S49 (33(34 loop aK 39 2.88 3.00
P50 (33(34 loop aK 38 2.43 3.65
aK 39 4.39 4.40





Table 5.1. Comparison of intermolecular distances, continued.
TSST-1
Residue
Location D R l
Residue
*
W ild Type 
TSST-1 
D istance 






to  D R l 
Residue
(A)t
Q73 P i (3L60 4.78 2.73
(3A64 3.97 2.95
T75 P i (3D66 8.19 6.12
pAlO 4.46 6.15
p A ll 3.09 3.81
pA13 3.58 3.69
S76 (34/35 loop PA12 1.22 6.84
pA13 1.91 4.16
* a  ind icates th e  D R la  chain, /3 indicates DRI/3 chain  an d  p  ind icates th e  b o u n d  p ep tide  
fragm ent, f  coordinates from  this study. t  coord inates from  Don W iley (personal 
com m unication).
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Figure 5.1 Residues and regions on TSST-1 implicated in binding to MHC II and TcR. 
The TSST-1 molecule has been rotated 180° about a vertical axis. Regions implicated by 
peptide data in MHC II binding (Section 5.3) are coloured yellow (residues 39 - 78) and 
green (residues 155 - 194), the remainder of the molecule is blue. Residues implicated 
in mitogenic activity, based on mutational analysis (Section 5.5), are highlighted in red 
(Tyr 115, Glu 132, His 135, His 141 and Tyr 144). The cyan and green balls indicate 
the N and C termini, respectively.
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Figure 5.2 A proposed model for the interaction of TSST-1, TcR and MHC II molecules 
(Acharya et al., 1994). The interacting faces of TSST-1 and the complexes with the 
MHC II/TcR molecules are represented as each having 90° rotations about a vertical 
axis. The molecules represented by the space filled objects are as follows: white being 
TSST-1, mid-blue being MHC II and the pale blue the TcR (Va and V(3 domains). The 
interaction between MHC II and TcR are modelled from Bjorkman and Davis (1989) 
using MHC I and immunoglobulin light chain domain coordinates respectively. Site A 
in TSST-1 (residues 39 to 78 and 170 to 180) and site B (residues 115, 132, 135 and 
140), thought to be involved in MHC II and TcR binding, are respectively coloured in 
dark blue and red. The yellow area on the MHC II molecule locates the «40 to a50 and 
(381 to (390 residues. These residues are located to one end of the peptide binding cleft. 
And finally, the green region of the TcR indicates the DE loop on the external (3 sheet 
of the V/3 domain (Choi et al., 1990).
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Figure 5.3 The DRl/TSST-1 complex determined by X-ray crystallography (Kim et 
al., 1994; Figure from the same paper). TSST-1 is coloured red, the a l  and /31 domains 
of DRl are light blue and blue, and the antigenic peptide fragment is yellow. The 
TSST-1 residues Y115, E132, H135, 1140, H141 and Y144 have been implicated in TcR 
binding (Section 5.5) and are represented as ball and stick models.
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A p p en d ix  A
Phosphate buffered saline (PB S)/100m l, pH7.4:
NaCl 8g 






0.8% Sodium barbito l 
0.001% M ethylate
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A ppendix  B
1) A Sum m ary of the Program s Used in the  wild type TSST-1 D ata  Col­
lection and  Processing Using the Im aging P la te
IM S T IL L S  Using two still images 90° ap art, IM STILLS locates the  direct 
beam  coordinates, determines the background count and looks for spot 
intensities above a predeterm ined value w ith respect to  the background 
count. It then  decides what the m edian spot size is for the fram e and 
rejects any th a t are too large or too small. T he list of coordinates, in x 
and  y, and their corresponding intensities for th e  rem aining spots, is then  
the inpu t for the next program  R EFIX  and ID X R EF.
R E F I X  A program  by Kabsch (1988) which calculates an orientation m a­
trix  w ith inform ation given from IM STILLS and  refines the inpu t unit cell 
param eters. This orientation m atrix  will then  be used in another program
OSCGEN.
ID X R E F  This program  indexes the diffraction spots, refines the unit cell 
param eters, the crystal to plate distance and also the crystal orientation 
from  R EFIX , by making use of partia l reflections from d a ta  given by IM­
STILLS. In  order for this program  to  run  satisfactorily, the unit cell pa­
ram eters m ust be known to within 1% and the  crystal orientation to  within 
lo  from  the  d a ta  given in the still photographs.
O S C G E N  This program  generates a list of spots predicted to  occur in 
fu rther oscillation frames with their coordinates using the m atrix  from 
ID X REF.
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IP -M O S F L M  Using the generated list file from  OSCGEN, IP-M OSFLM  
performs a num ber of operations. It m easures the reflection intensities 
by creating a ‘m easurem ent box’ around the spots. This m easurem ent box 
allows the form ation of an estim ate for the in tegra ted  intensity of each spot 
which has been corrected for background. It therefore includes not only 
pixels which make up each spot bu t also a  sm all region of the background 
surrounding it. M easuring the spot intensities by this m ethod of profile 
fitting means th a t it is particularly sensitive to  any errors in the predicted 
spot coordinates from  OSCGEN. So it is vital th a t the unit cell param eters 
and crystal orientation are all known accurately in order to  get positional 
errors of less th an  50 microns.
A B S C A L E  Applies a num ber of correction factors to  the data: 1) absorp­
tion, 2) Lorentz and 3) Polarization. ABSCALE calculates the correlation 
coefficients between a reference d a ta  set of intensities and new data. It then 
averages the scaled m easurem ents and assesses any discrepancies. These 
corrected intensities are then w ritten to  an LCF (Labelled Column Form at) 
file.
R O T O V A T A  Calculates and refines the scale and tem peratu re  factors 
between overlapping sets of da ta  by the m ethod of Fox and Holmes (1966). 
Use is m ade not only of sym m etry related reflections bu t also any repeated 
fully recorded reflections which occur more th a n  once.
A G R O V A T A  This program  applies the scale and tem perature  factors 
from ROTOVATA with a view to take account of any poor agreements 
between the fully recorded sym m etry equivalents, by rejecting them , to  give 
an averaged value as an output. It also adds together partially recorded
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reflections.
3 D S C A L E  A series of program s to  average any sym m etry repeats within 
a d a ta  set, consequently scaling and m erging all d a ta  sets with sum m ing 
of any partially recorded reflections.
D I F F E R  Analyses the isom orphous differences in scattering due to  the 
binding of a heavy atom .to  the native protein.
P H A S E  Calculates the best or m ost probable phases.
R E F I N E  Refines the heavy atom  param eters by minimizing the lack of 
closure error.
G A P  Averages the electron density m ap of the  molecules related by non­
cry stallographic sym m etry to  be found in th e  asym m etric unit. Using 
each envelope-bound molecule the contents of the  defined m aps are then 
averaged (S tuart and Grimes, unpublished).
C A L P H A  This program  uses a database to  build a model of a  protein 
using only the coordinates of the Ca atom s. In  the  initial steps of model 
building the program  can remove any stereochem ical stra in  until b e tte r 
angles are obtained (R.Esnouf, unpublished).
G R O P A T  The au tom ated  P atterson  search program  GROPAT was (Jones 
et al., 1991) used to  interpret the isom orphous difference P atterson  maps 
for the heavy atom  derivatives. This com puter package GROPAT consists 
of a num ber of program s which establish the  ‘goodness of fit’ of the dif­
ference P atterson  m ap. The program  generates a large num ber of possible
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solutions and by systematically filtering out the false solutions by certain 
criteria . The first program  GROPAT1 generates a ranked list of ~200 
possible single sites judged on either self peaks or if there is more th an  one 
fixed site, the cross peaks from a ‘coarse’ grid search. The second program  
DUP then  checks for duplicate solutions in one or m ore lists. PA TREFIN E 
instigates a refinement of each potential solution from the first list by using 
a finer grid and thereby optimise the agreem ent w ith the P a tte rson  m ap. 
The fourth  program  GROPAIR then  checks the  sites in a list of cross vec­
tors in a pairwise m anner. CLUSTER checks the  single site list for any 
potential non crystallographically related sites. Finally PREPA T will then 
plot the  P atterson  vectors for the best sites.
2 ) Having perform ed an initial m anual m anipulation of the m odel on a 
dedicated com puter graphics system , X PLO R  perform s an au tom ated  re­
finem ent on it to  find the global energy m inim um .
G E N E R A T E  This first program  analyses the  m odel in order to  generate 
a molecular topology file which defines the coordinates in term s of atom  
type, charge, angles, disulphides as well as hydrogen bonds, electrostatic 
and Van der W aals forces. This inform ation is then  collated into a protein 
s truc tu re  file to  be used throughout the rem ainder of the refinem ent.
C H E C K  This program  is sometimes used in order to  calculate an  ‘ideal’ 
weighting factor for the structure  factors used in the  next stage of refine­
m ent. It also determ ines the initial R -factor for the model.
P R E P  S T A G E  This perform s a restrained energy m inim isation to  relieve 
bad contacts and strain  from the initial rough m odel using a conventional
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least squares refinement. The weight derived from  CHECK can be added 
to  the above equation. It gives an approxim ate value to  the  X-ray term  
relative to the geometric term s. Tem perature  factors and occupancies are 
usually fixed and all d a ta  above a certain a  cut-off are used. Then the 
conjugate gradient minimisation can be perform ed.
S L O W C O O L  This is the sim ulated annealing refinem ent procedure us­
ing molecular dynamics. The theory behind this stage is as follows: The 
protein can be thought of existing in a heat b a th  in which the tem perature  
increases to a certain predeterm ined level guaranteeing all atom s within 
the protein are in a state  of random  m otion. Once at this tem perature  the 
b a th  is then cooled slowly, allowing the atom s to  enter their lowest energy 
state, it. a global energy minimum . This procedure is a great improve­
m ent over previous m ethods by providing sufficient energy for energetically 
unfavourable transitions to be explored (Briinger and Nilges, 1993).
B R E F  This performs individual B -factor refinem ent on all atom s within 
the protein to minimise the angle and bond term s to  be com pared against 
the observed structure factors.
A N A L Y S IS  Analysis is m ade of the rm s deviations from ideality for the 
whole structure  for bond lengths, bond angles, im propers and dihedral 
angles. This can reveal how good the refinem ent process has progressed.
3) XDS is a suite of com puter program s used for the autom atic  on-line 
processing, bo th  collection and reduction, of X-ray diffraction d a ta  from 
the Siemens multiwire area detector.
X Y C O R R  Due to the geometry of the concave multiwire area detector,
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distortion of the diffraction p a tte rn  occurs. To reduce such distortion a 
brass plate placed in front of the detector face is exposed to  a 55 Fe source. 
The brass plate inform ation is used and a correction m ade for the  position 
of each reflection from the crystal in subsequent frames.
I N I T  Using the first 30 frames as an  inpu t, IN IT  calculates the average 
background reading, removes any shadow produced by the backstop and 
determines the region of the detector exposed
C O L S P O T  The autoindexing routine begins using the first 30 frames. 
The positions of the strongest reflections above a threshold are given co­
ordinates x and y. Spots on adjacent fram es found to  be equivalent are 
merged. The ou tpu t is a list of coordinates, their indices and the crystal 
position.
ID X R E F  Using the ou tpu t from C O LSPO T the unit cell param eters, 
and perform ing an iterive least squares analysis the crystal orientation 
and crystal to detector distance are determ ined and refined. It predicts 
positions of reflections to be found in subsequent frames.
C O L P R O F  Collects 3D reflection profiles using integration. Assigns those 
pixels which belong to  a particular spot an h k l  value. Any small slippage 
of the crystal can be accom m odated here w ith re-refinem ent.
P R O F I T  Integrates the intensities of all reflections by fitting a ‘3D n e t’ 
over each spot and then removing the local background count.
C O R R E C T  The spot intensities are all scaled due to crystal degradation. 
Corrections are m ade for decay, absorption and  detector surface sensitivity.
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G L O R E F  A more accurate refinement of the unit cell param eters, crystal 
to  detector distance and crystal ro ta tion  angle th a n  ID X R EF are estim ated 
here because all reflections from this d a ta  collection run  are used.
4) A brief explanation of the program s w ithin M ERLO T.
P R O  R E F  Processes the reflection intensity d a ta  for the unknown and is 
then ready for use in the other program s within M ERLO T.
P R O C O R  The centre of mass is calculated and  the  molecule is then moved 
to the origin. S tructure factors are then  generated for the model.Processed 
coordinate d a ta  of the search model for inpu t to  the o ther program s in 
M ERLOT.
R O T A T IO N  Calculates the spherical harm onic coefficients and expands 
the d a ta  in the form of a Bessel function. D eterm ines the orientation of the 
search m odel in the cell of the unknown using the  Fast ro ta tion  function of 
Crow ther (1972), in term s of Eulerian angles a . f3 and 7  on a coarse grid. 
A m ap is then  m ade in which any peaks are indicated.
R O T A T IO N -F IN E  Refines the f3 angle only from  ROTATION using 
finely sam pled transform s. Any peaks found in the m ap are indicated.
LA T Refines the  a  and 7  angles from  ROTATION using the L attm an  
rotation function (1972). Again a m ap is m ade and  any peaks are indicated.
T R A N S  Calculates the positions of the search model in the cell of the 
unknown ie. translation function (C row ther and  Blow, 1967). Sets up a 
continuous transform  for subsequent program s to  calculate struc tu re  fac-
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tors.
5) AMoRE is a new molecular replacem ent com puter package and involves 
m ore powerful algorithm s (Dodson et al., 1992; Navaza, 1994). It is a 
much quicker au tom ated  package of program s which allows a great many 
potential solutions to be explored. AM oRE makes use of a correlation 
coefficient as its m ain selection criteria for peaks as well as an  R-factor 
value. This im proved algorithm  is used to  calculate the  s tructu re  factors of 
the ro ta ted  and translated  search model. For a m athem atical explanation 
the reader is invited to read the above references.
S O R T  This is the first of AMoREs prelim inary program s which sorts, 
packs and assesses the quality of the  d a ta  supplied such as the  hkls  and 
F o b s -
T A B  L IN  The second prelim inary program  which places the centre of mass 
of the search m odel a t the origin and optim ise its position there by aligning 
its principal axes of inertia with th a t of the unit cell axes. TABLIN then 
calculates and tabu lates a continuous Fourier coefficients from the search 
model.
R O T A  Calculates a fast rotation function based on Crow ther (1972). The 
radius of integration used here is taken from the  o u tp u t of TABLIN it. the 
distance from  the centre of mass to  the atom  fu rthest away from this point. 
Next the s truc tu re  factors for the search m odel are calculated. The outpu t 
consists of a list of all peaks with a value greater th an  50% the m axim um  
value of the ro ta tion  function.
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T R A IN G  The whole peak list as the  ou tpu t of ROTA is then  used as the 
input for TRAING. The translation function is then  calculated for each 
line. The outpu t of TRAING is a list of peaks, again greater th an  50% the 
m axim um  for the translation function w ith an given correlation coefficient.
F I T IN G  This stage of AMoRE then  perform s a rigid body refinement of 
the fist given as the ou tpu t of TRA IN G .
6 ) Miscellaneous. D S S P  A program m  (K absch, 1988) which generates 
secondary structure features ( ie. (3 sheet and a  helix) from the protein 
coordinate file.
A S H  A program  which compares two protein molecules using their atomic 
coordinates and gives a residue by residue rm s deviation (S tuart, 1979).
M O L S C R IP T  A program  which creates a d iagram  of the  protein  from 
the coordinate file (Kraulis, 1991).
P R O C H E C K  A program  which checks the stereochemical quality of the 
protein (Laskowski et al., 1993).
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High yields of toxic shock syndrome toxin-1, from Staphylococcus aureus, have been purified 
(> 9 9 % ) using a novel, simple, two-step procedure involving dye ligand chromatography. 
Crystals suitable for X -ray diffraction work were obtained by vapour diffusion using 
ammonium sulphate and polyethylene glycol as precipitants. They belong to the 
orthorhombic space group (7222^ with unit cell dimensions a = 108 6 A, b =  177 6 A and 
c =  97-5 A, with three molecules per asymmetric unit. The crystals diffract to a t least 2-5 A 
resolution and are suitable for three-dimensional X -ray structural analysis.
Keywords: toxic shock syndrome toxin-1; toxin purification; dye ligand chromatography;
crystallization; X -ray diffraction
Toxic shock syndrome toxin-1 (TSST-1 J) is an 
extracellular protein produced by some, bu t not all, 
strains of Staphylococcus aureus (Chesney et al., 
1984). I t  is recognized as the m ajor factor respons­
ible for toxic shock syndrome, an acute life- 
threatening multisystem disease (Todd et al., 1978). 
The disease is characterized by high fever, hypoten­
sion, scarlatiniform erythem atous rash, desquama­
tion of the skin and dysfunction of three or more 
organs, including the gastro-intestinal tract, liver, 
kidney, muscles, the blood and the central nervous 
system. The m ajority of cases are epidemiologically 
associated with tam pons used in menstruating 
young women (Shands et al., 1980). However, about 
15% to 30%  of cases occur in male or female 
individuals w ith focal, non-genital wounds or soft 
tissue infections (Schlievert, 1983). Other toxins 
such as the staphylococcal exterotoxins A, B and C 
are also capable of causing toxic shock-like illness 
(De Azavedo, 1989).
Studies with TSST-1 and the functionally related 
staphylococcal enterotoxins (SE) have also revealed 
them to be highly potent polyclonal activators of T 
cells in the presence of cells bearing class I I  antigens 
of the m ajor histocom patability complex (MHC;
f  Author for correspondence.
t Abbreviations used: TSST-1, toxic shock syndrome 
toxin-1; SE, staphylococcal enterotoxins; MHC, major 
histocompatability complex; SRD, single radial 
immunodiffusion.
Wood et al., 1991). The toxins act a t nanomolar 
concentrations and are not processed internally in 
comparison with nominal antigens. Each toxin type 
is capable of stimulating a subpopulation of peri­
pheral T lymphocytes possessing a specific variable 
j8 (V/f) gene segment. This property, together w ith 
the resultant release of cytokines, is characteristic of 
a group of molecules called superantigens (Marrack 
& Kappler, 1990) Currently, these molecules are the 
subject of intense study as workers attem pt to 
correlate immunological and pathological activity 
with molecular structure.
TSST-1 is a single-chain polypeptide consisting of 
194 amino acid residues; the predicted MT from the 
gene sequence is 22,049 (Blom ster-Hautam aa et al., 
1986), although values of 22,000 to 24,000 have 
been reported following SDS/polyacrylamide gel 
electrophoresis (PAGE) of purified protein (Reiser et 
al., 1983). There is little sequence homology 
between the SE and TSST-1 based on amino acid or 
nucleotide d ata  (Blom ster-Hautam aa et al., 1986; 
Goshorn & Schlievert, 1989). Indeed, the absence of 
cysteine residues and emetic activity can be used to 
differentiate TSST-1 from the SE. However, TSST-1 
and the SE show striking similarities in biological 
properties th a t may be a function of the three- 
dimensional arrangement of the molecular structure 
of these toxins. Using far ultraviolet light circular 
dichroism spectra, Singh et al. (1988) were able to 
identify a similarity in secondary structure between 
TSST-1 and the enterotoxins but there is no
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information available on the tertiary  structure of 
these molecules. An early report on the crystalliza­
tion of SEB (Swaminathan et al., 1988) has not 
revealed an insight on the molecular structure of 
these toxins. However, more recently the crystal­
lization of SEC3 was reported (Bohach et al., 1992) 
which identified both triclinic and tetragonal forms 
of crystal with one toxin molecule per asymmetric 
unit.
The present study describes the production of 
diffraction quality crystals of TSST-1 which will be 
used to determine the three-dimensional structure 
of this molecule. Such studies, together with similar 
ones using the SE, may provide information on 
these toxins to explain their biological relatedness in 
the absence of any obvious sequence homology. 
Furtherm ore, structural information may be useful 
in studying the binding domains of the toxin with 
the MHC I I  complex and T cells especially since the 
probable three-dimensional structure of the MHC 
class II  molecule has been elucidated (Brown et al.,
1988). The toxin in this work was purified by a 
modification of the dye ligand chromatography 
method developed initially for the staphylococcal 
enterotoxins (Reynolds et al., 1988; Brehm et al., 
1990). This method is particularly suited for the 
present study due to  its ability to give large 
am ounts of highly purified toxin.
Staphylococcus aureus strain MN8 was used for 
the production of TSST-1. The strain was grown in 
medium containing 20-0 g/1 of proteose peptone 
no. 3 (Difco Laboratories) and 20-0 g/1 of N-Z 
amine A (Sheffield Products) adjusted to pH 7-0 
and sterilized by autoclaving (121 °C for 20 min). 
A seed inoculum (400 ml), prepared in a 2 1 flask 
was shaken (200 revs/min) a t 37 °C overnight and 
used to inoculate a 35 1 Chemap AG fermenter 
containing 25 1 of the same medium to which 0-03 % 
(final concentration) polypropylene glycol 2000 
antifoam (KW; Revai Chemicals Ltd) had been 
added. The culture was grown in the fermenter for 
19 hours with a stirrer speed of 280 revs/min and in 
the presence of an 0 2/C 0 2 (1:1) m ixture sparged a t 
2 1/min.
Bacterial cells were removed and the culture 
filtrate concentrated to 1 1 by cross-flow filtration 
with a Pellicon system (Millipore U.K. Ltd: Brehm 
et al., 1990). To prevent pro tease activity and 
growth contam ination during downstream 
processing, 0-5 m-EDTA was added to the culture 
filtrate to a final concentration of 2 mM. The 
concentrated culture supernatant fluid containing 
1*5 mg/ml TSST-1 was dialysed overnight a t 4°C 
against 20 mM-potassium phosphate buffer, pH  6*5.
A portion (300 ml) of the dialysed culture filtrate 
containing 0-3 g TSST-1 was diluted with 1-5 
volumes of 20 mM-phosphate buffer, pH  6 5, 
and loaded onto a 500 ml Red A column 
(4 5 cm x31  cm; Amicon Ltd) which had been pre­
equilibrated w ith 20 mM-phosphate buffer, pH  6-5. 
The column was washed with 1-4 1 of the equili­
bration buffer followed by the same volume of 
60 mM-potassium phosphate buffer, pH 6 5. Toxin
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Figure 1. Dye ligand chromatography of TSST-1 on 
Red A. The column (4-5 cm x 31 cm) was equilibrated in 
20 mM-potassium phosphate buffer, pH 6-5, and eluted 
with a stepwise increase in molarity of phosphate buffer, 
pH 6-5. Fractions (10 ml) were collected at a flow rate of 
40 ml/h (during binding) and 80 ml/h (during elution).
was eluted with 2 1 of 150 mM-potassium phosphate 
buffer, pH 6 5 (Fig. 1). The protein content of frac­
tions was estim ated by measuring the ^4280 w ith a 
PU 8600 UV/VIS spectrophotometer (Pye-Unicam) 
and toxin content determined by single radial 
immunodiffusion (SRD; Meyer & Palmieri, 1980) 
using polyclonal rabbit anti-TSST-1. Fractions 
containing toxin were pooled and concentrated by 
ultrafiltration (Minitan system, Millipore U.K. Ltd) 
using 10,000 molecular weight cut off membranes 
(PLGC). Recovery of TSST-1 from the Red A 
column was estim ated to be 80%.
Concentrated toxin fractions collected from the 
Red A column were refractionated by fast protein 
liquid chromatography. For this, the fractions were 
dialysed against 50 mM-sodium acetate buffer, 
pH 5-0, overnight a t 4°C. After dialysis, 30 ml 
portions were injected into a 20 ml HiLoad S 
Sepharose, high performance 16/10 column 
(Pharmacia), previously equilibrated with 
50 mM-sodium acetate buffer, pH 5 0. The column 
was eluted with a 150 ml linear gradient of 
increasing NaCl concentration (up to 250 mM) a t a 
flow rate of 2 ml/min. The toxin eluted as a single 
peak a t 170 mM-NaCl in 50 mM-sodium acetate 
buffer, pH  5 0. All fractions th a t gave an absorb­
ance (^4280) of greater than  0-1 unit were collected 
and tested (SRD) against anti-TSST-1. After elution 
the column was regenerated with 30 ml of equili­
bration buffer containing 1 M-NaCl. The overall 
process yield was 60% . The purified toxin was 
dialysed against MilliQ water (18 MQ cm-1 ) then 
1 mg am ounts were pu t into small vials and lyo- i 
philized. The concentration of the pure toxin was ! 
determined by using the extinction coefficient E {0/°m 
of 9 5  a t 280 nm (Reiser et al., 1983). Analysis of the 
final toxin by SDS/PAGE indicated th a t the toxin 
was > 9 9 %  pure (Fig. 2).
Crystals of purified TSST-1 were grown a t ] 
am bient tem perature using the hanging-drop
- 0.90






100 500 600400200 300
Crystallization Notes 985




p * 20.1Ml mm 14.4
B c D
Figure 2. SDS/polyacrylamide gradient (8 to 18%) gel 
analysis of stages in the purification of TSST-1. Lane A, 
pooled fractions from fast protein liquid chromatography. 
Lane B, pooled fractions eluted from Red A. Lane C 
concentrated culture supernatant fluid. Lane D, 
molecular mass markers (kDa): phosphorylase b, 94; 
albumin, 67; ovalbumin, 43; carbonic anhydrase, 30; 
trypsin inhibitor, 20* 1; and a-lactalbumin, 14 4. Lanes A 
to C were loaded with 10 pi of sample containing 0-5 to 
1*0 mg protein per ml.
method (McPherson, 1982) in 24-well Linbro plastic 
tissue culture plates (Flow Labs). Equal volumes (4 
to 5 pi) of purified protein (20 mg/ml) and reservoir 
solution were mixed on plastic coverslips 
(Thermanox) and the coverslips inverted over the 
wells and sealed using silicone grease. Crystals suit­
able for diffraction were produced when the reser­
voir solution (1 ml) consisted of 01 M-acetate 
buffer, pH 4-6, with 0*2 M-ammonium sulphate and 
23% to 25% polyethylene glycol 3350 (Sigma) as 
co-precipitants. Parallelepiped crystals appeared 
between seven and ten days and growth reached a 
maximum (0-3 mm x 0-4 mm x 0 8 mm) after 
three weeks (Fig. 3).
Crystals were mounted in a thin walled quartz 
capillary tube and data were collected on a Siemens 
area detector mounted on a Rigaku rotating anode 
X-ray source using CuKa radiation operating at 
50 kV and 80 mA. The crystals were well ordered 
and diffracted to a t least 2-5 A resolution 
(1 A = 01 nm) with little sign of decay after expo­
sure for 48 hours. They belong to orthorhombic 
space group C222x (a = 108-6 A, b = 1776 A, 
c =  97-5 A). Assuming a trimer per asymmetric 
unit, the specific volume of the protein is 
3-55 A3/Da, which falls within the range normally 
observed for protein crystals, and corresponds to a 
65% (v/v) solvent content (Matthews, 1968).
Figure 3. Orthorhombic crystals of toxic shock 
syndrome toxin-1.
A preliminary 2-8 A data set has been collected 
and a search for suitable heavy-atom derivatives is 
in progress.
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High yields of staphylococcal enterotoxin C2, from Staphylococcus aureus, have been 
purified using dye ligand chromatography. Crystals suitable for X-ray diffraction work were 
obtained by vapour diffusion using ammonium sulphate and polyethylene glycol as 
precipitants. They belong to the tetragonal space group P 4 :22 with unit cell dimensions 
a =  6 =  432 A and c =  290-9 A with one molecule per asymmetric unit. The crystals diffract 
to a t least 2-8 A resolution and are suitable for three-dimensional X -ray structural analysis.
Keywords: Staphylococcal enterotoxin; crystallization; X-ray diffraction; superantigen
The staphylococcal enterotoxins (SEsJ) are a 
family of structurally related proteins produced by 
Staphylococcus aureus which cause food poisoning 
and various forms of gastro-intestinal illness 
(Bergdoll, 1990). The toxins may also be involved in 
other forms of acute disease because of their ability 
to induce lymphocyte mitogenesis, immunosuppres­
sion, cytokine production, fever and to  enhance 
endotoxin shock, properties they share with the 
pyrogenic toxins (SPEs) produced by Streptococcus 
pyrogenes (Alouf et al., 1991). Collectively these 
toxins are known ■ also as microbial superantigens 
because of their ability to stim ulate T cells bearing 
particular T-cell receptor Vfi regions (Kappler et al.,
1989). Recently it has been shown th a t class I I  
m ajor histocom patibility complex (MHC) molecules 
are the specific receptors responsible for antigen 
presentation to the T cells (Fraser, 1989); unlike 
classically presented antigens however, the SEs are 
not processed prior to binding (Fleischer & 
Schrezenmeier, 1988).
The SEs can be classified into five serologically 
distinct groups SE (A to E) with molecular masses 
in the range 27 to 30 kDa. Due to differences in 
minor epitopes SEC can be subdivided into SEC1,
f  Author to whom all correspondence should be 
addressed.
J Abbreviations used: SE, staphylococcal enterotoxin; 
MHC, major histocompatibility complex.
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SEC2 and SEC3 (Bergdoll, 1979). An examination 
of amino acid sequences has revealed a high degree 
of homology, ranging from 30 to 86%, among the 
toxins (Marrack & Kappler, 1991). SEA is more 
related to SED and SEE whereas SEB has greater 
homology with SEC. Until recently all attem pts to 
assign biological activity to areas within the entero­
toxin molecules had come from the use of synthetic 
peptides (Pontzer et al., 1989) or interpretation of 
secondary structure from circular dichroism and 
tryptophan quenching studies (Singh et al., 1988; 
Singh & Betley, 1989). However the crystal struc­
ture of SEB has just been reported (Swaminathan et 
al., 1992) which consists of two domains within the 
enterotoxin molecule and provides information 
concerning the stereochemistry of putative MHC I I  
and T cell receptor binding sites. Recently condi­
tions for the crystallization of SEC3 have been 
reported (Bohach et al., 1992) together with those 
for crystallization of toxic shock syndrome toxin-1, 
a toxin which shares similar biological properties 
with the enterotoxins bu t has very little sequence 
homology (approx. 24% ; Passalacqua et al., 1992). 
The X -ray crystallographic studies on these toxins 
should provide information on the three-dimen­
sional structure of the molecules which would 
enable the identification of areas of common struc­
tural features within the different toxins. In  this 
communication we describe the production of 
crystals of SEC2 suitable for X-ray diffraction.
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Figure 1. Final purification of SEC2 by FPLC after 
initial chromatography on Red A. The column (20 ml) 
HiLoad S Sepharose, high performance 16/10 
(Pharmacia) was equilibrated with 50 mM sodium acetate 
buffer (pH 5-0). Toxin was eluted using 100 mM NaCl in 
50 mM sodium acetate buffer (pH 5-0) at a flow rate of 
2 ml/min. (----- , A280; --------- , NaCl concentration).
These crystals will be used to determine the three- 
dimensional structure of the SEC2 molecule and 
define regions of antigenic variability known to 
exist among the SEC molecules.
Staphylococcal enterotoxin C2 was produced 
during the ferm entation of S. aureus 361 (supplied 
by M. S. Bergdoll, Food Research Institu te , 
D epartm ent of Food Science and Industry, 
University of Wisconsin, Madison) in a 15 litre 
B iostat E fermenter as previously published (Brehm 
et al., 1990). Toxin was initially purified from 
concentrated spent culture fluid by dye ligand 
chromatography on Red A gel (Amicon Ltd.). For 
crystallization the toxin was refractionated by fast 
protein liquid chromatography. Toxin was dialysed 
overnight a t 4°C against 50 mM sodium acetate 
buffer (pH 5-0) and 20 ml portions were injected 
onto a 20 ml HiLoad S Sepharose, high performance 
16/10 column (Pharmacia) previously equilibrated 
with the same buffer. The column was eluted with 
100 mM NaCl in 50 mM sodium acetate buffer 
(pH 5-0) a t a flow ra te of 2 ml/min. All fractions 
th a t gave an absorbance (.428o) ° f  >0*1 unit were 
collected and tested in a single radial immunodiffu­
sion test using rabbit anti-SEC2 (Meyer & Palmieri, 
1980). Toxin eluted as the m ajor peak (Fig. 1) and 
after dialysis against MilliQ w ater (18 MQ cm-1 ) 
was distributed (2 mg) into small vials, lyophilized 
and stored a t — 20 °C. After elution the column was 
regenerated with 16 ml of euqilibration buffer 
containing 1 M NaCl. Analysis of the final toxin by 
SDS PAGE indicated th a t the toxin was > 9 9 %  
pure.
Crystals of purified SEC2 were grown a t am bient 
tem perature using the hanging drop method 
(McPherson, 1982) in 24-well Linbro plastic tissue 
culture plates (Flow Labs). Equal volumes (3 to 
5 y\) of the protein (2 mg/ml) and reservoir solution 
were mixed on plastic coverslips (Thermanox) and 
the coverslips inverted over the wells and sealed
using silicone grease. Crystals suitable for diffrac­
tion were produced when the reservoir solution 
(1 ml) consisted of 01 M cacodylate buffer (pH 6-5) 
w ith 015 M ammonium sulphate, 0-02% sodium 
azide and 25 to 28%  polyethylene glycol 8000 
(Sigma) as co-precipitants. Rectangular crystals 
appeared between 3 and 4 weeks and growth 
reached a maximum (0*3 mm x 0-4 mm x 0 8 mm) 
after 6 to 8 weeks.
Crystals were mounted in a th in  walled quartz 
capillary tube and data  collected on a Siemens area 
detector mounted on a Siemens rotating anode 
X -ray source using CuKa radiation operating a t 
50 kV and 76 mA. The crystals were well ordered 
and diffracted to a t least 2*8 A resolution with little 
sign of decay after exposure for 50 hours. They 
belong to tetragonal space group P 4 X22 (a = b = 
43-2 A, c =  290-9 A). Assuming a monomer per 
asymmetric unit, the specific volume of the protein 
is 2-46 A3/Da, which falls within the range normally 
observed for protein crystals, and corresponds to  a 
50%  (v/v) solvent content (Matthews, 1968).
A preliminary 2-9 A data  set has been collected 
and a search for suitable heavy atom  derivatives is 
in progress.
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S u p e r a n t i g e n s  stimulate T cells bearing particular T-cell receptor 
Vp sequences1’2, so they are extremely potent polyclonal T-cell 
mitogens. T-cell activation is preceded by binding of superantigens 
to class II major histocompatibility complex (MHC) molecules3. 
To further the structural characterization of these interactions, the 
crystal structure of a toxin associated with toxic-shock syndrome, 
TSST-1, which is a microbial superantigen, has been determined 
at 2.5 A resolution. The N- and C-terminal domains of the struc­
ture both contain regions involved in MHC class II association; 
the C-terminal domain is also implicated in binding the T-cell 
receptor. Despite low sequence conservation, the TSST-1 topology 
is similar to the structure reported for the superantigen staphylo­
coccal enterotoxin B4. But TSST-1 lacks several of the structural 
features highlighted as central to superantigen activity in the 
staphylococcal enterotoxin B and we therefore reappraise the 
structural basis of superantigen action.
Toxic-shock syndrome toxin-1 (TSST-1) is secreted by 
Staphylococcus aureus and is important in the genesis of human 
toxic-shock syndrome5. The protein has 194 residues and is
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monomeric in solution (data not shown). The crystal structure 
determination is described in Table 1. The two domains of TSST- 
1 are packed tightly together to form a compact molecule of 
dimensions ~45 x 45 x 58 A3 (Fig. 1). After a short N-terminal 
portion, which spans the domain interface and includes an a- 
helix (al), the polypeptide folds in a continuous Toll’ of /2- 
strands (/21 — /25) to form the distinctive /2-barrel of the N-termi­
nal domain. This motif has also been noted in four other proteins 
of unrelated sequence6, including two bacterial toxins, the heat- 
labile toxin and verotoxin-1 from Escherichia coli. A piece of 
extended chain caps one end of the /I-barrel in TSST-1, replacing 
the a-helix observed in the other structures. However, the top­
ology and positioning of the structural elements is conserved 
(Fig. 1). In TSST-1, the concave /21/22/23 face of this domain 
is distinguished by a prominent clustering of solvent-accessible 
hydrophobic residues (Fig. 2a). The C-terminal domain is com­
posed of one particularly long a-helix (a2) with a highly twisted 
/2-sheet (/26-/212) cupped around it (Fig. 2b). As the N-terminal 
domain packs against the other face of a 2, this helix serves as 
the ‘backbone’ of the molecule. The overall topology of the C- 
terminal domain is unique so far to the microbial superantigens, 
although it may be considered to be an elaborated form of the 
/2-grasp motif6.
Figure 2a shows the buried residues of TSST-1 and, on the 
basis of the structure, possible linear epitopes can be suggested. 
Data for the location of biologically active sites on TSST-1 are 
related to the structure shown in Fig. 3a and b. Two results are 
specific for MHC class II binding. A peptide corresponding to 
residues 58-78, which reacts with neutralizing monoclonal anti­
bodies against whole TSST-1 and demonstrates some of the 
immunoregulatory properties of the whole molecule, has been 
implicated in binding to MHC class II molecules7. Similarly, 
peptides 39-68 and 155-194 have been reported to compete with 
whole TSST-1 for MHC class II binding8. Thus, many of the 
data on specific binding to MHC class II molecules centre on 
residues 39-78 in the N-terminal /2-barrel domain. In contrast, 
a C-terminal 12K fragment (Mr 12,000; residues 88-194, in effect 
the C-terminal domain) of TSST-1 has been reported to have 
mitogenic activity and to contain the epitope for antibody 8-5- 
7, which is able to neutralize the major clinical signs of toxic- 
shock syndrome9,10. As superantigen/MHC class II binding is a 
prerequisite of subsequent T-cell antigen receptor (TCR) 
binding and mitogenic activity, this fragment must retain some 
MHC class II binding affinity in addition to the TCR binding 
site. Site-directed mutagenesis1113 has implicated residues 
Tyr 115, Glu 132, His 135, lie 140, His 141 and Tyr 144 in mito­
genic activity. Tyrosine 115 is exposed to solvent in the /27/28 
loop and as mutation to alanine abrogates antibody 8-5-7 
binding, it appears to contribute directly to this key neutralizing 
epitope. Glutamic acid 132, His 135 and lie 140 are all located 
on helix a 2 and are exposed to solvent. It has been reported12 
that replacement of residue His 135 by alanine abolishes mito­
genic activity, although the mutant protein is still recognized 
by antibody 8-5-7. Residues 141 and 144 are both buried, and 
mutation of these residues may well result in conformational 
changes influencing the nature of the molecular surface in the 
region of the a 2/29 loop (situated above Tyr 115 in the orienta­
tion of Fig. 3a, b). The extent of such changes is not sufficient 
to impinge on the 8-5-7 epitope for His 141 but may be for the 
deeply buried Tyr 144 (ref. 11). In total, the available data for 
the superantigenic activity of TSST-1 appear to cluster into two 
sites, one (site A) involving the concave face of the N-terminal 
/3-barrel, the other (site B) containing a2 and the /27/28 and 
a2/29 loops in the C-terminal domain. Site A is associated with 
MHC class II binding. But as the C-terminal domain alone9, 
and a portion of the polypeptide chain between residues 155 and 
194 in particular, have also been implicated in MHC binding8, 
we predict that the residues between 170 and 180, where the 
chain packs closely against the concave face of the N-terminal 
/2-barrel (Fig. 3a, b), form part of site A. Data for site B do not
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TABLE 1 Statistics for crystallographic structure determination
Diffraction data
Unique
No. of reflections Emerge
Dataset d min (A) measurements (% complete) (all data) MFID
Native (IP Lab 1) 3.5 20,717 11 ,231  (94) 7.5 —
Native (IP Lab 2) 2.5 49 ,530 29 ,155  (87) 7.5 —
Native (IP Lab
1 + 2) 2.5 70,247 30 ,007  (89) 8 .6  —
Uranyl acetate 3.5 11,104 9 ,186  (77) 8 .4  29 .9
Uranyl fluoride 3.5 13 ,938 10 ,536  (88) 4 .5  17.1
MIR phasing
Rc to 6.0 A Phasing power
Derivative No. of sites (3.5 A) to 6 .0  A (3.5 A)
Uranyl acetate (10 mM) 5 0.55 1.9
Uranyl fluoride (10 mM) 3 0 .49  (0.56) 2 .1 (1.7)
Solvent flattening
Pre-Wang Wang R Phase
dmin (A) FM % Solvent factor change Wang FM
6.0 0 .60 65 26.3  41.3° 0 .78
3.5 — 65 (55) 22.6  (18.7) 50.5° (48.3) 0 .77  (0.80)
TSST-1 was purified and crystallized as described24. The crystals belong to 
orthorhombic space group C 222i (cell dimensions a =  108.6 , b =  177.6, c =
97.5 A) with 3  molecules per asymmetric unit, but possess pseudo-hexagonal 
symmetry space group P6322  (cell dimensions a = b =  104.1 , c =  97.5A; with 1 
molecule per asymmetric unit). Diffraction data from native crystals (3.5 A and
2.5 A resolution) and from two heavy-atom derivatives (3.5 A resolution) were 
collected using an MAR-research imagining-plate system with CuKa X-rays gener­
ated by a Rigaku RU200 rotating anode with a graphite monochromator. 
Data were_ processed using the MOSFLM package (A. Leslie) 
(Rmerge=Z(/, obs- / / ) / £  /; MFID, mean fractional isomorphous difference). Heavy- 
atom sites were identified using the automatic Patterson search program 
GROPAT25 and difference Fourier analyses. Heavy-atom parameters were refined 
and MIR phases calculated using the programs REFINE and PHASE (P. Shaw, 
unpublished) respectively (Rc: Cullis R-factor for centric reflections; phasing power: 
mean value of the heavy-atom structure factor amplitudes divided by the residual 
lack-of-closure error). The MIR phases were improved by solvent flattening (65% 
solvent) to give a 3.5 A electron density map from which we established the 
relationship between the non-crystallographically related molecules. The pseudo­
symmetry arises because the orthorhombic asymmetric unit contains one half of a 
crystallographic dimer and one non-crystallographic dimer arranged on a pseudo- 
hexagonal net (FM, mean figure of merit; Wang R factor, crystallographic R factor 
between observed structure factor amplitudes and those calculated from the 
solvent-flattened map; phase change, difference between MIR phases and phases 
from the solvent flattened map). Ab initio phase extension to 2.5 A was achieved 
using the GAP program suite (D.I.S. and J. Grimes, unpublished) by 3-fold real- 
space averaging, which resulted in an R-factor and correlation coefficient of 0.31  
and 0.91, respectively, between observed data and data obtained by inversion of 
the averaged solvent-flattened map. Owing to the 3-fold averaging, the 2.5 A 
resolution electron density map was quite clear. Initially a skeletal model for one 
monomer (all 194  residues) was fitted to the 2 .5  A electron density map (program 
FR0D026) and the appropriate amino-acid sequence incorporated using the pro­
gram CALPHA (R. Esnouf, unpublished). The structure was refined by simulated 
annealing with strict non-crystallographic symmetry constraints (program 
XPLOR27). In the final round, the non-crystallographic constraints were relaxed and 
the 3 molecules were individually checked and refined with non-crystallographic 
restraints. The current model, which includes 4 ,677  non-hydrogen atoms (for 3  
molecules), has a crystallographic R factor of 0 .213  for all data to 2.5 A (15.6% 
for 3a). No bound waters have been modelled, although a correction for the 
bulk solvent has been made. The root-mean-square (r.m.s.) deviation from ideal 
values for bond lengths is 0 .011 A and for bond angles is 2.68°. The r.m.s. devia­
tion of atomic coordinates for all atoms between monomer pairs 1 -2 , 1 -3  and 
2 -3  are 0.13, 0 .15, 0 .15  A, respectively. With the exception of S er8 6  (0 =  61°, 
ip =  -1 5 7 °) , main-chain torsion angles for.all residues lie within allowed regions 
of the Ramachandran plot. Atomic coordinates will be deposited in the Brookhaven 
Protein Data Bank.
distinguish between MHC class II or TCR binding, but we sug­
gest that its position (diametrically opposed on the TSST-1 
molecule to site A) makes it the likely site of TCR interaction.
TSST-1 shares little amino-acid sequence identity (~24%) 
with the staphylococcal enterotoxins (SEs: SEA-SEE) but 
shares similar biological functions. A comparison on the basis 
of secondary structure assignments is shown for TSST-1 and 
SEB in Fig. 2b. The smaller protein, TSST-1, has the same core 
topology as SEB but is extensively truncated in several loop
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regions, including some that incorporate secondary structure ele­
ments. Thus there are no structural equivalents in TSST-1 for 
much o f the SEB N-terminal region, including SEB a l .  Simi­
larly, helices a3 and a 5, situated in loops between /?3j34 and 
/310/n i in SEB, are respectively lost and truncated to a single 
turn o f 310 helix in TSST-1, whereas the >82)33 and (34/35 loops 
are markedly shorter. This latter loop is often referred to as the 
‘cysteine loop’ o f the SEs, and residues in this region have been 
implicated in SE emetic activity14. The lack o f emetic activity 
in TSST-1 is consistent with the marked difference we observe 
between TSST-1 and SEB structures in this region. The many 
alterations in TSST-1 as compared with SEB, particularly in the 
N-terminal region and SEB a5, both o f which are situated at 
the domain interface, also have considerable bearing on the 
superantigenic sites, as predicted from inspection o f the SEB 
structure4. Inhibition of intact SEA by synthetic peptides has 
implicated the N-terminal domain o f SEA in MHC class II 
binding15’16. Mutagenesis17 o f the solvent-accessible Asn 23 of 
SEB implicates a2 o f that molecule in TCR binding. Data from 
the same study for the exposed hydrophobic residue Phe 44 (in 
SEB) associate the (3\(32 turn with MHC class II binding. This 
study also demonstrated T/?-specific binding effects at the tip of 
the (32/33 loop and some MHC class II binding dependency on 
a l (SEB); these areas have no structural equivalents in TSST- 
1. In SEA, mutants that affect V(3 specificity1 map onto residues 
just preceding the start o f a5 in SEB; again, there are no struc­
tural equivalents in TSST-1. With the exception o f Asn 23 
(SEB), mutations in SEA and SEB reported to affect TCR 
binding abrogate binding to only some o f the V(3 elements 
known to recognize the native protein.
Many o f the detailed elements o f both TCR and MHC binding 
sites appear to be altered between TSST-1 and the SE family, 
as represented by SEB. Overall, the evidence for MHC class II 
binding to these microbial superantigens focuses onto the front 
(a5 in SEB) face o f the molecule (Fig. 3a, b), which includes 
the concave surface o f the /71/32/I3 sheet in the N-terminal 
domain. It is therefore o f particular interest that this surface, 
delineated by the >31 >32, P3>34 and /?4/)5 loops, is the site o f 
oligonucleotide or oligosaccharide binding in the structurally 
analogous domains o f other proteins6. The specific site o f TCR 
binding involves several amino acids on the top and back (a4  
in SEB) face o f the molecule (Fig. 3a, b) and appears to vary 
between different superantigens and/or different TCR V(3 
variants.
Any discussion of superantigen binding must consider the 
structure of the MHC class II and TCR molecules. MHC class 
II/superantigen binding is believed to involve regions to the
FIG. 1 The polypeptide fold for TSST-1. Helices are coloured red (3 i0 
helices being drawn more thinly than a-helices), /J-strands green and 
loops yellow. Blue and red balls represent N and C termini, respectively.
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a l 12-17 -
ct2 21-29 a l  7-15
PI 33-39 31 18-29
32 48-52 32 32-37
33 63-68 P3 41-47
a3 70-78
34 81-89 34 60-75
35 112-120 35 79-89
36 127-138 36 101-106
37 141-151 37 109-111
|18 154-156 38 119-124
a4 157-172 a2 125-140
39 182-190 39 152-158
310 195-200 310 161-166
a5 210-217 310-1 173-177
p ll 222-225 311 181-182
- 3m-2 183-185
312 229-236 312 186-193
FIG. 2 a, Amino-acid sequence of TSST-1. Positions of the secondary 
structural elem ents in TSST-1 (based on program DSSP) are indicated, 
and solvent-inaccessible residues (less than 20 A2) of exposed surface) 
are indicated by asterisks. Residues implicated in mitogenic activity 
(based on site-directed mutagenesis) are represented by plus signs. 
b, Comparison of the secondary structural elem ents for SEB4 and 
TSST-1.
side o f the antigen-binding cleft19,20. Superantigen binding to the 
TCR is thought to be to the solvent-exposed face o f a /I-sheet 
(the BED /3-sheet) in the V(3 component o f the TCR Va V(3 
dimer21,22. Combination o f these observations with a model for 
the M HC/TCR antigen recognition complex enables us to rep­
resent superantigen action schematically (Fig. 3c)23. Figure 3d 
shows that these proposed sites o f interaction between TSST-1 
and the MHC and TCR molecules are entirely consistent with 
such a model. In the absence o f high-resolution evidence for the 
structure o f the ternary complex, such models may prove helpful 
for understanding the microbial superantigen mechanism of 
pathogenicity and enable therapeutic compounds to be engin­
eered that target appropriate epitopes derived from the molecu­
lar structures o f these toxins. □
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